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Kimberly Sherrelle Burgess 
 
MICRO-RNA REGULATION OF HEPATIC DRUG METABOLISM: AGE-RELATED 
CHANGES IN MICRO-RNA EXPRESSION AND GENETIC VARIANTS IN MICRO-RNA 
TARGET SITES 
 
Developmental changes in the liver significantly impact drug disposition. Due to the 
emergence of microRNAs as important regulators of drug disposition, we hypothesize that 
age-dependent change in microRNA expression and genetic variants in microRNA target 
sites contribute to variability in drug disposition. In human liver tissues, expression of 533 
microRNAs and over 14,000 genes were measured. In all, 114 microRNAs were 
upregulated and 72 downregulated from fetal to pediatric, and 2 and 3, respectively, from 
pediatric to adult. Among these microRNAs, 99 microRNA-mRNA interactions were 
predicted or have previously been validated to target drug disposition genes and over 
1,000 significant negative correlations were observed between miRNA-mRNA pairs. We 
validated these interactions using various cell culture models. Genetic variants in the 
promoter and coding regions of drug disposition genes have also been shown to alter 
enzyme expression and/or activity. However, these variants do not account for all 
variability in enzyme activity. Emerging evidence has shown that variants in the 3’UTR 
may explain variable drug response by altering microRNA regulation. Five 3’UTR variants 
were associated with significantly altered CYP2B6 activity in healthy human volunteers. 
The rs70950385 (AG>CA) variant was associated with decreased CYP2B6 activity among 
normal metabolizers. In vitro luciferase assays confirmed that the CA allele altered miR-
1275 targeting of CYP2B6 mRNA. Due to the large number of 3’UTR variants predicted 
to alter microRNA regulation, a high-throughput method, PASSPORT-seq, was developed 
to test over 100 3’UTR variants simultaneously in different cell lines. Thirty-eight variants 
 vii 
resulted in FDR-significant altered expression between wild-type and variant sequences. 
Our data suggest a mechanism for the marked changes in hepatic gene expression 
between the fetal and pediatric developmental periods, support a role for these age-
dependent microRNAs in regulating drug disposition, and provide strong evidence that 
3’UTR variants are also an important source of variability in drug disposition. 
 
 
Todd C. Skaar, Ph.D., Chair 
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INTRODUCTION 
Introduction to pharmacogenes 
Pharmacogenes are genes that encode for proteins responsible in the absorption, 
distribution, metabolism, and excretion of drugs. These include phase I and II enzymes 
responsible for biotransformation of drugs in order to make them more hydrophilic and 
easily eliminated, transporters that allow drugs to move across various membranes, and 
upstream transcription factors that regulate the expression of the previously mentioned 
proteins. Together, these pharmacogenes play a critical role in drug pharmacokinetics and 
impact the safety and efficacy of drug treatments. 
 
The most well-studied Phase I enzymes include members of the cytochrome P450 (CYP) 
superfamily. The CYPs are a superfamily of heme-thiolate monooxygenase enzymes 
involved in oxidative metabolism that are essential for the production of cholesterol, 
steroids, prostacyclins and thromboxane A2, as well as metabolism of exogenous drugs 
and carcinogens (Slaughter and Edwards, 1995). These CYPs were named due to being 
bound to membranes within a cell (cyto), containing a heme pigment (chrome and P) which 
absorbs light at a wavelength of (450) nm in its reduced state when complexed with carbon 
monoxide (Klingenberg, 1958; Lu and Coon, 1968; Omura and Sato, 1964a, b). In 
humans, there are 57 functional CYPs and 18 families (Guengerich, 2008; Nelson et al., 
2004). These CYPs are expressed in the endoplasmic reticulum of different tissues such 
as the liver, small intestines, lungs, placenta, and kidneys (Nelson et al., 2004; Slaughter 
and Edwards, 1995). 
 
Of these CYPs, members of families 1-3 are responsible for metabolism of 70-80% of 
clinically used drugs and are less conserved across species (Bertz and Granneman, 1997; 
Evans and Relling, 1999). These CYPs determine the rate of biotransformation of a parent 
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drug into an active/inactive metabolite which affect drug concentrations in the body and 
subsequent effects. In the case of CYP2D6, it is responsible for the biotransformation of 
codeine to morphine, a more pharmacologically active analgesic used to alleviate pain 
(Caraco et al., 1999). Members of these CYP families are also associated with the 
metabolism of endogenous substrates such as testosterone and cortisol by CYP3A and 
endocannabinoids by CYP2D6 (Kim et al., 2017; Snider et al., 2008; Uehara et al., 2017). 
Members of the remaining CYP families (4, 5, 7, 8, 11, 17, 19, 20, 21, 24, 26, 27, 39, 46 
and 51) are more closely associated with metabolism of endogenous substrates and 
conserved across other species (Ingelman-Sundberg and Rodriguez-Antona, 2005). For 
example, CYP19A1 is an aromatase responsible for the biosynthesis of estrogens 
(Czajka-Oraniec and Simpson, 2010).  
 
Phase II enzymes are responsible for conjugation reactions to serve as a detoxification 
step in drug metabolism. These are mostly transferases such as uridine 5’-diphospho-
glucuronosyltransferase (UGTs), sulfotransferases (SULTs), N-acetyltransferases 
(NATs), glutathione S-transferases (GSTs) and methyltransferases such as thiopurine S-
methyl transferase (TPMT). UGTs are of the most clinically-important Phase II enzymes 
and are responsible for transferring a glucuronide from glucuronic acid to its substrate, a 
process called glucuronidation. This results in the glucuronidated product being eliminated 
in the bile or urine as it becomes more hydrophilic and unable to be reabsorbed. UGTs 
are responsible for glucuronidation of over 40% of clinically-used drugs, and in 
combination with CYPs, they metabolize over 90% of drugs (Evans and Relling, 1999; 
Rowland et al., 2013). After codeine is metabolized to morphine, morphine is then 
glucuronidated by UGT2B7. The morphine-6-glururonide is 100 times more potent as an 
opioid receptor agonist than morphine (Paul et al., 1989). 
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In humans, there are five UGT families consisting of 22 proteins. As the liver is the main 
organ for detoxification, UGTs are expressed more abundantly in the liver, but are also 
expressed in other organs such as the intestines and kidneys (Rowland et al., 2013). 
Phase II enzymes are responsible in the elimination of many endogenous substrates as 
well. SULTs are known to metabolize estrogens whereas UGTs eliminate endogenous 
compounds such as bilirubin, steroids, and fat soluble vitamins (Liu et al., 2017; Miners 
and Mackenzie, 1991). Specifically, UGT1A1 is responsible for the conjugation of bilirubin, 
a by-product of red blood cell catabolism. Measurement of conjugated and unconjugated 
bilirubin levels in the blood is a classic test used to measure liver function, as increased 
levels of unconjugated bilirubin is associated with reduced liver function (Clarke et al., 
1997). 
 
Another group of pharmacogenes include transporters, which facilitate the movement of 
compounds across biological membranes. Among these transported compounds include 
both exogenous and endogenous compounds. Common “drug” transporters include 
members of the ATP-binding cassette (ABC) and solute carrier (SLC) superfamilies. Due 
to substrate redundancy of transporters, studying the effects of a single transporter on a 
specific drug can be difficult (Hillgren et al., 2013). As such, ABCB1 has been shown to 
export many drugs, steroids, lipids, and bilirubin and is ubiquitously expressed, but mainly 
located in the intestine, brain, liver and kidney. SLC22A1 is mainly expressed in the liver 
and a few known substrates include metformin, acyclovir, monoamine neurotransmitters 
and choline (Liang et al., 2015). 
 
Lastly, upstream transcription factors have been shown to regulate drug metabolism and 
disposition through regulating the expression of Phase I and II enzymes and transporters. 
Many of these transcription factors have been labelled as orphan transcription factors, as 
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endogenous ligands remain to be elucidated. Studies have identified endogenous ligands 
in one species, but findings did not hold true for the mammalian version of the gene (Moore 
et al., 2000). In the case of hepatic nuclear factor 4α (HNF4A), an essential fatty acid, 
linoleic acid, has been identified as an endogenous ligand for both mice and mammalian-
expressed HNF4A (Yuan et al., 2009). HNF4A is a highly conserved nuclear receptor, 
known as a “master” regulator of liver-specific gene expression. HNF4A was first identified 
in the rat liver where it was found to be bound to the apolipoprotein C-III gene and was 
identified as the gene mutated in an inheritable form of non-insulin-dependent diabetes 
called maturity onset diabetes of the young so it was thought to be associated with 
carbohydrate and lipid metabolism (Ellard and Colclough, 2006; Sladek et al., 1990). This 
nuclear receptor has been shown to be highly expressed in the liver, kidney, and 
intestines, where most drug metabolism occurs and known to regulate the expression of 
many Phase I and II enzymes (Aueviriyavit et al., 2007; Goodwin et al., 2002; Jover et al., 
2009; Tirona et al., 2003). Furthermore, HNF4A binds DNA as a homodimer and has been 
shown to be required for other nuclear receptors, such as PXR and CAR, to induce 
expression (Tirona et al., 2003). 
 
The pregnane X-receptor (PXR) and constitutive androstane receptor (CAR) are main 
members of the nuclear receptor (NR1I) family that have been shown to regulate 
transcription of many pharmacogenes and are mainly expressed in the liver and intestines. 
In general, ligand binding results in PXR and CAR forming heterodimers with retinoid X 
receptor in order to be translocated into the nucleus and bind to response elements in the 
promoter region of target genes (Baes et al., 1994; Wang et al., 2015). Many exogenous 
ligands have been identified for these nuclear receptors, but no obvious common 
structural features have been deciphered (Waxman, 1999). PXR and CAR also overlap in 
ligand binding and DNA binding regions so they have been shown to co-regulate many 
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genes; however, PXR is a well-known CYP3A inducer and CAR as a CYP2B inducer 
(Wang et al., 2003; Wei et al., 2002). In the case of many CYPs, their expression levels 
increase with drug exposure and return to normal levels after exposure is gone. This 
response is thought to be an adaptive response established to protect against foreign 
compounds. In the case of polypharmacy, this can pose a problem in drug response. 
Especially when commonly used drugs such as rifampicin (antibiotic), troglitazone 
(diabetes drug) and dexamethasone (anti-inflammatory) have been identified as PXR 
ligands. So induction of CYP3A4 mediated by PXR will increase the rate of 
biotransformation of CYP3A4 substrates (Lehmann et al., 1998; Li et al., 1995). This can 
have serious consequences in drug treatment as CYP3A4 is responsible for the 
biotransformation of 50-60% of clinically-used drugs. 
 
Developmental changes in pharmacogenes 
Developmental changes in drug disposition create the need for age-appropriate 
pharmacotherapy (Hines, 2008, 2013; Kearns et al., 2003; Van Driest and McGregor, 
2013). Although there have been many approaches for estimating pediatric drug dosing 
(e.g. extrapolation from adult data), these approaches are not adequate for many children 
(Sage et al., 2014). Developmental changes in drug response are difficult to predict at the 
individual patient level, in part due to our poor understanding of the mechanisms that 
regulate these developmental changes. Consequently, the high off-label use of drugs in 
this pediatric population is associated with an increased number of adverse events 
(Cuzzolin et al., 2006). Although more clinical studies are now being conducted in pediatric 
populations as a result of the Pediatric Exclusivity and the Best Pharmaceuticals for 
Children Acts, a fundamental understanding of the ontogeny of pharmacogenes is still 
needed to develop more accurate dosing guidelines for both the clinical trials and clinical 
care in the young.  
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The majority of drug disposition genes, those involved in drug distribution and elimination, 
are known to change during early and late developmental stages in humans; however, 
little is understood about the mechanisms that control these changes. The most well 
characterized age-associated drug disposition genes involve expression of drug 
metabolizing enzymes in the liver (Blake et al., 2005; Blake et al., 2007; de Wildt et al., 
1999; Hines, 2007). These include the phase I and II enzymes that are responsible for the 
modification and elimination of many drugs. The most notable of the phase I enzymes are 
the CYPs and many developmental changes have been observed in their expression 
patterns (Blake et al., 2005; Blake et al., 2007; de Wildt et al., 1999; Hines, 2007). For 
example, the predominant CYP gene expressed in fetal liver, CYP3A7, peaks shortly after 
birth and becomes undetectable in most children and adults. In contrast, CYP1A1, 2C9, 
2C19, 2D6, and 2E1 are undetectable or expressed extremely low in the fetus, but are 
expressed at high levels after birth (Lacroix et al., 1997; Sonnier and Cresteil, 1998; 
Treluyer et al., 1997; Treluyer et al., 1991; Vieira et al., 1996). A well-documented example 
of phase II enzyme ontogeny is the delayed onset of a member of the UGT2B family 
responsible for “gray baby” syndrome in neonates as an adverse event of chloramphenicol 
therapy (McCarver and Hines, 2002). There is also data indicating that UGT1A6 and 
UGT1A9 function increases in older children and adults compared to younger children 
(Miller et al., 1976). Recently, developmental patterns of drug transporter expression 
indicates that hepatic MDR1 (ABCB1), MRP (ABCC2), OATP1B1 (SLCO1B1) and 
OATP1B1 (SLCO1B3) expression is also increased in adults compared to fetal and 
neonates (Mooij et al., 2014). 
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Mechanisms of developmental changes in pharmacogenes 
Many developmental changes in pharmacogenes have been identified, but a fundamental 
understanding of mechanisms that facilitate these changes are necessary for safer and 
more effective drug therapy. Emerging evidence has shown that epigenetic regulation may 
explain some of the observed developmental changes in pharmacogenes (Fisel et al., 
2016; Kacevska et al., 2012). Epigenetics refers to heritable changes in gene expression 
without altering the DNA sequence.  Such modifications include DNA/histone methylation 
and non-coding RNAs such as miRNAs (Goldberg et al., 2007). These epigenetic 
modifications may fluctuate over time and in response to various stimuli, which may 
explain some of the unknown reasons for developmental changes in pharmacogenes 
(Holliday, 2006; Jones and Baylin, 2007). Epigenetic regulation of pharmacogenes, 
pharmacoepigenetics, may not only explain variability in drug response, it can also affect 
the metabolism of endogenous substrates and lead to the progression of various diseases. 
 
Pharmacogepigenetics and its implications in the ontogeny of drug disposition genes are 
limited. Many studies focused on DNA methylation of pharmacogenes have been 
associated with their gene expression in different cancers (Belanger et al., 2010; Okino et 
al., 2006; Olsson et al., 2007). However, hyper-methylation has been shown to contribute 
to the lack of CYP3A4 expression in the fetal liver, whereas after birth, the methylation 
patterns are altered to increase expression (Kacevska et al., 2012). In HepG2 liver cells, 
treatment with 5-aza-2’-deoxycytidine, a DNA methyltransferase inhibitor, resulted in 
upregulation of CYP3A7 mRNA expression suggesting that DNA methylation may explain 
this CYPs expression in the fetal liver and downregulation in pediatric and adults 
(Dannenberg and Edenberg, 2006).  
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MicroRNAs, the main focal point of this project, are another source of epigenetic 
modification that may contribute to variability in gene expression of pharmacogenes. 
These miRNAs are small noncoding RNAs, approximately 17 to 22 nucleotides in length 
that bind to mRNAs and regulate their translation and stability. These miRNAs have 
previously been shown to negatively regulate the expression of pharmacogenes such as 
CYP1B1 and miR-27b, UGT1A1 and miR-491-3p, and HNF4A and miR-34a-5p (Dluzen 
et al., 2014; Ramamoorthy et al., 2012; Tsuchiya et al., 2006). A single miRNA can also 
regulate the expression of many protein coding genes. This promiscuity can make it 
difficult to understand miRNA-mediated regulatory networks. In order to understand how 
miRNAs can alter pharmacogene expression to contribute to ontogenesis and inter-
individual variability in gene expression, much is needed to be studied regarding the 
regulation of miRNAs themselves. 
 
Aging has been associated with alterations in the hepatic expression of several miRNAs 
in rats (Mimura et al., 2014), which may be true for humans as well. These age-dependent 
changes in hepatic miRNAs may contribute to known age-related changes in 
pharmacogene expression and activity. MicroRNAs have been implicated in many 
biological processes and hepatic miRNA expression has also been shown to be altered 
under a variety of conditions. Hepatic diseases, such as liver cancer, cirrhosis, and 
hepatitis C infection, are associated with altered miRNA expression (Gupta et al., 2014; 
Liang et al., 2013; Tao et al., 2013). We have previously shown that rifampin, a known 
inducer of drug metabolism genes (Anderson et al., 2013; Rae et al., 2001), alters miRNA 
expression patterns in primary human hepatocytes (Ramamoorthy et al., 2013). Altered 
hepatic miRNA expression patterns may contribute to rifampin-mediated drug interactions. 
Understanding these changes in miRNA expression may prove miRNAs to be useful as 
biomarkers for drug response, disease progression and diagnoses. 
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Discovery of miRNAs, biogenesis and mechanisms of action 
The first miRNA, lin-4, was discovered in 1993 by Victor Ambros in C. elegans. It was 
shown to negatively regulate levels of LIN-14 protein involved in postembryonic 
development in C. elegans (Lee et al., 1993). These miRNAs are endogenous to humans 
and known to be transcribed by RNA polymerase II/III into primary miRNA, cleaved by the 
Drosha-DGCR8 microprocessor complex to precursor miRNA, and exported into the 
cytoplasm by Exportin-5-Ran-GTP as shown in Figure 1. Next, they are cleaved into 
microRNA duplexes by Dicer-TRBP where one strand is loaded into the RNA-induced 
silencing complex (RISC) to guide the complex to its target. The other strand is degraded 
(Winter et al., 2009). 
 
The majority of miRNAs bind imperfect complimentary sequences in the 3’UTRs of target 
mRNAs (Liu, 2008; Olsen and Ambros, 1999; Selbach et al., 2008; Xie et al., 2008). In 
addition, a minority of miRNAs target other regions of the mRNA such as the 5’UTR and 
coding regions to repress translation, and in some cases, have even increased gene 
expression (Duursma et al., 2008; Orom et al., 2008; Place et al., 2008). The 3’UTR ‘seed 
sequence’ located at the 5’ end from bases 2-8 is a critical feature required for miRNA 
binding to its target mRNA (Lambert et al., 2011). This ‘seed sequence’ binding is critical 
for many miRNA-mRNA prediction databases such as TargetScan (Agarwal et al., 2015), 
which includes the identification of several classes of target sites. Listed in order of 
effectiveness are the 8mer site (perfect complimentary binding at positions 2-8 with an A 
at the first position), 7mer-m8 site (perfect complimentary binding at positions 2-8), 7mer-
A1 site (positions 2-7 with an A at the first position), 6mer (positions 2-7) and offset-6mer 
(position 3-8) (Brennecke et al., 2005; Friedman et al., 2009; Krek et al., 2005; Lewis et 
al., 2005). The adenosine located on the mRNA sequence, opposite of position one on 
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the miRNA has been shown to improve miRNA binding due to recognition within a binding 
pocket of the Argonaute protein (Schirle et al., 2014). 
 
While the biogenesis and post-transcriptional activity of miRNAs has been extensively 
studied, much remains to be elucidated about the regulation of these miRNAs. Studies 
regarding miRNA stability, expression in various tissues, and transport between tissues 
are only a few of the questions that need to be answered to enable a better understanding 
of how miRNAs function. Such regulatory networks of miRNAs remain to be fully 
elucidated. As miRNAs are transcribed from DNA, they are also subject to epigenetic 
factors such as DNA methylation. Changes in miRNA expression levels have been 
observed when cells were treated with histone deacetylase inhibitors (Scott et al., 2006). 
Methylation patterns in the promoter region of miRNAs have also been observed in various 
diseases. For example, let-7a-3 was found to be hypo-methylated in some lung cancers, 
but hyper-methylated in normal human tissues (Brueckner et al., 2007). To further 
complicate miRNA regulation, miRNAs can target DNA and histone methylation genes (Li 
et al., 2009). As these regulatory networks of miRNAs become uncovered, better 
understanding of miRNA regulation of pharmacogenes and miRNAs as diagnostic 
markers will follow. 
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Figure 1: The canonical pathway of microRNA processing 
The miRNA processing pathway has long been viewed as linear and universal to all 
mammalian miRNAs. This canonical maturation includes the production of the primary 
miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA 
by the microprocessor complex Drosha-DGCR8 (Pasha) in the nucleus. The resulting 
precursor hairpin, the pre-miRNA, is exported from the nucleus by Exportin-5-Ran-GTP. 
In the cytoplasm, the RNAse Dicer complex with the double-stranded RNA-binding protein 
TRBP cleaves the pre-miRNA hairpin to its mature length. The functional strand of the 
mature miRNA (red) is loaded together with Argonaute (Ago2) proteins into the RNA-
induced silencing complex (RISC), where it guides RISC to silence target mRNAs through 
mRNA cleavage, translational repression, or deadenylation, whereas the passenger 
strand (black) is degraded. [figure reproduced and modified from Winter et al., 2009] 
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Genetic variants in miRNA target sites 
Pharmacogenetics, a term coined by Friedrich Vogel in the 1950s, is defined as the use 
of a persons’ genomic information to guide medical management (Vogel, 1959). This area 
of research has focused on identifying the genetic foundations of diseases, how genes 
and the environment interact to cause disease, and using genetics to facilitate effective 
drug treatment among individuals. The clinical implementation of pharmacogenetics has 
grown rapidly as the FDA has revised drug labels to include pertinent pharmacogenetic 
information (Frueh et al., 2008; Lesko and Zineh, 2010). The incorporation of genetic 
testing at various medical institutions is also becoming more routine in order to facilitate 
the individualization of healthcare. 
 
As discussed previously, codeine is bioactivated to morphine, by CYP2D6. Approximately 
5-10% of individuals carry two nonfunctional CYP2D6 alleles, such as CYP2D6*4 
characterized by a single nucleotide change from G to A (Crews et al., 2012). The variant 
A allele disrupts proper formation of CYP2D6 mRNA resulting in a nonfunctional protein. 
As a consequence, these individuals are unable to produce morphine to achieve its 
analgesic effects, so a different drug therapy is required (Desmeules et al., 1991). 
Variations also impact the metabolism of endogenous substrates, such as the UGT1A1*28 
allele and altered bilirubin conjugation. The UGT1A1*28 allele has been identified as the 
causal genetic variant of Gilbert’s syndrome, a form of unconjugated hyperbilirubinemia, 
and is characterized by seven TA repeats in the promoter region versus the wild-type allele 
having six repeats (Bosma et al., 1995). This additional TA repeat results in the reduced 
transcription of UGT1A1 by decreasing the binding affinity of the TATA-binding protein to 
the promoter (Hsieh et al., 2007). This interaction is also important as atazanavir, an 
antiretroviral protease inhibitor, inhibits UGT1A1. The resultant hyperbilirubinemia, which 
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can lead to jaundice, can cause patients to discontinue treatment, in which patients with 
already reduced functioning UGT1A1 are at an increased risk for (Gammal et al., 2016). 
 
In an effort to summarize information on pharmacogenetics, organizations have curated 
these data into website such as PharmGKB (https://www.pharmgkb.org/), PharmaADME 
“Core ADME Gene List” (http://www.pharmaadme.org/), and The Human CYP Allele 
Nomenclature Database (http://www.cypalleles.ki.se/). However, much of the information 
regarding the use of genetic variants to predict an individual’s response to a drug focuses 
on variations in the promoter and coding regions of genes. As there are over 2500 miRNAs 
identified to date (miRBase Registry version 20), miRNAs have been shown to regulate 
many genes, including pharmacogenes (Jin et al., 2016; Li et al., 2016; Pan et al., 2009; 
Ramamoorthy et al., 2012; Shi et al., 2007; Takagi et al., 2008; To et al., 2008). Emerging 
evidence has shown that genetic variations in the 3’UTR may contribute to variability in 
drug response by altering miRNA regulation as well (Ramamoorthy et al., 2012; Swart and 
Dandara, 2014). Variants within the seed sequence of miRNA target sites may abolish 
miRNA target sites, as well as create new miRNA target sites (Bhattacharya et al., 2014). 
These genetic variations in miRNA binding sites of pharmacogenes may explain some of 
the inter-subject variability in pharmacokinetics and drug response. One particular 
example that we highlight in this study involves genetic variant effects on miRNA 
regulation of CYP2B6. Various miRNAs have been predicted and experimentally validated 
to alter expression and activity of CYP2B6 (Burgess et al., 2015; Jin et al., 2016; Rieger 
et al., 2015).  
 
CYP2B6 is a highly polymorphic cytochrome P450. Of these variants, the CYP2B6*6 
(516G>T, Q172H and 785A>G, K262R) and CYP2B6*18 (983T>C, I328T) haplotypes, 
have been shown to be the most clinically important by causing a reduction in protein 
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expression and activity (Desta et al., 2007; Hofmann et al., 2008; Klein et al., 2005). The 
CYP2B6*6 haplotype results in a splice variant that lacks exons 4 to 6, and has been 
associated with altered elimination and response of many clinically-relevant drugs, such 
as efavirenz, bupropion, methadone, and cyclophosphamide (Desta et al., 2007; Eap et 
al., 2007; Hofmann et al., 2008; Nakajima et al., 2007); however, these and other 
frequently studied genetic variants do not account for all inter-variability observed for drugs 
undergoing CYP2B6 metabolism. 
 
Efavirenz, a non-nucleoside reverse transcriptase inhibitor, is prescribed as part of the 
World Health Organization recommended first-line combination antiretroviral therapy to 
treat HIV type 1 infection (Organization, 2016). However, efavirenz has been associated 
with central nervous system adverse events such as hallucinations and insomnia and with 
treatment failure in some patients (Adkins and Noble, 1998). Higher efavirenz plasma 
concentrations have also been associated with increased likelihood of adverse CNS 
effects, whereas lower levels more likely result in treatment failure (Marzolini et al., 2001). 
Efavirenz has also been shown to have wide variability in plasma concentrations among 
patients, some of which has been accounted for by genetic polymorphisms in CYP2B6, 
the enzyme primarily responsible for efavirenz biotransformation. Variability in CYP2B6-
mediated biotransformation has been observed for other CYP2B6 substrates after the 
more well-studied polymorphisms have been accounted for, such as the variability in 
methadone metabolism and clearance (Kharasch et al., 2015). As some drugs have 
narrow therapeutic windows, better understanding of the inter-individual variability in drug 
concentrations and response will facilitate better treatment regimens to reduce treatment 
failure and adverse events in individuals that differ from what is considered standard. 
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Summary and research aims 
The main objective of this proposal is to evaluate developmentally-regulated miRNA 
regulation of drug disposition genes. My central hypothesis is that hepatic miRNAs post-
transcriptionally regulate expression of drug metabolizing genes and their upstream 
regulatory genes, and that genetic variants in the miRNA target sites within these genes 
alter the ability of miRNAs to regulate targeted mRNAs. Studies outlined in this dissertation 
test this hypothesis through the following specific aims: 
 
Specific Aim 1. Identify hepatic miRNAs that have age-related expression patterns. 
Specific Aim 2. Determine the ability of developmentally-regulated miRNAs to post-
transcriptionally modify the expression of drug metabolism genes. 
Specific Aim 3. Identify and functionally validate polymorphisms in predicted miRNA target 
sites and evaluate their association with clinical drug metabolism. 
 
To test this hypothesis, we measured and analyzed miRNA and mRNA expression in 
human liver tissues from subjects in three different age groups (fetal, pediatric, and adult). 
We then validated in silico miRNA-mRNA predictions using in vitro cell culture models. 
Next, we identified genetic variants in the 3’UTR of CYP2B6 of healthy volunteers that 
were administered efavirenz. Genetic variants that were associated with CYP2B6 activity 
were further characterized with in vitro functional assays to assess their impact on miRNA 
regulation of CYP2B6 expression. Due to the large number of genetic variants, a high-
throughput method was developed to test hundreds of 3’UTR variants simultaneously in 
multiple cell lines. 
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CHAPTER 1 
Age-related changes in microRNA expression and pharmacogenes in human liver 
Introduction 
The expression of hepatic drug disposition genes undergo large changes during liver 
development; however, the mechanisms behind these changes remain unknown. 
Emerging evidence implicate miRNAs in regulation of drug disposition genes. In this study, 
we hypothesize that miRNA expression in human liver tissue changes with age and that 
this variable expression contributes to the developmental changes in drug metabolism and 
disposition genes. To test this hypothesis, we measured and analyzed miRNA and mRNA 
expression in human liver tissues from subjects in three different age groups: fetal, 
pediatric, and adult. Our results suggest that miRNAs are likely to regulate these genes 
directly or indirectly through upstream regulatory genes (Burgess et al., 2015). 
 
Materials and Methods 
Tissue samples, RNA preparation and cDNA 
Human liver tissue specimens were obtained from the NIH-supported tissue programs: 
the Liver Tissue Cell Distribution System (LTCDS) (n=22), the Minnesota and Pittsburg 
collection centers (n=35) and the Laboratory of Developmental Biology at the University 
of Washington (Seattle, WA; n=30). Three liver tissue samples were provided by 
XenoTech, LLC (Lenexa, KS). Liver tissues were stored at -80ºC. This study was 
approved by the Indiana University Institutional Review Board. 
 
Total RNA was extracted from 90 human liver samples (fetal, pediatric, and adult; n=30 
each). Estimated fetal ages ranged from 15-24 weeks (average=18.8 weeks), pediatric 
ages from 1-17 years (average=8.6 years), and adult ages 28-80 years (average=54.5 
years). This cohort consisted of tissue specimen from 43 male and 35 female donors (the 
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sex of the remaining samples was unknown). Of the 90 tissue samples, 16, 10, 1 and 63 
samples were from Caucasian, African-American, Hispanic or donors of unknown 
ethnicity, respectively.  
 
Total RNA, including small RNAs, was extracted with the Qiagen miRNeasy Mini Kit 
(Valencia, CA). Briefly, approximately 30 mg frozen liver tissue was excised and 
homogenized for 30 sec with a PRO 200 rotary homogenizer (PRO Scientific, Oxford, CT) 
in QIAzol Lysis Reagent. Subsequently, chloroform was added, mixed, centrifuged, and 
the aqueous phase transferred to a new tube and mixed with 100% ethanol. The sample 
was applied onto an RNeasy Mini spin column and washed as recommended by the 
protocol. To avoid any DNA contamination, an on-column DNase digest was performed 
using Qiagen RNase-Free DNAse Set (Valencia, CA). After 2 additional washes of the 
column, RNA was eluted twice with 30 µL of RNase-free water. RNA quality (RQI; RNA 
quality index) was determined on an Experion StdSens RNA chip (Bio-Rad, Hercules, CA) 
and concentration measured with a NanoDrop 1000 instrument (Thermo Scientific, 
Wilmington, DE). The RQI values of the RNA preparations ranged between 7.0 and 9.9. 
Seventy-six RNA samples had RQI values above 8.1. RNA preparations were stored at  
-80ºC until analysis. 
 
cDNA for the miRNA panel was made with Megaplex Primer Pools A and B and individual 
miRNAs tested using TaqMan MicroRNA Assays (hsa-miR-431, hsa-miR-668, hsa-let-7b) 
with the supporting TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA). cDNA was made according to manufacturer’s protocol using the Applied 
Biosystems GeneAmp PCR System 9700 (Foster City, CA). 
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miRNA expression profiling 
Expression of 754 microRNAs was measured using TaqMan OpenArray Human miRNA 
Panel using the NT Cycler (Applied Biosystems, Foster City, CA). The threshold cycles 
were set manually based on visual inspection of real-time amplification curves of each 
miRNA. 
 
Bioinformatics analysis of the miRNA expression data 
The miRNA expression data was quantile normalized using the threshold cycle values of 
miRNA data obtained from the TaqMan OpenArray. Differential expression of the miRNAs 
was determined by p-value comparisons between the 60 fetal and pediatric samples and 
between the 59 pediatric and adult samples (one outlying adult sample was removed from 
statistical analyses). They were corrected for by false discovery rate (FDR) using the 
Benjamini Hochberg equation (Benjamini et al., 2001). The top absorption, distribution, 
metabolism, excretion (ADME) genes (http://www.pharmaadme.org/joomla/) that were 
predicted to be targeted by the differentially expressed miRNAs in this study were 
determined using Ingenuity Pathway Analysis (Qiagen, Valencia, CA). The IPA program 
extracts predicted and experimentally validated miRNA targets from TargetScan, 
miRecords, TarBase, and text mining through Ingenuity Expert Findings and Ingenuity 
Expert Assisted Findings. 
 
Measurement of mRNA expression in human liver samples 
RNA-seq was performed as previously described (Ramamoorthy et al., 2012). Standard 
methods were used for RNA-sequencing library construction, EXBead preparation, and 
Next-Generation sequencing, based on the protocol provided for the Life Technologies 
SOLiD4 system. Briefly, 2 µg of total RNA per sample of only 30 of the 90 total samples 
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(fetal, pediatric, and adult; n=10) were used for library preparation. The ribosomal RNA 
was depleted using RiboMinus Eukaryote Kit for RNA-Seq (Invitrogen, Carlsbad, CA). 
 
Bioinformatics analysis of RNA-seq data 
RNA-seq data analysis included the following steps: quality assessment, sequence 
alignment, and gene expression analysis. 
 
Data processing and quality assessment 
We used SOLiD Instrument Control Software and SOLiD Experiment Tracking System 
software for the read quality recalibration. Each sequence read was scanned for low-
quality regions, and if a 5-base sliding window had an average quality score less than 20, 
the read was truncated at that position. Any reads less than 35 bases were discarded. Our 
experience suggested that this strategy effectively eliminated low-quality reads while high-
quality regions were retained (Breese and Liu, 2013; Juan et al., 2013; Todd et al., 2013). 
 
Sequence alignment 
The BFAST (http://bfast.sourceforge.net) (Homer et al., 2009) was used as the primary 
alignment algorithm because it has high sensitivity for aligning reads on loci containing 
small insertions and deletions compared to the reference genome (hg19). NGSUtils 
(http://ngsutils.org/) (Breese and Liu, 2013), a TopHat-like strategy (Trapnell et al., 2009), 
was employed to align the sequencing reads that crossed splicing junctions. After aligning 
the sequence reads to a filtering index including repeats, ribosomal RNAs, and other 
sequences that were not of interest, a sequence alignment was conducted for three levels: 
genome, known junctions (University of California Santa Cruz Genome Browser), and 
novel junctions (based on the enriched regions identified in the genomic alignment). We 
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restricted our analysis to the uniquely aligned sequences with no more than two 
mismatches.  
 
RNA-Seq differential expression analysis 
Differentially expressed genes were identified using edgeR (Robinson et al., 2010), a 
Bioconductor package for differential expression analysis of digital gene expression data, 
based on a negative binomial distribution. To ensure reliable gene expression 
measurements, genes with less than 1 read per million mappable reads were removed. A 
p-value was calculated both for differential expression of the drug disposition genes 
between the 20 fetal and pediatric samples and between the 20 pediatric and adult 
samples analyzed for RNA-seq. Benjamini-Hochberg’s algorithm was used to control the 
FDR (Benjamini et al., 2001). 
 
Inverse correlations 
A linear regression model considering developmental periods as a cofactor was used to 
identify inverse correlations between the expression levels of the developmentally 
changing miRNAs and the drug disposition mRNA expression levels. The resultant p-
values were FDR corrected using Benjamini-Hochberg (Benjamini et al., 2001). 
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Results 
miRNA expression changes with developmental periods 
To determine miRNA expression patterns across the fetal, pediatric (0-18 years old), and 
adult (over 18 years old) developmental periods, we detected the expression of 533 
miRNAs in 90 liver samples using a predesigned, commercially-available TaqMan 
OpenArray MicroRNA panel for humans. The estimated fetal ages ranged from 15-24 
weeks, pediatric from 1-17 years (average=8.6 years), and adults 28-80 years 
(average=54.5). These liver samples consisted of 43 male and 35 female donors (the sex 
of the remaining samples was unknown) and 16, 10, 1 and 63 samples were from 
Caucasian, African-American, Hispanic or unknown ethnicity, respectively. We also 
measured three of these miRNAs, each in a unique set of 20 samples using single TaqMan 
assays to validate patterns in the Open Array platform (Figure 2). miRNAs that did not 
generate threshold cycle values in at least 6 samples in a given developmental period 
were excluded from analysis unless that miRNA was not expressed in the group at all. 
Only miRNAs that were statistically significant after false discovery rate (FDR) correction 
are discussed. FDR was used to adjust for multiple comparisons as the expression of over 
500 miRNAs were measured which could lead to increased Type I error (false positives). 
It is of note that, FDR is a less stringent correction method than the Bonferroni correction, 
which is designed to eliminate the probability of even one Type I error at the risk of 
increasing the Type II error. Since our next steps are to validate these changes in miRNA 
expression and determine their targets, the FDR correction method was appropriate.  
  
 22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Quantification of selected miRNAs by TaqMan OpenArrays and by 
individual TaqMan assays 
Comparison of miRNA expression among 20 randomly selected human liver samples 
between TaqMan OpenArray (OA) and individual TaqMan assays (S). Fetal (Red), 
Pediatric (Blue), Adult (Green). 
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Next, we created a Principal Components Analysis (PCA), a tool that is often used to 
visualize the distance and relatedness between populations. As shown in the PCA, the 
expression profiles for the fetal group are distinctly separated from the pediatric and adult 
groups (Figure 3). Hierarchical clustering, using Spearman Rank Dissimilarity, was 
implemented to depict the grouping of both samples and miRNAs (Figure 4) and reveal 
71% dissimilarity between the fetal group and the pediatric/adult groups. Although not as 
dramatic, there are notable dissimilarities among the pediatric and adult groups as well. 
There are also clusters of miRNAs that are significantly upregulated and downregulated 
together among the developmental groups. We primarily focus on the top 45 
developmentally-regulated miRNAs between the groups (first 20 in each category of Table 
2 and all in Table 3) in the results and discussion. To enable comparisons with previously 
published literature, the alternative nomenclature for select miRNAs are provided (Table 
1). The -5p and -3p refers to the mature products produced by either the 5’ or 3’ arm of 
the hairpin precursor (i.e. miR-625-5p and miR-625-3p). The # or * refers to the strand of 
the miRNA considered nonfunctional or expressed at lower concentrations. However, it 
has been shown that that the miR* sequences can be functional and may be dependent 
on tissue type and other factors (Czech and Hannon, 2011; Griffiths-Jones et al., 2011; 
Yang et al., 2011). 
 
During the transition from the fetal to the pediatric period, 114 miRNAs were upregulated 
and 72 miRNAs were downregulated (Table 2). Between the pediatric and adult periods, 
two miRNAs were upregulated and three were downregulated (Table 3). An example of 
miRNA expression changes in each category of Table 2 & 3 is provided in dot plots of 
individual miRNA threshold cycle (CT) values (Figure 5) (Note: An increase in CT values 
indicate a decrease in miRNA expression. miRNAs that do not generate a CT value are 
assigned a value of 40 indicating that it is undetected). Figure 5A shows an increase in 
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let-7a-5p between the fetal and pediatric/adult group whereas Figure 5B shows a 
decrease in miR-431-5p expression between these groups. Figure 5C & 5D depicts the 
gradual increase and decrease in expression of miR-34a-5p and miR-18a-5p, 
respectively, across the developmental periods. 
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Figure 3: Principal components analysis of developmentally-regulated miRNAs 
Principal components analysis of all 533 miRNAs measured using TaqMan OpenArray. 
Axes are principal components 1, 2, and 3. Fetal (Red), Pediatric (Blue), Adult (Green). 
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Figure 4: Heatmap of all developmentally-regulated miRNAs in human liver samples 
Hierarchical clustering of miRNA expression levels using Spearman Rank Dissimilarity. X-
axis: miRNAs. Y-axis: 90 samples across the 3 developmental periods. Fetal (Red), 
Pediatric (Blue), Adult (Green). Color scale below the figure shows increasing expression 
from blue to gray to red. 
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Table 1: miRNA naming using alternative designations 
miRNA 
Alternative 
Name 
TaqMan 
Assay # 
Sequence 
let-7a-5p let-7a 377 UGAGGUAGUAGGUUGUAUAGUU 
let-7b-5p let-7b 2619 UGAGGUAGUAGGUUGUGUGGUU 
let-7e-5p let-7e 2406 UGAGGUAGGAGGUUGUAUAGUU 
let-7f-5p let-7f 382 UGAGGUAGUAGAUUGUAUAGUU 
let-7g-5p let-7g 2282 UGAGGUAGUAGUUUGUACAGUU 
miR-106a-5p miR-106a 2169 AAAAGUGCUUACAGUGCAGGUAG 
miR-10a-5p miR-10a 387 UACCCUGUAGAUCCGAAUUUGUG 
miR-10b-5p miR-10b 2218 UACCCUGUAGAACCGAAUUUGUG 
miR-10b-3p miR-10b# 2315 ACAGAUUCGAUUCUAGGGGAAU 
miR-122-3p miR-122# 2130 AACGCCAUUAUCACACUAAAUA 
miR-1244 miR-1244 2791 AAGUAGUUGGUUUGUAUGAGAUGGUU 
miR-125b-5p miR-125b 449 UCCCUGAGACCCUAACUUGUGA 
miR-126-5p miR-126# 451 CAUUAUUACUUUUGGUACGCG 
miR-1271-5p miR-1271 2779 CUUGGCACCUAGCAAGCACUCA 
miR-1275 miR-1275 2840 GUGGGGGAGAGGCUGUC 
miR-128a-3p miR-128a 2216 UCACAGUGAACCGGUCUCUUU 
miR-130a-3p miR-130a 454 CAGUGCAAUGUUAAAAGGGCAU 
miR-132-3p miR-132 457 UAACAGUCUACAGCCAUGGUCG 
miR-136-3p miR-136# 2100 CAUCAUCGUCUCAAAUGAGUCU 
miR-139-3p miR-139-3p 2313 GGAGACGCGGCCCUGUUGGAGU 
miR-139-5p miR-139-5p 2289 UCUACAGUGCACGUGUCUCCAG 
miR-140-3p miR-140-3p 2234 UACCACAGGGUAGAACCACGG 
miR-144-5p miR-144# 2148 GGAUAUCAUCAUAUACUGUAAG 
miR-148b-3p miR-148b 471 UCAGUGCAUCACAGAACUUUGU 
miR-154-3p miR-154# 478 AAUCAUACACGGUUGACCUAUU 
miR-18a-5p miR-18a 2422 UAAGGUGCAUCUAGUGCAGAUAG 
miR-20a-3p miR-20a# 2437 ACUGCAUUAUGAGCACUUAAAG 
miR-200a-3p miR-200a 502 UAACACUGUCUGGUAACGAUGU 
miR-200b-3p miR-200b 2251 UAAUACUGCCUGGUAAUGAUGA 
miR-219a-5p miR-219 522 UGAUUGUCCAAACGCAAUUCU 
miR-30a-3p miR-30a-3p 416 CUUUCAGUCGGAUGUUUGCAGC 
miR-34a-5p miR-34a 426 UGGCAGUGUCUUAGCUGGUUGU 
miR-382-5p miR-382 572 GAAGUUGUUCGUGGUGGAUUCG 
miR-409-3p miR-409-3p 2332 GAAUGUUGCUCGGUGAACCCCU 
miR-411-5p miR-411 1610 UAGUAGACCGUAUAGCGUACG 
miR-431-5p miR-431 1979 UGUCUUGCAGGCCGUCAUGCA 
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miR-432-5p miR-432 1026 UCUUGGAGUAGGUCAUUGGGUGG 
miR-433-3p miR-433 1028 AUCAUGAUGGGCUCCUCGGUGU 
miR-483-3p miR-483-3p 2339 UCACUCCUCUCCUCCCGUCUU 
miR-485-3p miR-485-3p 1277 GUCAUACACGGCUCUCCUCUCU 
miR-487a-3p miR-487a 1279 AAUCAUACAGGGACAUCCAGUU 
miR-512-3p miR-512-3p 1823 AAGUGCUGUCAUAGCUGAGGUC 
miR-515-3p miR-515-3p 2369 GAGUGCCUUCUUUUGGAGCGUU 
miR-519a-3p miR-519a 2415 AAAGUGCAUCCUUUUAGAGUGU 
miR-519e-5p miR-519e# 1166 UUCUCCAAAAGGGAGCACUUUC 
miR-539-5p miR-539 1286 GGAGAAAUUAUCCUUGGUGUGU 
miR-625-5p miR-625 2431 AGGGGGAAAGUUCUAUAGUCC 
miR-668-3p miR-668 1992 UGUCACUCGGCUCGGCCCACUAC 
miR-889-3p miR-889 2202 UUAAUAUCGGACAACCAUUGU 
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Table 2: List of differentially expressed miRNAs between fetal and pediatric 
samples 
 
Upregulated     
miRNAs* p-value FDR** Fold Change 
miR-497-5p 8.60E-27 2.90E-25 > 500 
miR-139-5p 6.20E-26 2.00E-24 3.7 
miR-29c-3p 2.00E-23 5.00E-22 7.9 
miR-195-5p 1.80E-20 3.70E-19 34 
miR-23b-3p 4.80E-19 8.90E-18 4.9 
miR-579-3p 9.60E-19 1.60E-17 131.4 
miR-576-3p 3.20E-18 5.30E-17 18.3 
miR-29a-5p 1.80E-17 2.60E-16 21.2 
miR-29b-2-5p 2.10E-17 3.00E-16 > 500 
miR-511-5p 4.00E-17 5.40E-16 10 
miR-145-3p 1.40E-16 1.80E-15 178.5 
miR-22-5p 2.60E-16 3.20E-15 6.2 
let-7a-5p 4.70E-16 5.50E-15 2.1 
miR-505-3p 1.40E-15 1.60E-14 64.1 
miR-505-5p 1.80E-15 1.90E-14 33.5 
miR-29b-3p 2.30E-15 2.40E-14 7.4 
miR-99a-3p 3.40E-15 3.40E-14 44 
miR-628-3p 8.30E-15 7.80E-14 58.1 
miR-27b-5p 9.40E-15 8.60E-14 5.5 
miR-193b-5p 3.40E-14 2.90E-13 42.3 
miR-10a-5p 4.90E-14 4.00E-13 3.4 
miR-374a-3p 6.00E-14 4.60E-13 79.9 
miR-590-5p 2.60E-13 1.90E-12 4 
miR-132-3p 2.70E-13 2.00E-12 3.7 
miR-146b-3p 1.40E-12 9.80E-12 43.3 
miR-378a-5p 1.90E-12 1.20E-11 246.8 
miR-885-5p 2.80E-12 1.80E-11 2.6 
let-7b-5p 5.00E-12 3.20E-11 > 500 
miR-30a-3p 5.50E-12 3.50E-11 3.3 
miR-152-3p 5.80E-12 3.60E-11 2.5 
miR-340-3p 6.40E-12 3.90E-11 4.1 
miR-194-3p 2.30E-11 1.40E-10 12.4 
miR-24-2-5p 2.40E-11 1.40E-10 92.9 
miR-146b-5p 3.40E-11 2.00E-10 3.6 
miR-590-3p 3.70E-11 2.10E-10 13.3 
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Upregulated cont’d     
miRNAs* p-value FDR** Fold Change 
miR-193a-5p 5.00E-11 2.90E-10 2.4 
miR-148b-5p 5.70E-11 3.20E-10 13.3 
miR-125b-5p 6.80E-11 3.80E-10 2.2 
miR-362-3p 6.90E-11 3.80E-10 8.5 
miR-422a 1.20E-10 6.60E-10 242.7 
miR-374a-5p 3.00E-10 1.50E-09 1.9 
miR-455-5p 8.90E-10 4.20E-09 2.1 
miR-211-5p 9.10E-10 4.30E-09 106.8 
miR-151a-5p 1.40E-09 6.60E-09 4.3 
miR-30e-3p 2.10E-09 9.60E-09 2 
miR-24-3p 3.30E-09 1.50E-08 2 
miR-192-3p 5.10E-09 2.30E-08 4.3 
miR-27a-5p 5.60E-09 2.40E-08 10.8 
miR-744-3p 9.00E-09 3.90E-08 4.1 
miR-32-5p 1.20E-08 5.00E-08 22.8 
miR-95-3p 1.40E-08 5.80E-08 27.6 
miR-27a-3p 1.40E-08 6.10E-08 2.4 
miR-383-5p 2.00E-08 8.60E-08 9.9 
miR-592 2.30E-08 9.80E-08 13.1 
let-7g-5p 3.10E-08 1.30E-07 1.7 
miR-1275 3.30E-08 1.30E-07 3 
miR-939-5p 3.60E-08 1.50E-07 61.3 
miR-597-5p 3.90E-08 1.60E-07 24.9 
miR-186-5p 5.90E-08 2.30E-07 1.8 
miR-28-3p 1.60E-07 6.40E-07 2.2 
miR-28-5p 2.00E-07 7.80E-07 2 
miR-99a-5p 2.30E-07 8.60E-07 1.8 
miR-122-3p 3.00E-07 1.10E-06 9.2 
miR-502-3p 3.40E-07 1.20E-06 8.6 
miR-26b-5p 6.50E-07 2.30E-06 1.9 
miR-200a-3p 7.00E-07 2.40E-06 2.7 
miR-628-5p 7.00E-07 2.40E-06 48.5 
miR-455-3p 9.30E-07 3.20E-06 1.9 
miR-21-5p 1.60E-06 5.20E-06 13.4 
miR-452-5p 1.60E-06 5.30E-06 4.1 
miR-148b-3p 4.30E-06 1.30E-05 1.8 
miR-155-5p 4.60E-06 1.40E-05 7.1 
miR-194-5p 6.90E-06 2.10E-05 1.8 
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Upregulated cont’d     
miRNAs* p-value FDR** Fold Change 
miR-375 1.30E-05 3.60E-05 2.7 
miR-143-3p 1.50E-05 4.20E-05 1.8 
miR-1271-5p 2.30E-05 6.40E-05 4.2 
miR-139-3p 2.40E-05 6.80E-05 19.5 
miR-128a-3p 3.10E-05 8.70E-05 1.6 
miR-223-5p 4.80E-05 1.30E-04 3.2 
miR-26a-5p 5.40E-05 1.50E-04 1.7 
miR-625-5p 6.30E-05 1.70E-04 3.2 
miR-216b-5p 7.70E-05 2.10E-04 9.6 
miR-423-5p 8.50E-05 2.30E-04 1.6 
miR-26b-3p 1.10E-04 2.90E-04 4 
miR-17-5p  1.20E-04 3.00E-04 469.2 
miR-34a-5p 1.60E-04 4.10E-04 1.7 
miR-31-5p 2.10E-04 5.20E-04 9.8 
miR-212-3p 2.20E-04 5.60E-04 7.6 
miR-10b-5p 5.60E-04 1.30E-03 9.1 
miR-106a-5p 7.50E-04 1.80E-03 151.9 
miR-199a-5p 9.40E-04 2.20E-03 1.7 
miR-146a-5p 1.00E-03 2.30E-03 38 
miR-126-5p 1.30E-03 3.00E-03 1.5 
miR-330-3p 2.00E-03 4.60E-03 3.9 
miR-320b 2.20E-03 4.90E-03 1.9 
miR-150-5p 2.40E-03 5.30E-03 6.7 
miR-10b-3p 2.80E-03 6.10E-03 17.3 
miR-27b-3p 3.30E-03 7.20E-03 1.4 
let-7f-5p 3.50E-03 7.60E-03 1.5 
miR-331-3p 3.70E-03 8.00E-03 1.4 
miR-424-5p 4.30E-03 9.10E-03 3.8 
miR-140-3p 4.50E-03 9.50E-03 2.2 
miR-145-5p 5.60E-03 1.20E-02 22.2 
miR-532-3p 6.10E-03 1.30E-02 1.2 
miR-142-5p 6.60E-03 1.40E-02 3.4 
let-7e-5p 8.80E-03 1.80E-02 1.3 
miR-671-3p 8.60E-03 1.80E-02 2.9 
miR-30a-5p 9.60E-03 1.90E-02 1.5 
miR-197-3p 1.20E-02 2.40E-02 1.3 
miR-1244 1.80E-02 3.40E-02 1.9 
miR-15a-3p 2.20E-02 4.10E-02 6.7 
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miR-199a-3p 2.20E-02 4.20E-02 1.4 
miR-30d-5p 2.20E-02 4.20E-02 1.5 
miR-19b-3p 2.70E-02 4.90E-02 12.7 
Downregulated     
miRNAs p-value FDR Fold Change 
miR-431-5p 1.00E-58 5.50E-56 < -500 
miR-668-3p 5.00E-42 1.30E-39 < -500 
miR-539-5p 3.30E-36 4.30E-34 -101.6 
miR-411-5p 8.30E-36 8.90E-34 -18.2 
miR-409-3p 2.10E-34 1.60E-32 -30.8 
miR-889-3p 4.70E-32 3.10E-30 -39 
miR-433-3p 6.00E-32 3.60E-30 < -500 
miR-483-3p 2.00E-30 1.10E-28 -52.6 
miR-136-3p 3.20E-30 1.50E-28 -26.1 
miR-512-3p 5.50E-30 2.50E-28 < -500 
miR-432-5p 5.90E-28 2.20E-26 < -500 
miR-485-3p 5.60E-28 2.20E-26 < -500 
miR-382-5p 8.70E-28 3.10E-26 < -500 
miR-487a-3p 3.80E-25 1.10E-23 < -500 
miR-519e-5p 1.20E-24 3.40E-23 < -500 
miR-130a-3p 3.10E-24 8.30E-23 -3.7 
miR-515-3p 7.30E-23 1.80E-21 < -500 
miR-154-3p 1.00E-22 2.30E-21 < -500 
miR-144-5p 2.60E-21 5.80E-20 < -500 
miR-519a-3p 2.20E-20 4.40E-19 < -500 
miR-526b-5p 4.00E-20 7.60E-19 < -500 
miR-377-5p 8.40E-19 1.50E-17 < -500 
miR-221-3p 6.90E-18 1.10E-16 -3 
miR-654-5p 2.30E-17 3.20E-16 < -500 
miR-301a-3p 7.50E-17 1.00E-15 -4.9 
miR-519d-3p 1.90E-16 2.40E-15 < -500 
miR-494-3p 6.40E-16 7.20E-15 < -500 
miR-487b-3p 7.30E-16 8.10E-15 -389.5 
miR-18a-5p 2.30E-15 2.40E-14 -5.1 
miR-370-3p 4.70E-15 4.50E-14 -55.2 
miR-493-3p 1.60E-14 1.40E-13 < -500 
miR-154-5p 1.70E-14 1.40E-13 < -500 
miR-9-3p 2.80E-14 2.40E-13 -13.9 
miR-323a-3p 5.40E-14 4.20E-13 < -500 
miR-337-5p 8.00E-14 6.10E-13 -121.5 
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miR-543 1.60E-13 1.20E-12 -67 
miR-411-3p 3.00E-13 2.10E-12 < -500 
miR-758-3p 1.70E-12 1.10E-11 < -500 
miR-654-3p 3.30E-11 1.90E-10 -118.7 
miR-184 8.50E-11 4.60E-10 < -500 
miR-206 1.60E-10 8.10E-10 -234.8 
miR-324-5p 1.30E-09 6.00E-09 -2 
miR-185-5p 2.80E-09 1.30E-08 -2.6 
miR-376c-3p 3.10E-09 1.40E-08 < -500 
miR-9-5p 3.90E-08 1.60E-07 -15.6 
miR-410-3p 6.90E-08 2.70E-07 -98.7 
miR-652-3p 1.00E-07 4.00E-07 -2 
miR-1180-3p 1.10E-07 4.40E-07 -3.2 
miR-106b-5p 2.40E-07 8.90E-07 -1.6 
miR-20a-5p 4.40E-07 1.60E-06 -1.8 
miR-127-3p 4.70E-07 1.70E-06 -19.4 
miR-376a-3p 1.10E-06 3.90E-06 -30.5 
miR-99b-5p 1.60E-06 5.20E-06 -1.7 
miR-942-5p 2.50E-06 8.20E-06 -2.6 
miR-106b-3p 3.30E-06 1.00E-05 -5.1 
miR-19b-1-5p 5.00E-06 1.50E-05 -2.5 
miR-337-3p 7.50E-06 2.20E-05 -62.9 
miR-1247-5p 3.20E-05 8.80E-05 -117 
miR-25-3p 8.90E-05 2.40E-04 -1.6 
miR-181a-5p 1.00E-04 2.70E-04 -1.5 
miR-369-3p 3.10E-04 7.70E-04 -51.7 
miR-381-3p 4.20E-04 1.00E-03 -36.9 
miR-20b-5p 9.20E-04 2.20E-03 -5.5 
miR-93-3p 1.70E-03 4.00E-03 -1.8 
miR-744-5p 2.60E-03 5.80E-03 -1.6 
miR-335-5p 3.90E-03 8.40E-03 -1.5 
miR-339-3p 9.50E-03 1.90E-02 -1.4 
miR-222-3p 1.00E-02 2.00E-02 -1.6 
miR-425-5p 1.00E-02 2.00E-02 -3.5 
miR-16-5p 1.90E-02 3.60E-02 -1.3 
miR-141-3p 2.50E-02 4.60E-02 -8.1 
miR-483-5p 2.70E-02 4.90E-02 -4.4 
*The alternative nomenclature for select miRNAs and TaqMan assay IDs are provided in 
Table 1, to allow relation of our data to that utilized in other reports using the # 
designation over the -3p or -5p designations. 
**False discovery rate comparing fetal vs. pediatric 
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Note: A 2-fold change means there is a 2-fold higher increase in miRNA expression from 
fetal to pediatric human liver tissues.  
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Table 3: List of differentially expressed miRNAs between pediatric and adult 
samples 
 
Downregulated       
miRNA p-value FDR* Fold Change 
miR-18a-5p 1.4E-05 3.7E-03 -2.0 
miR-20a-3p 7.8E-05 1.4E-02 -2.0 
miR-219a-5p 1.7E-04 2.3E-02 -12.0 
Upregulated       
miRNA p-value FDR* Fold Change 
miR-34a-5p 1.6E-06 8.3E-04 2.1 
miR-30a-3p 3.2E-04 3.4E-02 1.7 
*False discovery rate comparing pediatric vs. adult 
Note: A 2-fold change means there is a 2-fold higher increase in miRNA expression from 
pediatric to adult. 
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Figure 5:  Dot plots of miRNAs that changed across the developmental periods 
Dot plots of individual miRNA threshold cycle (CT) values in the 90 samples. (Note: Increase in CT value indicates a decrease in miRNA 
expression) A. let-7a-5p increasing expression between fetal and pediatric/adult groups. B. miR-431-5p decreasing expression 
between fetal and pediatric/adult groups. C. miR-34a-5p gradually increasing in expression with age. D. miR-18a-5p gradually 
decreasing in expression with age. X-axis: There are three batches across the 90 samples, 1, 2, 3 as the qPCR instrument could only 
analyze a max of 30 samples at a time. As a result, there is a batch effect that was corrected for in all statistical analyses. Y-axis: CT 
Values. Fetal (Red), Pediatric (Blue), Adult (Green).                                                                                  .
A 
C 
B 
D  
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Inverse correlation of expression of miRNAs and pharmacogene mRNAs 
Over 14,000 human genes were analyzed using RNA-seq in 30 randomly selected liver 
samples from our 90 human liver samples (10 samples per age group). Figure 6 displays 
the developmental expression patterns of 34 genes involved in drug absorption, 
distribution, metabolism, excretion (ADME); also included are several genes that regulate 
the expression of these ADME genes (Figure 6 & Table 4). Among those genes, 
expression of 28 mRNAs increased and expression of 3 decreased from fetal to pediatric 
and two increased and five decreased from pediatric to adult. CYP2D6 and UGT2B17 
gene expression levels were among those that increased from pediatric to adult while 
CYP1A1, CYP1A2, CYP2C19, GSTM1, and SLCO1B3 expression levels decreased from 
pediatric to adult. CYP3A7, GSTP1, and SLC15A2 expression decreased from fetal to 
pediatric/adult while most of the others increased. These findings are consistent with 
previous findings regarding the developmental expression profiles for these 
pharmacogenes (de Wildt et al., 1999; Hines, 2008, 2013; Mooij et al., 2014). 
 
A linear regression model was used to determine negative correlations between the 
expression levels of the developmentally changing miRNAs and the mRNA expression 
levels of pharmacogenes. In order to eliminate bias due to the difference in the expression 
levels of these miRNAs and mRNAs, we considered developmental periods as a cofactor 
while searching for inverse correlations between the miRNA and target genes. The 
negative estimates shown in Table 5 indicate the changes in mRNA expression. Estimates 
indicate the changes in mRNA expressed as RPKM (reads per kilobases per million) per 
one CT value decrease in miRNA expression. More abundantly expressed mRNA in our 
data such as CYP2E1 (RPKM values ranging from 3.3-3085) will result in larger estimated 
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changes of mRNA levels compared to genes with less abundant mRNA such as ABCG2 
(.4-7.5) (data not shown). We observed over 1000 negative correlations (Table 5). 
 
In silico identification of miRNAs predicted to target the mRNA of top 
pharmacogenes 
Predicted miRNA target analysis was performed using Ingenuity Pathway Analysis. This 
program identifies predicted and experimentally validated targets from multiple databases. 
Among the developmentally-regulated miRNAs and 34 pharmacogenes, 93 predictions 
and six experimentally validated targets were revealed involving 27 genes and 67 miRNAs 
(Table 6). Eighteen of these predictions overlapped with the negatively correlated miRNA-
mRNA combinations (Table 5). 
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Figure 6: Heatmap of the mRNA expression of pharmacogenes across the 
developmental periods 
Hierarchical clustering of ADME and regulatory gene mRNA using Spearman Rank 
Dissimilarity. X-axis: mRNAs. Y-axis: 30 samples across the 3 developmental periods 
(Red: Fetal, Blue: Pediatric, Green: Adult). Color scale below the figure shows increasing 
expression from blue to gray to red. *SLC22A2 and SLC22A6 are excluded due to 
insufficient reads in the majority of samples. 
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Table 4: mRNA expression of pharmacogenes 
 
  Fetal vs. Pediatric Pediatric vs. Adult 
Gene logFC1 logCPM2 p-value FDR3 logFC logCPM p-value FDR 
ABCB1 3.1 5.8 3.0E-37 6.1E-36 0.0 6.5 9.9E-01 1.0 
ABCC2 1.8 8.6 4.0E-15 2.9E-14 -0.5 8.9 1.1E-01 7.5E-01 
ABCG2 -0.3 5.0 5.8E-02 9.4E-02 -0.4 4.5 2.8E-01 1.0 
CYP1A1 6.8 6.4 2.2E-111 4.0E-109 -1.9 6.8 2.0E-04 1.4E-02 
CYP1A2 8.7 7.4 4.4E-150 5.5E-147 -1.9 7.8 3.9E-05 3.9E-03 
CYP2A6 8.2 7.7 2.8E-144 1.9E-141 -0.4 8.4 2.8E-01 1.0 
CYP2B6 7.8 9.2 2.3E-143 1.4E-140 -0.9 9.7 8.5E-03 2.0E-01 
CYP2C19 7.9 6.9 1.3E-132 3.8E-130 -2.5 7.0 1.9E-15 3.8E-12 
CYP2C8 7.3 9.2 2.7E-133 8.1E-131 -0.5 9.9 1.6E-01 8.6E-01 
CYP2C9 7.5 8.8 6.0E-134 1.9E-131 -0.5 9.5 2.4E-01 1.0 
CYP2D6 4.9 5.2 1.6E-71 9.2E-70 0.9 6.6 1.4E-04 1.1E-02 
CYP2E1 8.2 11.6 1.3E-159 3.2E-156 -0.4 12.2 2.0E-01 9.1E-01 
CYP3A4 7.1 9.4 3.7E-128 9.8E-126 0.0 10.5 1.2E-01 7.7E-01 
CYP3A5 3.8 8.7 7.8E-55 2.8E-53 -0.2 9.4 6.7E-01 1.0 
CYP3A7 -3.2 9.8 8.4E-43 2.1E-41 0.4 7.5 5.2E-02 5.5E-01 
DPYD 0.3 6.9 2.0E-01 2.7E-01 -0.1 6.9 7.6E-01 1.0 
GSTM1 3.4 4.5 1.2E-40 2.8E-39 -2.1 4.6 1.4E-13 2.1E-10 
GSTP1 -3.0 5.8 9.6E-35 1.8E-33 -0.2 3.5 6.6E-01 1.0 
GSTT1 2.0 4.9 1.2E-16 9.8E-16 -0.8 5.1 2.2E-03 7.9E-02 
HNF4A 1.1 6.8 5.4E-07 2.0E-06 -0.1 7.1 7.8E-01 1.0 
NAT1 0.4 3.0 1.1E-01 1.6E-01 0.1 3.1 8.0E-01 1.0 
NAT2 7.0 3.6 3.6E-80 2.6E-78 0.0 4.5 9.1E-01 1.0 
NR1I2 3.8 5.1 2.4E-50 7.2E-49 0.1 5.9 9.0E-01 1.0 
NR1I3 1.8 4.7 4.5E-14 3.1E-13 -0.5 5.0 9.9E-02 7.2E-01 
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SLC15A2 -1.1 2.4 1.1E-04 2.9E-04 0.7 1.9 5.9E-02 5.9E-01 
SLC22A1 7.1 7.1 4.6E-124 1.1E-121 -0.1 7.9 6.8E-01 1.0 
SLCO1B1 1.5 7.5 5.1E-10 2.6E-09 -0.1 7.9 9.6E-01 1.0 
SLCO1B3 1.3 7.4 3.1E-09 1.5E-08 -1.0 7.3 1.6E-04 1.2E-02 
SULT1A1 0.6 4.6 6.3E-03 1.3E-02 0.0 4.7 8.6E-01 1.0 
TPMT 2.2 5.1 8.6E-21 9.0E-20 -0.2 5.6 4.5E-01 1.0 
UGT1A1 8.1 8.3 5.4E-146 5.0E-143 -0.5 9.0 1.9E-01 9.0E-01 
UGT2B15 4.4 5.7 1.9E-64 8.8E-63 0.7 6.9 8.6E-03 2.0E-01 
UGT2B17 3.6 0.9 3.4E-21 3.6E-20 3.0 3.9 1.2E-23 8.2E-20 
UGT2B7 4.5 6.6 2.0E-64 9.4E-63 -0.2 7.3 6.6E-01 1.0 
1 log2 fold change 
2 log2 counts per million 
3 false discovery rate 
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Table 5: Negative correlations between developmental miRNA and the mRNA of top 
pharmacogenes 
 
  Gene miRNA p-value FDR Estimate* 
Phase I CYP1A1 miR-223-5p 4.44E-03 2.32E-02 -7.2 
  CYP1A1 miR-27b-5p 8.83E-03 3.73E-02 -13.1 
  CYP1A1 miR-497-5p 9.68E-03 3.95E-02 -4.2 
  CYP1A2 miR-223-5p 4.86E-05 1.50E-03 -13.8 
  CYP1A2 miR-27b-5p 2.59E-04 3.96E-03 -24.8 
  CYP1A2 miR-592 4.27E-04 5.32E-03 -8.8 
  CYP1A2 miR-744-3p 6.61E-04 6.72E-03 -13.5 
  CYP1A2 miR-148b-5p 9.48E-04 8.48E-03 -9.7 
  CYP1A2 miR-99a-3p 3.19E-03 1.87E-02 -7.1 
  CYP1A2 miR-31-5p 3.49E-03 1.97E-02 -4.3 
  CYP1A2 miR-199a-5p 4.92E-03 2.50E-02 -16.7 
  CYP1A2 miR-497-5p 5.87E-03 2.82E-02 -6.4 
  CYP1A2 miR-200a-3p 6.40E-03 2.98E-02 -21.1 
  CYP1A2 miR-151a-5p 7.03E-03 3.18E-02 -9.5 
  CYP1A2 miR-505-5p 8.58E-03 3.66E-02 -5.6 
  CYP1A2 miR-30e-3p 8.75E-03 3.70E-02 -21.3 
  CYP2A6 miR-505-5p 1.95E-05 8.58E-04 -20.2 
  CYP2A6 miR-192-3p 2.54E-05 1.02E-03 -37.5 
  CYP2A6 miR-625-5p 5.87E-05 1.66E-03 -18.3 
  CYP2A6 miR-151a-5p 8.20E-05 2.02E-03 -31.8 
  CYP2A6 miR-375 8.75E-05 2.09E-03 -25.4 
  CYP2A6 miR-340-3p 1.05E-04 2.26E-03 -41.1 
  CYP2A6 miR-99a-3p 1.20E-04 2.44E-03 -21.6 
  CYP2A6 miR-194-3p 1.30E-04 2.56E-03 -24.7 
  CYP2A6 miR-26b-3p 1.63E-04 2.94E-03 -31.0 
  CYP2A6 miR-148b-5p 2.27E-04 3.59E-03 -26.0 
  CYP2A6 miR-505-3p 3.66E-04 4.92E-03 -19.0 
  CYP2A6 miR-195-5p 3.86E-04 5.04E-03 -28.7 
  CYP2A6 miR-28-5p 4.11E-04 5.21E-03 -63.3 
  CYP2A6 miR-576-3p 4.72E-04 5.64E-03 -23.4 
  CYP2A6 miR-146b-3p 4.77E-04 5.67E-03 -19.2 
  CYP2A6 miR-331-3p 4.85E-04 5.71E-03 -62.0 
  CYP2A6 miR-452-5p 5.48E-04 6.13E-03 -29.4 
  CYP2A6 miR-197-3p 6.45E-04 6.63E-03 -82.0 
  CYP2A6 miR-324-5p 6.98E-04 6.95E-03 -79.3 
  CYP2A6 miR-590-3p 7.41E-04 7.22E-03 -31.9 
  CYP2A6 miR-497-5p 7.88E-04 7.46E-03 -18.5 
  CYP2A6 miR-320b 8.53E-04 7.90E-03 -24.9 
  CYP2A6 miR-335-5p 8.78E-04 7.99E-03 -71.4 
  CYP2A6 miR-30e-3p 9.43E-04 8.45E-03 -63.9 
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  CYP2A6 miR-223-5p 1.01E-03 8.81E-03 -28.8 
  CYP2A6 miR-31-5p 1.27E-03 1.00E-02 -11.5 
  CYP2A6 miR-199a-5p 1.40E-03 1.07E-02 -45.8 
  CYP2A6 miR-152-3p 1.51E-03 1.12E-02 -73.0 
  CYP2A6 miR-22-5p 1.97E-03 1.35E-02 -25.9 
  CYP2A6 miR-301a-3p 2.00E-03 1.37E-02 -50.9 
  CYP2A6 miR-511-5p 2.19E-03 1.45E-02 -30.2 
  CYP2A6 miR-148b-3p 2.44E-03 1.55E-02 -57.2 
  CYP2A6 miR-221-3p 2.72E-03 1.66E-02 -79.2 
  CYP2A6 miR-216b-5p 3.53E-03 1.99E-02 -12.1 
  CYP2A6 miR-29b-3p 3.62E-03 2.01E-02 -48.6 
  CYP2A6 miR-28-3p 3.75E-03 2.07E-02 -43.5 
  CYP2A6 miR-592 4.14E-03 2.20E-02 -18.2 
  CYP2A6 miR-26b-5p 6.20E-03 2.91E-02 -107.7 
  CYP2A6 miR-193a-5p 6.62E-03 3.04E-02 -55.9 
  CYP2A6 miR-199a-3p 7.71E-03 3.39E-02 -40.6 
  CYP2A6 miR-30d-5p 8.58E-03 3.66E-02 -50.4 
  CYP2A6 miR-10a-5p 1.08E-02 4.27E-02 -44.2 
  CYP2A6 miR-590-5p 1.09E-02 4.28E-02 -67.1 
  CYP2A6 miR-27a-3p 1.15E-02 4.44E-02 -47.1 
  CYP2A6 miR-502-3p 1.23E-02 4.68E-02 -14.4 
  CYP2A6 miR-27b-5p 1.30E-02 4.84E-02 -44.4 
  CYP2A6 miR-378a-5p 1.31E-02 4.85E-02 -11.7 
  CYP2B6 miR-223-5p 1.93E-05 8.58E-04 -52.0 
  CYP2B6 miR-592 2.15E-05 9.14E-04 -36.7 
  CYP2B6 miR-505-5p 2.74E-05 1.05E-03 -29.5 
  CYP2B6 miR-151a-5p 3.28E-05 1.18E-03 -48.8 
  CYP2B6 miR-192-3p 3.40E-05 1.20E-03 -54.8 
  CYP2B6 miR-148b-5p 4.10E-05 1.35E-03 -41.6 
  CYP2B6 miR-99a-3p 6.21E-05 1.70E-03 -32.9 
  CYP2B6 miR-340-3p 1.96E-04 3.25E-03 -58.9 
  CYP2B6 miR-146b-3p 2.94E-04 4.24E-03 -29.2 
  CYP2B6 miR-26b-3p 3.18E-04 4.51E-03 -44.3 
  CYP2B6 miR-375 3.71E-04 4.95E-03 -34.8 
  CYP2B6 miR-194-3p 4.15E-04 5.21E-03 -34.3 
  CYP2B6 miR-31-5p 4.49E-04 5.46E-03 -18.2 
  CYP2B6 miR-497-5p 5.58E-04 6.16E-03 -28.0 
  CYP2B6 miR-30e-3p 5.73E-04 6.23E-03 -97.6 
  CYP2B6 miR-199a-5p 5.82E-04 6.23E-03 -72.0 
  CYP2B6 miR-195-5p 5.77E-04 6.23E-03 -41.4 
  CYP2B6 miR-625-5p 7.09E-04 7.02E-03 -23.8 
  CYP2B6 miR-576-3p 1.20E-03 9.73E-03 -32.6 
  CYP2B6 miR-221-3p 1.57E-03 1.15E-02 -122.4 
  CYP2B6 miR-28-5p 1.61E-03 1.17E-02 -85.4 
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  CYP2B6 miR-197-3p 1.71E-03 1.22E-02 -113.3 
  CYP2B6 miR-27b-5p 1.76E-03 1.24E-02 -80.0 
  CYP2B6 miR-744-3p 1.79E-03 1.26E-02 -46.0 
  CYP2B6 miR-335-5p 1.94E-03 1.33E-02 -99.6 
  CYP2B6 miR-29a-5p 2.13E-03 1.42E-02 -20.9 
  CYP2B6 miR-331-3p 2.27E-03 1.48E-02 -82.2 
  CYP2B6 miR-30d-5p 3.20E-03 1.87E-02 -82.2 
  CYP2B6 miR-452-5p 3.28E-03 1.90E-02 -38.1 
  CYP2B6 miR-320b 3.36E-03 1.93E-02 -33.1 
  CYP2B6 miR-324-5p 3.81E-03 2.09E-02 -102.8 
  CYP2B6 miR-152-3p 4.00E-03 2.15E-02 -99.5 
  CYP2B6 miR-199a-3p 5.38E-03 2.65E-02 -62.3 
  CYP2B6 miR-511-5p 6.18E-03 2.90E-02 -40.5 
  CYP2B6 miR-505-3p 6.24E-03 2.92E-02 -22.6 
  CYP2B6 miR-22-5p 6.29E-03 2.93E-02 -34.4 
  CYP2B6 miR-590-3p 9.22E-03 3.82E-02 -38.0 
  CYP2B6 miR-29b-3p 9.58E-03 3.92E-02 -65.0 
  CYP2B6 miR-216b-5p 9.90E-03 4.01E-02 -16.0 
  CYP2B6 miR-27a-3p 9.98E-03 4.04E-02 -70.7 
  CYP2B6 miR-148b-3p 1.03E-02 4.12E-02 -73.2 
  CYP2B6 miR-27a-5p 1.18E-02 4.54E-02 -29.6 
  CYP2C19 miR-452-5p 1.54E-04 2.82E-03 -18.2 
  CYP2C19 miR-27a-3p 5.19E-04 5.90E-03 -35.4 
  CYP2C19 miR-26b-3p 1.58E-03 1.16E-02 -15.6 
  CYP2C19 miR-505-3p 1.85E-03 1.29E-02 -9.8 
  CYP2C19 miR-199a-3p 2.73E-03 1.66E-02 -25.9 
  CYP2C19 miR-31-5p 3.09E-03 1.82E-02 -6.2 
  CYP2C19 miR-200a-3p 4.07E-03 2.18E-02 -31.4 
  CYP2C19 miR-195-5p 4.12E-03 2.19E-02 -13.9 
  CYP2C19 miR-199a-5p 5.54E-03 2.71E-02 -23.5 
  CYP2C19 miR-192-3p 5.68E-03 2.75E-02 -15.5 
  CYP2C19 miR-497-5p 5.92E-03 2.83E-02 -9.0 
  CYP2C19 miR-505-5p 7.23E-03 3.24E-02 -8.1 
  CYP2C19 miR-186-5p 8.74E-03 3.70E-02 -47.3 
  CYP2C19 miR-223-5p 9.05E-03 3.77E-02 -13.7 
  CYP2C19 miR-216b-5p 9.40E-03 3.86E-02 -6.3 
  CYP2C19 miR-143-3p 1.24E-02 4.68E-02 -38.7 
  CYP2C8 miR-223-5p 8.74E-06 5.15E-04 -74.4 
  CYP2C8 miR-99a-3p 3.29E-05 1.18E-03 -47.1 
  CYP2C8 miR-148b-5p 4.84E-05 1.50E-03 -57.6 
  CYP2C8 miR-505-5p 1.14E-04 2.36E-03 -38.7 
  CYP2C8 miR-197-3p 1.62E-04 2.93E-03 -182.7 
  CYP2C8 miR-151a-5p 2.32E-04 3.66E-03 -62.3 
  CYP2C8 miR-199a-5p 2.60E-04 3.96E-03 -105.1 
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  CYP2C8 miR-30e-3p 2.63E-04 3.97E-03 -142.4 
  CYP2C8 miR-375 2.93E-04 4.24E-03 -49.2 
  CYP2C8 miR-497-5p 2.91E-04 4.24E-03 -40.5 
  CYP2C8 miR-216b-5p 3.26E-04 4.58E-03 -29.4 
  CYP2C8 miR-590-3p 3.29E-04 4.60E-03 -69.1 
  CYP2C8 miR-340-3p 5.57E-04 6.16E-03 -77.4 
  CYP2C8 miR-331-3p 6.27E-04 6.51E-03 -125.7 
  CYP2C8 miR-192-3p 6.69E-04 6.77E-03 -65.7 
  CYP2C8 miR-27b-5p 6.99E-04 6.95E-03 -119.0 
  CYP2C8 miR-505-3p 6.99E-04 6.95E-03 -37.6 
  CYP2C8 miR-31-5p 7.26E-04 7.15E-03 -24.6 
  CYP2C8 miR-625-5p 7.55E-04 7.31E-03 -33.0 
  CYP2C8 miR-22-5p 9.85E-04 8.67E-03 -56.1 
  CYP2C8 miR-590-5p 9.99E-04 8.73E-03 -172.0 
  CYP2C8 miR-29b-3p 1.02E-03 8.84E-03 -110.7 
  CYP2C8 miR-152-3p 1.28E-03 1.00E-02 -152.3 
  CYP2C8 miR-195-5p 1.47E-03 1.11E-02 -54.2 
  CYP2C8 miR-28-5p 1.88E-03 1.31E-02 -117.6 
  CYP2C8 miR-146b-3p 2.03E-03 1.38E-02 -35.8 
  CYP2C8 miR-592 2.17E-03 1.43E-02 -39.8 
  CYP2C8 miR-511-5p 2.98E-03 1.77E-02 -60.6 
  CYP2C8 miR-200a-3p 3.06E-03 1.81E-02 -115.2 
  CYP2C8 miR-320b 3.14E-03 1.84E-02 -46.4 
  CYP2C8 miR-532-3p 3.44E-03 1.96E-02 -226.9 
  CYP2C8 miR-576-3p 3.45E-03 1.96E-02 -41.7 
  CYP2C8 miR-27a-5p 3.48E-03 1.97E-02 -47.0 
  CYP2C8 miR-374a-3p 3.74E-03 2.06E-02 -30.2 
  CYP2C8 miR-26b-3p 4.99E-03 2.52E-02 -50.4 
  CYP2C8 miR-335-5p 5.08E-03 2.55E-02 -127.5 
  CYP2C8 miR-502-3p 6.59E-03 3.04E-02 -32.0 
  CYP2C8 miR-452-5p 7.80E-03 3.41E-02 -48.7 
  CYP2C8 miR-24-3p 8.38E-03 3.60E-02 -74.8 
  CYP2C8 miR-194-3p 8.84E-03 3.73E-02 -37.2 
  CYP2C8 miR-132-3p 1.32E-02 4.88E-02 -113.9 
  CYP2C8 miR-324-5p 1.34E-02 4.95E-02 -125.0 
  CYP2C8 miR-148b-3p 1.34E-02 4.95E-02 -98.8 
  CYP2C8 miR-378a-5p 1.34E-02 4.95E-02 -24.0 
  CYP2C9 miR-99a-3p 2.62E-05 1.04E-03 -37.7 
  CYP2C9 miR-505-5p 3.34E-05 1.19E-03 -32.4 
  CYP2C9 miR-223-5p 5.31E-05 1.58E-03 -55.3 
  CYP2C9 miR-192-3p 5.88E-05 1.66E-03 -59.3 
  CYP2C9 miR-148b-5p 8.85E-05 2.10E-03 -44.6 
  CYP2C9 miR-497-5p 1.25E-04 2.51E-03 -33.6 
  CYP2C9 miR-151a-5p 1.26E-04 2.52E-03 -51.0 
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  CYP2C9 miR-375 1.32E-04 2.57E-03 -40.7 
  CYP2C9 miR-340-3p 1.50E-04 2.79E-03 -66.0 
  CYP2C9 miR-199a-5p 1.93E-04 3.25E-03 -84.8 
  CYP2C9 miR-197-3p 2.20E-04 3.54E-03 -142.8 
  CYP2C9 miR-195-5p 2.60E-04 3.96E-03 -48.0 
  CYP2C9 miR-31-5p 2.61E-04 3.96E-03 -20.7 
  CYP2C9 miR-30e-3p 4.15E-04 5.21E-03 -110.2 
  CYP2C9 miR-216b-5p 4.16E-04 5.21E-03 -23.1 
  CYP2C9 miR-625-5p 4.41E-04 5.39E-03 -27.1 
  CYP2C9 miR-331-3p 4.92E-04 5.75E-03 -101.3 
  CYP2C9 miR-26b-3p 5.48E-04 6.13E-03 -47.5 
  CYP2C9 miR-505-3p 5.55E-04 6.16E-03 -30.3 
  CYP2C9 miR-146b-3p 6.05E-04 6.42E-03 -31.0 
  CYP2C9 miR-452-5p 6.09E-04 6.42E-03 -47.8 
  CYP2C9 miR-28-5p 7.45E-04 7.25E-03 -99.8 
  CYP2C9 miR-592 8.34E-04 7.76E-03 -33.9 
  CYP2C9 miR-29b-3p 1.06E-03 9.05E-03 -87.7 
  CYP2C9 miR-590-3p 1.07E-03 9.05E-03 -51.0 
  CYP2C9 miR-576-3p 1.09E-03 9.16E-03 -36.3 
  CYP2C9 miR-27b-5p 1.13E-03 9.39E-03 -91.5 
  CYP2C9 miR-152-3p 1.16E-03 9.55E-03 -121.8 
  CYP2C9 miR-194-3p 1.45E-03 1.10E-02 -34.9 
  CYP2C9 miR-320b 1.63E-03 1.18E-02 -38.9 
  CYP2C9 miR-335-5p 2.26E-03 1.48E-02 -108.9 
  CYP2C9 miR-511-5p 2.49E-03 1.58E-02 -48.8 
  CYP2C9 miR-22-5p 2.89E-03 1.74E-02 -41.0 
  CYP2C9 miR-27a-3p 2.89E-03 1.74E-02 -88.7 
  CYP2C9 miR-590-5p 2.94E-03 1.76E-02 -125.6 
  CYP2C9 miR-200a-3p 3.27E-03 1.90E-02 -91.0 
  CYP2C9 miR-502-3p 5.17E-03 2.58E-02 -26.0 
  CYP2C9 miR-148b-3p 5.73E-03 2.77E-02 -86.4 
  CYP2C9 miR-324-5p 5.76E-03 2.78E-02 -109.4 
  CYP2C9 miR-27a-5p 6.02E-03 2.85E-02 -35.4 
  CYP2C9 miR-221-3p 7.44E-03 3.30E-02 -117.6 
  CYP2C9 miR-199a-3p 7.77E-03 3.41E-02 -66.3 
  CYP2C9 miR-24-3p 8.38E-03 3.60E-02 -59.4 
  CYP2C9 miR-374a-3p 1.02E-02 4.10E-02 -21.6 
  CYP2C9 miR-28-3p 1.03E-02 4.13E-02 -64.0 
  CYP2C9 miR-532-3p 1.05E-02 4.18E-02 -160.5 
  CYP2C9 miR-193a-5p 1.05E-02 4.18E-02 -86.9 
  CYP2C9 miR-378a-5p 1.13E-02 4.38E-02 -19.5 
  CYP2C9 miR-26b-5p 1.34E-02 4.94E-02 -161.3 
  CYP2D6 miR-216b-5p 4.65E-07 7.27E-05 -3.5 
  CYP2D6 miR-497-5p 1.32E-05 6.82E-04 -4.3 
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  CYP2D6 miR-29b-3p 3.10E-05 1.13E-03 -12.4 
  CYP2D6 miR-502-3p 7.10E-05 1.85E-03 -4.1 
  CYP2D6 miR-374a-3p 9.78E-05 2.18E-03 -3.6 
  CYP2D6 miR-99a-3p 1.08E-04 2.31E-03 -4.2 
  CYP2D6 miR-31-5p 1.44E-04 2.70E-03 -2.5 
  CYP2D6 miR-30e-3p 2.14E-04 3.48E-03 -13.5 
  CYP2D6 miR-532-3p 2.39E-04 3.73E-03 -25.5 
  CYP2D6 miR-340-3p 2.74E-04 4.10E-03 -7.5 
  CYP2D6 miR-511-5p 2.83E-04 4.19E-03 -6.7 
  CYP2D6 miR-22-5p 3.39E-04 4.71E-03 -5.6 
  CYP2D6 miR-145-3p 4.98E-04 5.80E-03 -2.6 
  CYP2D6 miR-195-5p 5.25E-04 5.95E-03 -5.4 
  CYP2D6 miR-375 5.79E-04 6.23E-03 -4.4 
  CYP2D6 miR-320b 6.79E-04 6.84E-03 -4.9 
  CYP2D6 miR-590-5p 1.03E-03 8.88E-03 -16.1 
  CYP2D6 miR-28-5p 1.06E-03 9.04E-03 -11.5 
  CYP2D6 miR-590-3p 1.06E-03 9.04E-03 -6.0 
  CYP2D6 miR-132-3p 1.31E-03 1.02E-02 -13.3 
  CYP2D6 miR-152-3p 1.37E-03 1.05E-02 -14.2 
  CYP2D6 miR-579-3p 1.48E-03 1.11E-02 -4.5 
  CYP2D6 miR-199a-5p 1.58E-03 1.16E-02 -8.8 
  CYP2D6 miR-10b-3p 1.69E-03 1.21E-02 -2.3 
  CYP2D6 miR-24-3p 1.82E-03 1.27E-02 -8.1 
  CYP2D6 miR-505-3p 2.01E-03 1.37E-02 -3.3 
  CYP2D6 miR-452-5p 2.10E-03 1.41E-02 -5.2 
  CYP2D6 miR-505-5p 2.13E-03 1.42E-02 -3.0 
  CYP2D6 miR-331-3p 2.16E-03 1.43E-02 -10.8 
  CYP2D6 miR-592 2.30E-03 1.49E-02 -3.7 
  CYP2D6 miR-34a-5p 2.32E-03 1.51E-02 -13.3 
  CYP2D6 miR-30a-5p 2.35E-03 1.52E-02 -9.5 
  CYP2D6 miR-29c-3p 2.54E-03 1.60E-02 -9.9 
  CYP2D6 miR-576-3p 3.52E-03 1.98E-02 -3.9 
  CYP2D6 miR-223-5p 4.09E-03 2.19E-02 -5.0 
  CYP2D6 miR-155-5p 4.92E-03 2.50E-02 -6.1 
  CYP2D6 miR-200a-3p 5.25E-03 2.61E-02 -10.3 
  CYP2D6 miR-27b-5p 5.81E-03 2.80E-02 -9.4 
  CYP2D6 miR-197-3p 5.82E-03 2.80E-02 -13.2 
  CYP2D6 miR-148b-5p 5.84E-03 2.81E-02 -4.0 
  CYP2D6 miR-27b-3p 6.27E-03 2.93E-02 -9.4 
  CYP2D6 miR-625-5p 8.98E-03 3.76E-02 -2.5 
  CYP2D6 miR-30a-3p 1.22E-02 4.66E-02 -8.5 
  CYP2D6 miR-335-5p 1.23E-02 4.67E-02 -10.8 
  CYP2D6 miR-151a-5p 1.24E-02 4.69E-02 -4.2 
  CYP2D6 miR-125b-5p 1.30E-02 4.84E-02 -13.0 
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  CYP2E1 miR-216b-5p 1.53E-07 4.76E-05 -149.5 
  CYP2E1 miR-502-3p 5.54E-06 3.70E-04 -187.0 
  CYP2E1 miR-29b-3p 1.16E-05 6.48E-04 -539.2 
  CYP2E1 miR-31-5p 6.36E-05 1.73E-03 -109.7 
  CYP2E1 miR-125b-5p 7.89E-05 1.96E-03 -795.4 
  CYP2E1 miR-152-3p 1.03E-04 2.25E-03 -691.2 
  CYP2E1 miR-219a-5p 1.03E-04 2.25E-03 -131.8 
  CYP2E1 miR-497-5p 1.29E-04 2.55E-03 -165.7 
  CYP2E1 miR-24-3p 1.36E-04 2.61E-03 -397.0 
  CYP2E1 miR-199a-5p 1.49E-04 2.78E-03 -424.2 
  CYP2E1 miR-200a-3p 1.78E-04 3.09E-03 -546.1 
  CYP2E1 miR-452-5p 1.88E-04 3.21E-03 -252.3 
  CYP2E1 miR-29c-3p 2.08E-04 3.39E-03 -489.4 
  CYP2E1 miR-132-3p 4.62E-04 5.58E-03 -597.3 
  CYP2E1 miR-99a-3p 6.38E-04 6.58E-03 -159.4 
  CYP2E1 miR-532-3p 6.46E-04 6.64E-03 -1009.7 
  CYP2E1 miR-331-3p 6.64E-04 6.73E-03 -491.0 
  CYP2E1 miR-579-3p 6.90E-04 6.90E-03 -200.6 
  CYP2E1 miR-505-3p 7.10E-04 7.02E-03 -147.4 
  CYP2E1 miR-590-3p 7.17E-04 7.08E-03 -258.7 
  CYP2E1 miR-195-5p 7.28E-04 7.15E-03 -223.2 
  CYP2E1 miR-34a-5p 7.49E-04 7.27E-03 -604.7 
  CYP2E1 miR-27a-3p 8.34E-04 7.76E-03 -481.5 
  CYP2E1 miR-27b-5p 8.72E-04 7.99E-03 -460.1 
  CYP2E1 miR-28-5p 9.82E-04 8.67E-03 -484.0 
  CYP2E1 miR-23b-3p 1.34E-03 1.04E-02 -561.4 
  CYP2E1 miR-27b-3p 1.47E-03 1.11E-02 -447.5 
  CYP2E1 miR-30e-3p 1.48E-03 1.11E-02 -500.1 
  CYP2E1 miR-155-5p 1.60E-03 1.17E-02 -283.2 
  CYP2E1 miR-145-3p 1.71E-03 1.22E-02 -101.3 
  CYP2E1 miR-143-3p 1.78E-03 1.25E-02 -656.8 
  CYP2E1 miR-27a-5p 2.12E-03 1.41E-02 -192.2 
  CYP2E1 miR-375 2.40E-03 1.54E-02 -167.3 
  CYP2E1 miR-505-5p 2.47E-03 1.57E-02 -125.1 
  CYP2E1 miR-223-5p 2.70E-03 1.66E-02 -216.1 
  CYP2E1 miR-374a-3p 2.77E-03 1.68E-02 -121.6 
  CYP2E1 miR-378a-5p 3.25E-03 1.89E-02 -109.7 
  CYP2E1 miR-511-5p 3.49E-03 1.97E-02 -234.2 
  CYP2E1 miR-151a-5p 3.63E-03 2.02E-02 -201.7 
  CYP2E1 miR-186-5p 3.79E-03 2.08E-02 -721.6 
  CYP2E1 miR-29b-2-5p 4.53E-03 2.35E-02 -100.8 
  CYP2E1 miR-193a-5p 4.70E-03 2.42E-02 -467.9 
  CYP2E1 miR-590-5p 5.00E-03 2.52E-02 -590.6 
  CYP2E1 miR-10b-3p 5.76E-03 2.78E-02 -87.2 
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  CYP2E1 miR-628-3p 5.83E-03 2.80E-02 -117.9 
  CYP2E1 miR-340-3p 7.26E-03 3.25E-02 -246.1 
  CYP2E1 miR-21-5p 7.48E-03 3.32E-02 -168.1 
  CYP2E1 miR-26b-5p 9.37E-03 3.86E-02 -832.0 
  CYP2E1 miR-423-5p 9.64E-03 3.94E-02 -438.2 
  CYP2E1 miR-30a-3p 1.01E-02 4.06E-02 -365.1 
  CYP2E1 miR-625-5p 1.11E-02 4.36E-02 -102.0 
  CYP2E1 miR-26b-3p 1.17E-02 4.53E-02 -179.8 
  CYP2E1 miR-146b-3p 1.24E-02 4.69E-02 -117.1 
  CYP2E1 miR-197-3p 1.30E-02 4.84E-02 -506.6 
  CYP3A4 miR-375 8.52E-05 2.07E-03 -67.7 
  CYP3A4 miR-99a-3p 9.52E-05 2.17E-03 -58.3 
  CYP3A4 miR-340-3p 1.89E-04 3.22E-03 -106.4 
  CYP3A4 miR-505-5p 2.94E-04 4.24E-03 -47.7 
  CYP3A4 miR-576-3p 4.02E-04 5.15E-03 -63.0 
  CYP3A4 miR-148b-5p 4.05E-04 5.17E-03 -67.2 
  CYP3A4 miR-590-3p 4.83E-04 5.70E-03 -87.5 
  CYP3A4 miR-192-3p 5.51E-04 6.16E-03 -86.1 
  CYP3A4 miR-30e-3p 5.79E-04 6.23E-03 -176.0 
  CYP3A4 miR-31-5p 6.10E-04 6.42E-03 -32.2 
  CYP3A4 miR-320b 6.92E-04 6.90E-03 -67.3 
  CYP3A4 miR-223-5p 1.06E-03 9.05E-03 -76.6 
  CYP3A4 miR-151a-5p 1.30E-03 1.02E-02 -72.4 
  CYP3A4 miR-22-5p 1.39E-03 1.07E-02 -70.8 
  CYP3A4 miR-592 1.71E-03 1.22E-02 -52.5 
  CYP3A4 miR-194-3p 2.01E-03 1.37E-02 -55.5 
  CYP3A4 miR-27b-5p 2.43E-03 1.55E-02 -140.6 
  CYP3A4 miR-497-5p 2.62E-03 1.63E-02 -45.1 
  CYP3A4 miR-331-3p 2.72E-03 1.66E-02 -146.0 
  CYP3A4 miR-511-5p 2.73E-03 1.66E-02 -78.9 
  CYP3A4 miR-195-5p 3.44E-03 1.96E-02 -65.4 
  CYP3A4 miR-29b-3p 3.56E-03 2.00E-02 -129.7 
  CYP3A4 miR-199a-5p 4.32E-03 2.27E-02 -111.3 
  CYP3A4 miR-625-5p 4.49E-03 2.33E-02 -37.1 
  CYP3A4 miR-28-5p 4.81E-03 2.46E-02 -140.2 
  CYP3A4 miR-146b-3p 5.54E-03 2.71E-02 -42.3 
  CYP3A4 miR-152-3p 6.52E-03 3.01E-02 -170.9 
  CYP3A4 miR-26b-3p 7.04E-03 3.18E-02 -62.9 
  CYP3A4 miR-335-5p 7.33E-03 3.27E-02 -158.8 
  CYP3A4 miR-324-5p 7.64E-03 3.37E-02 -173.0 
  CYP3A4 miR-200a-3p 8.15E-03 3.53E-02 -135.3 
  CYP3A4 miR-197-3p 8.69E-03 3.70E-02 -175.5 
  CYP3A4 miR-30d-5p 8.90E-03 3.74E-02 -133.9 
  CYP3A4 miR-505-3p 8.93E-03 3.75E-02 -39.2 
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  CYP3A4 miR-29a-5p 1.02E-02 4.09E-02 -32.3 
  CYP3A4 miR-590-5p 1.04E-02 4.17E-02 -179.9 
  CYP3A4 miR-216b-5p 1.24E-02 4.69E-02 -28.1 
  CYP3A4 miR-221-3p 1.33E-02 4.91E-02 -179.0 
  CYP3A5 miR-216b-5p 6.33E-06 4.08E-04 -8.1 
  CYP3A5 miR-590-3p 1.23E-05 6.51E-04 -18.7 
  CYP3A5 miR-590-5p 4.74E-05 1.49E-03 -47.4 
  CYP3A5 miR-29b-3p 7.33E-05 1.88E-03 -30.0 
  CYP3A5 miR-99a-3p 1.53E-04 2.82E-03 -10.3 
  CYP3A5 miR-378a-5p 2.36E-04 3.70E-03 -7.8 
  CYP3A5 miR-497-5p 2.62E-04 3.96E-03 -9.5 
  CYP3A5 miR-152-3p 5.26E-04 5.95E-03 -37.8 
  CYP3A5 miR-27b-5p 6.80E-04 6.84E-03 -27.9 
  CYP3A5 miR-28-5p 9.32E-04 8.38E-03 -29.0 
  CYP3A5 miR-340-3p 1.11E-03 9.22E-03 -17.3 
  CYP3A5 miR-532-3p 1.15E-03 9.48E-03 -58.0 
  CYP3A5 miR-199a-5p 1.16E-03 9.53E-03 -22.4 
  CYP3A5 miR-22-5p 1.22E-03 9.81E-03 -12.9 
  CYP3A5 miR-151a-5p 1.27E-03 1.00E-02 -13.1 
  CYP3A5 miR-374a-3p 1.69E-03 1.21E-02 -7.6 
  CYP3A5 miR-148b-5p 1.80E-03 1.26E-02 -11.0 
  CYP3A5 miR-505-5p 1.84E-03 1.28E-02 -7.6 
  CYP3A5 miR-195-5p 1.85E-03 1.29E-02 -12.5 
  CYP3A5 miR-30e-3p 2.02E-03 1.37E-02 -29.1 
  CYP3A5 miR-576-3p 2.57E-03 1.60E-02 -10.0 
  CYP3A5 miR-375 2.71E-03 1.66E-02 -9.9 
  CYP3A5 miR-200a-3p 2.91E-03 1.75E-02 -27.1 
  CYP3A5 miR-625-5p 3.09E-03 1.82E-02 -6.9 
  CYP3A5 miR-320b 3.23E-03 1.88E-02 -10.8 
  CYP3A5 miR-192-3p 3.49E-03 1.97E-02 -13.6 
  CYP3A5 miR-23b-3p 3.59E-03 2.00E-02 -30.9 
  CYP3A5 miR-132-3p 3.73E-03 2.06E-02 -30.5 
  CYP3A5 miR-511-5p 3.84E-03 2.09E-02 -13.9 
  CYP3A5 miR-26b-5p 4.42E-03 2.31E-02 -53.7 
  CYP3A5 miR-331-3p 4.89E-03 2.49E-02 -25.0 
  CYP3A5 miR-27a-3p 5.07E-03 2.55E-02 -24.8 
  CYP3A5 miR-452-5p 5.96E-03 2.84E-02 -11.7 
  CYP3A5 miR-505-3p 5.97E-03 2.84E-02 -7.4 
  CYP3A5 miR-31-5p 6.14E-03 2.89E-02 -4.8 
  CYP3A5 miR-502-3p 6.46E-03 3.00E-02 -7.5 
  CYP3A5 miR-34a-5p 6.87E-03 3.12E-02 -30.0 
  CYP3A5 miR-193a-5p 7.08E-03 3.19E-02 -26.8 
  CYP3A5 miR-27b-3p 8.09E-03 3.51E-02 -22.9 
  CYP3A5 miR-148b-3p 8.51E-03 3.64E-02 -24.4 
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  CYP3A5 miR-223-5p 9.29E-03 3.84E-02 -11.4 
  CYP3A5 miR-24-3p 1.00E-02 4.06E-02 -17.1 
  CYP3A5 miR-27a-5p 1.05E-02 4.18E-02 -9.8 
  CYP3A5 miR-194-5p 1.25E-02 4.72E-02 -34.7 
  CYP3A7 miR-431-5p 2.97E-11 6.88E-08 -34.4 
  CYP3A7 miR-668-3p 1.25E-10 2.17E-07 -42.0 
  CYP3A7 miR-889-3p 8.14E-08 3.33E-05 -94.7 
  CYP3A7 miR-539-5p 1.43E-07 4.74E-05 -93.8 
  CYP3A7 miR-485-3p 1.64E-07 4.76E-05 -24.3 
  CYP3A7 miR-493-3p 2.78E-07 5.69E-05 -36.5 
  CYP3A7 miR-512-3p 2.67E-07 5.69E-05 -26.1 
  CYP3A7 miR-487a-3p 4.48E-07 7.27E-05 -33.6 
  CYP3A7 miR-483-3p 5.47E-07 7.46E-05 -73.1 
  CYP3A7 miR-487b-3p 1.80E-06 1.76E-04 -61.4 
  CYP3A7 miR-382-5p 3.14E-06 2.54E-04 -25.7 
  CYP3A7 miR-519a-3p 6.53E-06 4.17E-04 -29.4 
  CYP3A7 miR-433-3p 8.21E-06 4.88E-04 -31.2 
  CYP3A7 miR-323a-3p 1.26E-05 6.60E-04 -50.0 
  CYP3A7 miR-154-3p 7.48E-05 1.90E-03 -28.1 
  CYP3A7 miR-18a-5p 1.12E-04 2.35E-03 -109.7 
  CYP3A7 miR-654-5p 1.38E-04 2.63E-03 -26.2 
  CYP3A7 miR-19b-1-5p 1.75E-04 3.07E-03 -105.6 
  CYP3A7 miR-526b-5p 1.86E-04 3.20E-03 -38.2 
  CYP3A7 miR-370-3p 2.03E-04 3.35E-03 -28.9 
  CYP3A7 miR-144-5p 2.08E-04 3.39E-03 -35.4 
  CYP3A7 miR-411-5p 3.42E-04 4.71E-03 -98.7 
  CYP3A7 miR-483-5p 6.10E-04 6.42E-03 -110.9 
  CYP3A7 miR-410-3p 6.81E-04 6.85E-03 -27.4 
  CYP3A7 miR-758-3p 6.86E-04 6.89E-03 -24.6 
  CYP3A7 miR-494-3p 1.02E-03 8.84E-03 -26.5 
  CYP3A7 miR-519d-3p 1.87E-03 1.30E-02 -23.0 
  CYP3A7 miR-409-3p 1.92E-03 1.32E-02 -79.0 
  CYP3A7 miR-130a-3p 2.56E-03 1.60E-02 -188.2 
  CYP3A7 miR-136-3p 3.02E-03 1.79E-02 -82.6 
  CYP3A7 miR-519e-5p 3.54E-03 1.99E-02 -21.9 
  CYP3A7 miR-376a-3p 4.96E-03 2.51E-02 -70.1 
  CYP3A7 miR-432-5p 4.96E-03 2.51E-02 -24.2 
  CYP3A7 miR-16-5p 6.89E-03 3.12E-02 -78.4 
  CYP3A7 miR-19b-3p 9.38E-03 3.86E-02 -83.1 
  CYP3A7 miR-377-5p 1.01E-02 4.08E-02 -30.7 
  CYP3A7 miR-184 1.07E-02 4.25E-02 -19.2 
Phase II DPYD miR-223-5p 1.12E-02 4.38E-02 -0.6 
 GSTM1 miR-744-3p 6.33E-07 8.15E-05 -6.9 
 GSTM1 miR-592 3.46E-05 1.20E-03 -3.9 
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 GSTM1 miR-29a-5p 1.39E-04 2.64E-03 -2.7 
 GSTM1 miR-374a-3p 2.93E-03 1.75E-02 -2.4 
 GSTM1 miR-223-5p 6.77E-03 3.09E-02 -3.9 
 GSTM1 miR-497-5p 1.12E-02 4.38E-02 -2.3 
 GSTP1 miR-431-5p 3.57E-13 2.48E-09 -4.7 
 GSTP1 miR-668-3p 2.62E-11 6.88E-08 -5.7 
 GSTP1 miR-483-3p 5.16E-10 5.98E-07 -10.9 
 GSTP1 miR-382-5p 5.05E-10 5.98E-07 -4.0 
 GSTP1 miR-889-3p 4.98E-09 4.33E-06 -13.2 
 GSTP1 miR-493-3p 1.27E-07 4.66E-05 -5.0 
 GSTP1 miR-487a-3p 1.43E-07 4.74E-05 -4.6 
 GSTP1 miR-512-3p 2.45E-07 5.69E-05 -3.5 
 GSTP1 miR-485-3p 2.58E-07 5.69E-05 -3.2 
 GSTP1 miR-539-5p 3.66E-07 6.36E-05 -12.3 
 GSTP1 miR-487b-3p 9.26E-07 1.09E-04 -8.3 
 GSTP1 miR-654-5p 1.68E-06 1.70E-04 -4.1 
 GSTP1 miR-370-3p 2.16E-06 1.96E-04 -4.6 
 GSTP1 miR-519a-3p 5.11E-06 3.52E-04 -4.0 
 GSTP1 miR-323a-3p 5.39E-06 3.66E-04 -6.9 
 GSTP1 miR-154-3p 1.18E-05 6.49E-04 -4.0 
 GSTP1 miR-433-3p 1.96E-05 8.58E-04 -4.0 
 GSTP1 miR-18a-5p 5.66E-05 1.63E-03 -15.1 
 GSTP1 miR-758-3p 8.76E-05 2.09E-03 -3.7 
 GSTP1 miR-519d-3p 9.35E-05 2.15E-03 -3.7 
 GSTP1 miR-432-5p 1.22E-04 2.46E-03 -4.2 
 GSTP1 miR-526b-5p 1.34E-04 2.59E-03 -5.2 
 GSTP1 miR-411-5p 1.82E-04 3.14E-03 -13.6 
 GSTP1 miR-184 2.36E-04 3.70E-03 -3.5 
 GSTP1 miR-494-3p 2.78E-04 4.14E-03 -3.8 
 GSTP1 miR-19b-1-5p 3.86E-04 5.04E-03 -13.5 
 GSTP1 miR-409-3p 3.96E-04 5.10E-03 -11.7 
 GSTP1 miR-483-5p 8.12E-04 7.61E-03 -14.5 
 GSTP1 miR-410-3p 1.08E-03 9.11E-03 -3.6 
 GSTP1 miR-127-3p 1.16E-03 9.55E-03 -3.3 
 GSTP1 miR-130a-3p 1.17E-03 9.57E-03 -26.7 
 GSTP1 miR-144-5p 1.21E-03 9.78E-03 -4.3 
 GSTP1 let-7f-5p 2.30E-03 1.49E-02 -7.4 
 GSTP1 miR-19b-3p 5.50E-03 2.69E-02 -11.8 
 GSTP1 miR-515-3p 5.99E-03 2.84E-02 -3.2 
 GSTP1 miR-20b-5p 8.77E-03 3.71E-02 -3.0 
 GSTP1 miR-376c-3p 9.21E-03 3.81E-02 -1.8 
 GSTT1 miR-223-5p 9.91E-04 8.69E-03 -3.4 
 GSTT1 miR-197-3p 3.48E-03 1.97E-02 -8.4 
 GSTT1 miR-148b-5p 7.99E-03 3.48E-02 -2.3 
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 NAT1 miR-452-5p 4.33E-03 2.27E-02 -0.1 
 NAT1 miR-590-5p 5.98E-03 2.84E-02 -0.4 
 NAT1 miR-197-3p 8.15E-03 3.53E-02 -0.4 
 NAT1 miR-216b-5p 8.29E-03 3.57E-02 -0.1 
 NAT2 miR-216b-5p 2.58E-07 5.69E-05 -1.0 
 NAT2 miR-29b-3p 2.74E-05 1.05E-03 -3.7 
 NAT2 miR-497-5p 3.10E-05 1.13E-03 -1.2 
 NAT2 miR-532-3p 4.83E-05 1.50E-03 -8.1 
 NAT2 miR-197-3p 7.44E-05 1.90E-03 -5.2 
 NAT2 miR-502-3p 3.29E-04 4.60E-03 -1.1 
 NAT2 miR-99a-3p 3.76E-04 5.00E-03 -1.2 
 NAT2 miR-590-3p 5.19E-04 5.90E-03 -1.9 
 NAT2 miR-28-5p 5.63E-04 6.16E-03 -3.5 
 NAT2 miR-511-5p 5.79E-04 6.23E-03 -1.9 
 NAT2 miR-340-3p 6.62E-04 6.72E-03 -2.1 
 NAT2 miR-452-5p 7.84E-04 7.45E-03 -1.6 
 NAT2 miR-374a-3p 8.65E-04 7.97E-03 -0.9 
 NAT2 miR-590-5p 8.72E-04 7.99E-03 -4.8 
 NAT2 miR-199a-5p 8.86E-04 8.04E-03 -2.7 
 NAT2 miR-195-5p 1.02E-03 8.83E-03 -1.5 
 NAT2 miR-132-3p 1.19E-03 9.68E-03 -4.0 
 NAT2 miR-22-5p 1.36E-03 1.05E-02 -1.5 
 NAT2 miR-30e-3p 2.11E-03 1.41E-02 -3.4 
 NAT2 miR-378a-5p 2.16E-03 1.43E-02 -0.8 
 NAT2 miR-505-5p 2.69E-03 1.65E-02 -0.9 
 NAT2 miR-320b 2.70E-03 1.66E-02 -1.3 
 NAT2 miR-331-3p 3.00E-03 1.78E-02 -3.1 
 NAT2 miR-375 3.58E-03 2.00E-02 -1.1 
 NAT2 miR-625-5p 3.78E-03 2.08E-02 -0.8 
 NAT2 miR-34a-5p 4.79E-03 2.46E-02 -3.7 
 NAT2 miR-152-3p 5.17E-03 2.58E-02 -3.7 
 NAT2 miR-148b-5p 5.28E-03 2.62E-02 -1.2 
 NAT2 miR-579-3p 5.68E-03 2.75E-02 -1.2 
 NAT2 miR-146b-3p 5.89E-03 2.83E-02 -0.9 
 NAT2 miR-29c-3p 5.91E-03 2.83E-02 -2.7 
 NAT2 miR-24-3p 6.02E-03 2.85E-02 -2.1 
 NAT2 miR-505-3p 6.59E-03 3.04E-02 -0.9 
 NAT2 miR-592 6.98E-03 3.16E-02 -1.0 
 NAT2 miR-145-3p 7.37E-03 3.28E-02 -0.6 
 NAT2 miR-151a-5p 7.42E-03 3.30E-02 -1.3 
 NAT2 miR-335-5p 7.62E-03 3.36E-02 -3.4 
 NAT2 miR-31-5p 7.72E-03 3.39E-02 -0.6 
 NAT2 miR-223-5p 1.07E-02 4.23E-02 -1.3 
 NAT2 miR-193a-5p 1.08E-02 4.27E-02 -3.0 
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 NAT2 miR-155-5p 1.21E-02 4.62E-02 -1.6 
 NAT2 miR-29b-2-5p 1.27E-02 4.76E-02 -0.6 
 TPMT miR-216b-5p 1.14E-08 7.96E-06 -0.6 
 TPMT miR-29b-3p 1.59E-07 4.76E-05 -2.4 
 TPMT miR-497-5p 4.61E-07 7.27E-05 -0.8 
 TPMT miR-502-3p 7.06E-07 8.78E-05 -0.8 
 TPMT miR-99a-3p 1.09E-06 1.25E-04 -0.8 
 TPMT miR-452-5p 2.62E-06 2.25E-04 -1.2 
 TPMT miR-505-5p 9.11E-06 5.28E-04 -0.7 
 TPMT miR-511-5p 1.06E-05 5.99E-04 -1.3 
 TPMT miR-340-3p 1.26E-05 6.60E-04 -1.4 
 TPMT miR-199a-5p 1.36E-05 6.90E-04 -1.8 
 TPMT miR-195-5p 1.42E-05 7.13E-04 -1.1 
 TPMT miR-28-5p 1.96E-05 8.58E-04 -2.3 
 TPMT miR-590-3p 1.88E-05 8.58E-04 -1.2 
 TPMT miR-30e-3p 2.17E-05 9.14E-04 -2.4 
 TPMT miR-331-3p 2.78E-05 1.06E-03 -2.2 
 TPMT miR-375 4.31E-05 1.40E-03 -0.8 
 TPMT miR-320b 5.41E-05 1.59E-03 -0.9 
 TPMT miR-152-3p 6.08E-05 1.68E-03 -2.8 
 TPMT miR-151a-5p 6.13E-05 1.69E-03 -1.0 
 TPMT miR-625-5p 6.72E-05 1.78E-03 -0.6 
 TPMT miR-148b-5p 7.26E-05 1.87E-03 -0.9 
 TPMT miR-223-5p 9.33E-05 2.15E-03 -1.0 
 TPMT miR-31-5p 9.77E-05 2.18E-03 -0.4 
 TPMT miR-193a-5p 1.00E-04 2.22E-03 -2.4 
 TPMT miR-505-3p 1.25E-04 2.51E-03 -0.6 
 TPMT miR-532-3p 1.32E-04 2.57E-03 -4.3 
 TPMT miR-22-5p 1.32E-04 2.57E-03 -1.0 
 TPMT miR-592 2.49E-04 3.84E-03 -0.7 
 TPMT miR-34a-5p 2.88E-04 4.24E-03 -2.5 
 TPMT miR-24-3p 2.93E-04 4.24E-03 -1.5 
 TPMT miR-219a-5p 3.22E-04 4.55E-03 -0.5 
 TPMT miR-146b-3p 3.55E-04 4.82E-03 -0.6 
 TPMT miR-197-3p 4.35E-04 5.37E-03 -2.7 
 TPMT miR-374a-3p 4.38E-04 5.38E-03 -0.5 
 TPMT miR-192-3p 4.97E-04 5.80E-03 -1.0 
 TPMT miR-576-3p 6.31E-04 6.54E-03 -0.7 
 TPMT miR-29c-3p 7.61E-04 7.33E-03 -1.8 
 TPMT miR-579-3p 7.67E-04 7.36E-03 -0.8 
 TPMT miR-148b-3p 7.87E-04 7.46E-03 -2.0 
 TPMT miR-27b-3p 8.64E-04 7.97E-03 -1.8 
 TPMT miR-27b-5p 1.02E-03 8.83E-03 -1.8 
 TPMT miR-26b-3p 1.06E-03 9.04E-03 -0.9 
 55 
  Gene miRNA p-value FDR Estimate* 
 TPMT miR-23b-3p 1.37E-03 1.05E-02 -2.2 
 TPMT miR-26b-5p 1.55E-03 1.15E-02 -3.8 
 TPMT miR-27a-3p 1.62E-03 1.18E-02 -1.8 
 TPMT miR-186-5p 2.20E-03 1.45E-02 -3.0 
 TPMT miR-194-3p 2.24E-03 1.47E-02 -0.7 
 TPMT miR-28-3p 2.46E-03 1.56E-02 -1.4 
 TPMT miR-335-5p 2.50E-03 1.58E-02 -2.1 
 TPMT miR-378a-5p 2.71E-03 1.66E-02 -0.4 
 TPMT miR-301a-3p 2.95E-03 1.76E-02 -1.6 
 TPMT miR-27a-5p 3.36E-03 1.93E-02 -0.7 
 TPMT miR-125b-5p 3.69E-03 2.05E-02 -2.4 
 TPMT miR-590-5p 3.83E-03 2.09E-02 -2.4 
 TPMT miR-29b-2-5p 4.10E-03 2.19E-02 -0.4 
 TPMT miR-30a-3p 4.31E-03 2.27E-02 -1.6 
 TPMT miR-194-5p 5.33E-03 2.64E-02 -2.5 
 TPMT miR-145-3p 6.08E-03 2.87E-02 -0.4 
 TPMT miR-200a-3p 7.24E-03 3.24E-02 -1.6 
 TPMT miR-10a-5p 9.00E-03 3.77E-02 -1.4 
 TPMT miR-132-3p 1.28E-02 4.80E-02 -1.7 
 UGT1A1 miR-223-5p 1.60E-08 9.68E-06 -35.6 
 UGT1A1 miR-148b-5p 3.31E-08 1.77E-05 -29.0 
 UGT1A1 miR-505-5p 1.78E-07 4.76E-05 -19.6 
 UGT1A1 miR-99a-3p 3.56E-07 6.35E-05 -22.3 
 UGT1A1 miR-151a-5p 3.95E-07 6.70E-05 -32.2 
 UGT1A1 miR-375 2.03E-06 1.91E-04 -24.7 
 UGT1A1 miR-30e-3p 3.06E-06 2.53E-04 -70.3 
 UGT1A1 miR-340-3p 3.85E-06 2.94E-04 -39.7 
 UGT1A1 miR-192-3p 5.42E-06 3.66E-04 -33.7 
 UGT1A1 miR-497-5p 6.28E-06 4.08E-04 -19.7 
 UGT1A1 miR-199a-5p 7.93E-06 4.75E-04 -50.4 
 UGT1A1 miR-625-5p 1.02E-05 5.83E-04 -16.7 
 UGT1A1 miR-31-5p 1.14E-05 6.41E-04 -12.4 
 UGT1A1 miR-592 1.41E-05 7.11E-04 -21.5 
 UGT1A1 miR-27b-5p 2.00E-05 8.68E-04 -58.7 
 UGT1A1 miR-331-3p 2.75E-05 1.05E-03 -60.8 
 UGT1A1 miR-576-3p 3.33E-05 1.19E-03 -22.8 
 UGT1A1 miR-590-3p 3.57E-05 1.23E-03 -31.8 
 UGT1A1 miR-195-5p 3.85E-05 1.29E-03 -27.4 
 UGT1A1 miR-22-5p 4.26E-05 1.39E-03 -27.5 
 UGT1A1 miR-28-5p 5.94E-05 1.67E-03 -59.6 
 UGT1A1 miR-26b-3p 6.08E-05 1.68E-03 -27.8 
 UGT1A1 miR-505-3p 6.43E-05 1.73E-03 -17.7 
 UGT1A1 miR-320b 6.64E-05 1.78E-03 -24.4 
 UGT1A1 miR-152-3p 8.55E-05 2.07E-03 -73.7 
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  Gene miRNA p-value FDR Estimate* 
 UGT1A1 miR-194-3p 9.78E-05 2.18E-03 -21.4 
 UGT1A1 miR-511-5p 1.04E-04 2.26E-03 -31.1 
 UGT1A1 miR-146b-3p 1.04E-04 2.26E-03 -17.8 
 UGT1A1 miR-29b-3p 1.30E-04 2.56E-03 -51.7 
 UGT1A1 miR-216b-5p 1.43E-04 2.70E-03 -12.8 
 UGT1A1 miR-335-5p 2.47E-04 3.82E-03 -65.9 
 UGT1A1 miR-452-5p 3.30E-04 4.60E-03 -25.9 
 UGT1A1 miR-502-3p 3.38E-04 4.70E-03 -16.7 
 UGT1A1 miR-197-3p 6.25E-04 6.50E-03 -70.2 
 UGT1A1 miR-27a-5p 8.01E-04 7.53E-03 -21.8 
 UGT1A1 miR-200a-3p 8.78E-04 7.99E-03 -52.6 
 UGT1A1 miR-148b-3p 1.00E-03 8.74E-03 -52.3 
 UGT1A1 miR-374a-3p 1.08E-03 9.11E-03 -13.8 
 UGT1A1 miR-324-5p 1.16E-03 9.56E-03 -65.5 
 UGT1A1 miR-29a-5p 1.17E-03 9.57E-03 -12.6 
 UGT1A1 miR-221-3p 1.24E-03 9.93E-03 -72.0 
 UGT1A1 miR-301a-3p 1.33E-03 1.03E-02 -44.9 
 UGT1A1 miR-24-3p 1.70E-03 1.22E-02 -36.0 
 UGT1A1 miR-30d-5p 1.75E-03 1.24E-02 -50.0 
 UGT1A1 miR-193a-5p 2.25E-03 1.47E-02 -52.8 
 UGT1A1 miR-194-5p 3.32E-03 1.92E-02 -70.7 
 UGT1A1 miR-27a-3p 3.33E-03 1.92E-02 -45.8 
 UGT1A1 miR-199a-3p 3.34E-03 1.92E-02 -37.7 
 UGT1A1 miR-10a-5p 3.92E-03 2.13E-02 -42.0 
 UGT1A1 miR-28-3p 3.97E-03 2.14E-02 -36.9 
 UGT1A1 miR-26b-5p 4.63E-03 2.39E-02 -94.8 
 UGT1A1 miR-378a-5p 5.90E-03 2.83E-02 -11.0 
 UGT1A1 miR-532-3p 6.81E-03 3.11E-02 -88.0 
 UGT1A1 miR-186-5p 7.54E-03 3.34E-02 -71.2 
 UGT1A1 miR-590-5p 7.59E-03 3.35E-02 -59.8 
 UGT1A1 miR-27b-3p 7.76E-03 3.41E-02 -40.7 
 UGT1A1 miR-30a-3p 8.66E-03 3.68E-02 -39.3 
 UGT1A1 miR-744-3p 9.76E-03 3.97E-02 -22.6 
 UGT1A1 miR-30a-5p 1.13E-02 4.41E-02 -36.1 
 UGT1A1 miR-219a-5p 1.24E-02 4.69E-02 -9.7 
 UGT1A1 miR-339-3p 1.32E-02 4.90E-02 -40.0 
 UGT2B15 miR-497-5p 6.63E-06 4.19E-04 -4.5 
 UGT2B15 miR-99a-3p 1.62E-05 7.77E-04 -4.6 
 UGT2B15 miR-30e-3p 4.70E-05 1.48E-03 -14.6 
 UGT2B15 miR-374a-3p 7.56E-05 1.90E-03 -3.7 
 UGT2B15 miR-340-3p 9.30E-05 2.15E-03 -8.1 
 UGT2B15 miR-223-5p 1.33E-04 2.58E-03 -6.3 
 UGT2B15 miR-29b-3p 1.54E-04 2.82E-03 -11.7 
 UGT2B15 miR-592 1.66E-04 2.98E-03 -4.4 
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  Gene miRNA p-value FDR Estimate* 
 UGT2B15 miR-216b-5p 1.75E-04 3.07E-03 -2.9 
 UGT2B15 miR-320b 1.98E-04 3.27E-03 -5.3 
 UGT2B15 miR-511-5p 2.10E-04 3.42E-03 -6.9 
 UGT2B15 miR-576-3p 3.06E-04 4.37E-03 -4.7 
 UGT2B15 miR-502-3p 3.12E-04 4.43E-03 -3.8 
 UGT2B15 miR-22-5p 3.43E-04 4.71E-03 -5.7 
 UGT2B15 miR-375 3.42E-04 4.71E-03 -4.6 
 UGT2B15 miR-505-5p 3.55E-04 4.82E-03 -3.5 
 UGT2B15 miR-148b-5p 5.47E-04 6.13E-03 -4.8 
 UGT2B15 miR-31-5p 5.48E-04 6.13E-03 -2.4 
 UGT2B15 miR-331-3p 7.56E-04 7.31E-03 -11.8 
 UGT2B15 miR-744-3p 7.63E-04 7.33E-03 -6.5 
 UGT2B15 miR-195-5p 8.50E-04 7.88E-03 -5.3 
 UGT2B15 miR-151a-5p 1.02E-03 8.84E-03 -5.4 
 UGT2B15 miR-505-3p 1.10E-03 9.21E-03 -3.5 
 UGT2B15 miR-27b-5p 1.15E-03 9.50E-03 -10.9 
 UGT2B15 miR-29a-5p 1.17E-03 9.57E-03 -2.9 
 UGT2B15 miR-152-3p 1.18E-03 9.59E-03 -14.5 
 UGT2B15 miR-199a-5p 1.22E-03 9.82E-03 -9.0 
 UGT2B15 miR-30a-3p 1.41E-03 1.08E-02 -10.6 
 UGT2B15 miR-194-3p 1.53E-03 1.13E-02 -4.1 
 UGT2B15 miR-26b-3p 1.69E-03 1.21E-02 -5.2 
 UGT2B15 miR-192-3p 1.80E-03 1.26E-02 -5.8 
 UGT2B15 miR-219a-5p 1.95E-03 1.34E-02 -2.7 
 UGT2B15 miR-145-3p 2.05E-03 1.39E-02 -2.4 
 UGT2B15 miR-579-3p 2.59E-03 1.62E-02 -0.9 
 UGT2B15 miR-590-3p 2.97E-03 1.77E-02 -5.6 
 UGT2B15 miR-145-3p 3.09E-03 1.82E-02 -0.5 
 UGT2B15 miR-200a-3p 3.73E-03 2.06E-02 -10.7 
 UGT2B15 miR-186-5p 3.78E-03 2.08E-02 -17.4 
 UGT2B15 miR-28-5p 4.21E-03 2.23E-02 -10.4 
 UGT2B15 miR-452-5p 5.16E-03 2.58E-02 -4.8 
 UGT2B15 miR-24-3p 5.38E-03 2.65E-02 -7.4 
 UGT2B15 miR-34a-5p 6.15E-03 2.90E-02 -12.3 
 UGT2B15 miR-27b-3p 6.36E-03 2.96E-02 -9.5 
 UGT2B15 miR-30a-5p 6.47E-03 3.00E-02 -1.9 
 UGT2B15 miR-625-5p 6.72E-03 3.08E-02 -2.6 
 UGT2B15 miR-579-3p 6.77E-03 3.09E-02 -4.0 
 UGT2B15 miR-30a-5p 8.12E-03 3.52E-02 -8.6 
 UGT2B15 miR-29c-3p 8.32E-03 3.58E-02 -1.9 
 UGT2B15 miR-26b-5p 8.46E-03 3.63E-02 -20.3 
 UGT2B15 miR-125b-5p 8.77E-03 3.71E-02 -2.9 
 UGT2B15 miR-335-5p 9.01E-03 3.77E-02 -11.4 
 UGT2B15 miR-30a-3p 9.10E-03 3.79E-02 -1.9 
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  Gene miRNA p-value FDR Estimate* 
 UGT2B15 miR-378a-5p 1.07E-02 4.25E-02 -2.3 
 UGT2B15 miR-95-3p 1.15E-02 4.45E-02 -0.7 
 UGT2B15 miR-30d-5p 1.18E-02 4.54E-02 -9.5 
 UGT2B15 miR-29c-3p 1.19E-02 4.57E-02 -8.6 
 UGT2B15 miR-197-3p 1.23E-02 4.67E-02 -12.3 
 UGT2B15 miR-193a-5p 1.25E-02 4.71E-02 -10.1 
 UGT2B15 miR-219a-5p 1.32E-02 4.88E-02 -0.5 
 UGT2B15 miR-29b-2-5p 1.33E-02 4.92E-02 -2.2 
 UGT2B17 miR-579-3p 2.63E-03 1.63E-02 -0.8 
 UGT2B17 miR-145-3p 3.13E-03 1.84E-02 -0.4 
 UGT2B17 miR-30a-5p 6.74E-03 3.08E-02 -1.7 
 UGT2B17 miR-29c-3p 8.12E-03 3.52E-02 -1.7 
 UGT2B17 miR-125b-5p 8.21E-03 3.55E-02 -2.6 
 UGT2B17 miR-30a-3p 8.96E-03 3.76E-02 -1.7 
 UGT2B17 miR-95-3p 1.17E-02 4.53E-02 -0.7 
 UGT2B17 miR-219a-5p 1.31E-02 4.85E-02 -0.4 
 UGT2B7 miR-216b-5p 4.03E-06 2.95E-04 -4.5 
 UGT2B7 miR-497-5p 8.95E-06 5.23E-04 -6.0 
 UGT2B7 miR-223-5p 2.75E-05 1.05E-03 -9.1 
 UGT2B7 miR-99a-3p 3.08E-05 1.13E-03 -6.0 
 UGT2B7 miR-148b-5p 7.74E-05 1.94E-03 -7.2 
 UGT2B7 miR-27b-5p 8.62E-05 2.08E-03 -17.0 
 UGT2B7 miR-29b-3p 9.44E-05 2.16E-03 -16.1 
 UGT2B7 miR-199a-5p 1.12E-04 2.35E-03 -14.0 
 UGT2B7 miR-502-3p 1.15E-04 2.38E-03 -5.4 
 UGT2B7 miR-30e-3p 1.53E-04 2.82E-03 -18.6 
 UGT2B7 miR-31-5p 1.54E-04 2.82E-03 -3.4 
 UGT2B7 miR-505-5p 1.60E-04 2.91E-03 -4.8 
 UGT2B7 miR-452-5p 1.71E-04 3.04E-03 -8.2 
 UGT2B7 miR-340-3p 1.95E-04 3.25E-03 -10.5 
 UGT2B7 miR-151a-5p 2.74E-04 4.10E-03 -7.9 
 UGT2B7 miR-152-3p 3.53E-04 4.81E-03 -21.1 
 UGT2B7 miR-195-5p 3.69E-04 4.95E-03 -7.6 
 UGT2B7 miR-375 3.86E-04 5.04E-03 -6.2 
 UGT2B7 miR-590-3p 4.34E-04 5.36E-03 -8.7 
 UGT2B7 miR-331-3p 4.51E-04 5.47E-03 -16.3 
 UGT2B7 miR-374a-3p 4.69E-04 5.62E-03 -4.5 
 UGT2B7 miR-505-3p 5.80E-04 6.23E-03 -4.8 
 UGT2B7 miR-200a-3p 6.36E-04 6.57E-03 -16.5 
 UGT2B7 miR-28-5p 6.91E-04 6.90E-03 -16.1 
 UGT2B7 miR-320b 7.29E-04 7.16E-03 -6.6 
 UGT2B7 miR-192-3p 7.37E-04 7.20E-03 -8.3 
 UGT2B7 miR-22-5p 9.81E-04 8.67E-03 -7.1 
 UGT2B7 miR-511-5p 1.09E-03 9.14E-03 -8.3 
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  Gene miRNA p-value FDR Estimate* 
 UGT2B7 miR-592 1.14E-03 9.44E-03 -5.3 
 UGT2B7 miR-625-5p 1.26E-03 9.99E-03 -4.1 
 UGT2B7 miR-24-3p 1.28E-03 1.01E-02 -11.3 
 UGT2B7 miR-590-5p 1.73E-03 1.23E-02 -21.0 
 UGT2B7 miR-146b-3p 1.93E-03 1.33E-02 -4.6 
 UGT2B7 miR-378a-5p 2.44E-03 1.55E-02 -3.6 
 UGT2B7 miR-197-3p 2.65E-03 1.64E-02 -19.4 
 UGT2B7 miR-27a-3p 2.69E-03 1.66E-02 -14.3 
 UGT2B7 miR-576-3p 2.92E-03 1.75E-02 -5.4 
 UGT2B7 miR-26b-3p 3.42E-03 1.96E-02 -6.6 
 UGT2B7 miR-186-5p 3.49E-03 1.97E-02 -23.6 
 UGT2B7 miR-532-3p 4.05E-03 2.17E-02 -28.5 
 UGT2B7 miR-193a-5p 4.25E-03 2.25E-02 -15.3 
 UGT2B7 miR-26b-5p 4.80E-03 2.46E-02 -29.0 
 UGT2B7 miR-219a-5p 5.20E-03 2.60E-02 -3.3 
 UGT2B7 miR-27a-5p 5.34E-03 2.64E-02 -5.7 
 UGT2B7 miR-27b-3p 6.06E-03 2.87E-02 -12.8 
 UGT2B7 miR-145-3p 6.28E-03 2.93E-02 -2.9 
 UGT2B7 miR-148b-3p 7.37E-03 3.28E-02 -13.5 
 UGT2B7 miR-125b-5p 8.00E-03 3.48E-02 -18.7 
 UGT2B7 miR-335-5p 8.59E-03 3.66E-02 -15.4 
 UGT2B7 miR-30a-3p 9.32E-03 3.85E-02 -12.0 
 UGT2B7 miR-132-3p 1.21E-02 4.63E-02 -14.6 
 UGT2B7 miR-194-5p 1.24E-02 4.69E-02 -18.9 
 UGT2B7 miR-29c-3p 1.26E-02 4.73E-02 -11.4 
Transporters ABCB1 miR-502-3p 2.35E-07 5.69E-05 -1.2 
  ABCB1 miR-216b-5p 6.62E-07 8.38E-05 -0.8 
  ABCB1 miR-219a-5p 2.10E-06 1.95E-04 -0.9 
  ABCB1 miR-29b-3p 2.80E-06 2.35E-04 -3.2 
  ABCB1 miR-497-5p 4.93E-06 3.47E-04 -1.1 
  ABCB1 miR-24-3p 2.52E-05 1.02E-03 -2.4 
  ABCB1 miR-579-3p 2.74E-05 1.05E-03 -1.3 
  ABCB1 miR-511-5p 5.56E-05 1.61E-03 -1.7 
  ABCB1 miR-199a-5p 8.69E-05 2.08E-03 -2.5 
  ABCB1 miR-145-3p 8.67E-05 2.08E-03 -0.7 
  ABCB1 miR-34a-5p 9.16E-05 2.15E-03 -3.9 
  ABCB1 miR-29c-3p 1.14E-04 2.36E-03 -2.9 
  ABCB1 miR-30e-3p 1.39E-04 2.64E-03 -3.3 
  ABCB1 miR-31-5p 1.74E-04 3.07E-03 -0.6 
  ABCB1 miR-374a-3p 1.96E-04 3.25E-03 -0.8 
  ABCB1 miR-378a-5p 2.50E-04 3.84E-03 -0.7 
  ABCB1 miR-155-5p 2.63E-04 3.97E-03 -1.8 
  ABCB1 miR-590-3p 3.04E-04 4.36E-03 -1.6 
  ABCB1 miR-200a-3p 3.56E-04 4.82E-03 -3.0 
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  Gene miRNA p-value FDR Estimate* 
  ABCB1 miR-99a-3p 3.89E-04 5.06E-03 -0.9 
  ABCB1 miR-152-3p 4.05E-04 5.17E-03 -3.7 
  ABCB1 miR-331-3p 4.13E-04 5.21E-03 -2.9 
  ABCB1 miR-125b-5p 5.14E-04 5.88E-03 -4.1 
  ABCB1 miR-195-5p 5.62E-04 6.16E-03 -1.3 
  ABCB1 miR-27b-5p 6.22E-04 6.48E-03 -2.7 
  ABCB1 miR-21-5p 7.37E-04 7.20E-03 -1.2 
  ABCB1 miR-320b 8.70E-04 7.99E-03 -1.1 
  ABCB1 miR-27b-3p 8.79E-04 7.99E-03 -2.7 
  ABCB1 miR-28-5p 9.49E-04 8.48E-03 -2.8 
  ABCB1 miR-223-5p 1.01E-03 8.77E-03 -1.3 
  ABCB1 miR-452-5p 1.06E-03 9.05E-03 -1.3 
  ABCB1 miR-30a-3p 1.25E-03 9.98E-03 -2.5 
  ABCB1 miR-505-3p 1.33E-03 1.03E-02 -0.8 
  ABCB1 miR-532-3p 1.50E-03 1.12E-02 -5.4 
  ABCB1 miR-132-3p 1.50E-03 1.12E-02 -3.2 
  ABCB1 miR-375 1.53E-03 1.13E-02 -1.0 
  ABCB1 miR-505-5p 1.73E-03 1.23E-02 -0.7 
  ABCB1 miR-22-5p 1.80E-03 1.26E-02 -1.2 
  ABCB1 miR-340-3p 1.88E-03 1.31E-02 -1.6 
  ABCB1 miR-23b-3p 2.24E-03 1.47E-02 -3.1 
  ABCB1 miR-151a-5p 2.38E-03 1.53E-02 -1.2 
  ABCB1 miR-592 3.69E-03 2.04E-02 -0.9 
  ABCB1 miR-30a-5p 3.97E-03 2.14E-02 -2.2 
  ABCB1 miR-193a-5p 4.80E-03 2.46E-02 -2.7 
  ABCB1 miR-27a-5p 4.86E-03 2.48E-02 -1.0 
  ABCB1 miR-95-3p 6.55E-03 3.02E-02 -0.9 
  ABCB1 miR-197-3p 7.60E-03 3.35E-02 -3.1 
  ABCB1 miR-301a-3p 7.65E-03 3.37E-02 -2.1 
  ABCB1 miR-625-5p 7.95E-03 3.47E-02 -0.6 
  ABCB1 miR-423-5p 9.30E-03 3.85E-02 -2.5 
  ABCB1 miR-628-3p 9.31E-03 3.85E-02 -0.6 
  ABCB1 miR-576-3p 9.68E-03 3.95E-02 -0.8 
  ABCB1 miR-29b-2-5p 1.02E-02 4.11E-02 -0.5 
  ABCB1 miR-148b-5p 1.04E-02 4.17E-02 -0.9 
  ABCB1 miR-186-5p 1.11E-02 4.35E-02 -3.7 
  ABCB1 miR-28-3p 1.23E-02 4.67E-02 -1.8 
  ABCB1 miR-330-3p 1.26E-02 4.73E-02 -0.5 
  ABCC2 miR-223-5p 6.16E-05 1.69E-03 -9.6 
  ABCC2 miR-505-3p 1.27E-04 2.53E-03 -5.7 
  ABCC2 miR-452-5p 2.04E-04 3.35E-03 -8.9 
  ABCC2 miR-148b-5p 2.37E-04 3.70E-03 -7.4 
  ABCC2 miR-497-5p 3.73E-04 4.97E-03 -5.5 
  ABCC2 miR-505-5p 4.76E-04 5.67E-03 -5.0 
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  Gene miRNA p-value FDR Estimate* 
  ABCC2 miR-199a-5p 5.02E-04 5.82E-03 -14.1 
  ABCC2 miR-27a-3p 6.12E-04 6.42E-03 -17.4 
  ABCC2 miR-192-3p 6.49E-04 6.65E-03 -9.1 
  ABCC2 miR-216b-5p 6.54E-04 6.68E-03 -3.9 
  ABCC2 miR-625-5p 8.68E-04 7.98E-03 -4.5 
  ABCC2 miR-99a-3p 9.39E-04 8.44E-03 -5.5 
  ABCC2 miR-197-3p 1.08E-03 9.11E-03 -22.7 
  ABCC2 miR-151a-5p 1.16E-03 9.56E-03 -7.8 
  ABCC2 miR-195-5p 1.37E-03 1.05E-02 -7.6 
  ABCC2 miR-26b-3p 1.80E-03 1.26E-02 -7.6 
  ABCC2 miR-331-3p 2.08E-03 1.40E-02 -16.0 
  ABCC2 miR-186-5p 2.77E-03 1.68E-02 -26.3 
  ABCC2 miR-375 2.90E-03 1.74E-02 -5.8 
  ABCC2 miR-27b-5p 3.34E-03 1.92E-02 -14.7 
  ABCC2 miR-590-5p 3.47E-03 1.97E-02 -21.6 
  ABCC2 miR-146b-3p 3.72E-03 2.06E-02 -4.7 
  ABCC2 miR-27a-5p 3.78E-03 2.08E-02 -6.5 
  ABCC2 miR-152-3p 3.83E-03 2.09E-02 -19.3 
  ABCC2 miR-31-5p 3.99E-03 2.14E-02 -3.0 
  ABCC2 miR-148b-3p 4.08E-03 2.18E-02 -15.6 
  ABCC2 miR-28-5p 4.74E-03 2.44E-02 -15.1 
  ABCC2 miR-200a-3p 4.84E-03 2.47E-02 -15.3 
  ABCC2 miR-30e-3p 5.26E-03 2.61E-02 -15.9 
  ABCC2 miR-199a-3p 5.59E-03 2.72E-02 -12.0 
  ABCC2 miR-340-3p 5.67E-03 2.75E-02 -8.9 
  ABCC2 miR-29b-3p 6.42E-03 2.98E-02 -13.1 
  ABCC2 miR-590-3p 8.27E-03 3.57E-02 -7.4 
  ABCC2 miR-10a-5p 8.77E-03 3.71E-02 -13.0 
  ABCC2 miR-335-5p 1.06E-02 4.22E-02 -16.3 
  ABCC2 miR-576-3p 1.27E-02 4.77E-02 -5.0 
  ABCG2 miR-668-3p 4.08E-03 2.18E-02 -0.2 
  ABCG2 miR-431-5p 9.03E-03 3.77E-02 -0.2 
  ABCG2 miR-512-3p 1.09E-02 4.29E-02 -0.1 
  SLC15A2 miR-493-3p 3.63E-05 1.24E-03 -0.033 
  SLC15A2 miR-433-3p 5.35E-05 1.58E-03 -0.030 
  SLC15A2 miR-889-3p 1.19E-04 2.44E-03 -0.1 
  SLC15A2 miR-431-5p 1.67E-04 2.99E-03 -0.025 
  SLC15A2 miR-154-3p 1.77E-04 3.09E-03 -0.028 
  SLC15A2 miR-485-3p 1.92E-04 3.25E-03 -0.020 
  SLC15A2 miR-487b-3p 2.17E-04 3.51E-03 -0.1 
  SLC15A2 miR-668-3p 2.90E-04 4.24E-03 -0.031 
  SLC15A2 miR-539-5p 3.82E-04 5.03E-03 -0.1 
  SLC15A2 miR-758-3p 4.15E-04 5.21E-03 -0.026 
  SLC15A2 miR-409-3p 8.76E-04 7.99E-03 -0.1 
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  SLC15A2 miR-410-3p 1.05E-03 8.98E-03 -0.028 
  SLC15A2 miR-323a-3p 1.20E-03 9.70E-03 -0.041 
  SLC15A2 miR-144-5p 2.08E-03 1.40E-02 -0.032 
  SLC15A2 miR-411-5p 2.16E-03 1.43E-02 -0.1 
  SLC15A2 miR-130a-3p 2.57E-03 1.60E-02 -0.2 
  SLC15A2 miR-19b-1-5p 4.30E-03 2.27E-02 -0.1 
  SLC15A2 miR-519d-3p 4.35E-03 2.28E-02 -0.022 
  SLC15A2 miR-487a-3p 5.93E-03 2.83E-02 -0.022 
  SLC15A2 miR-654-3p 6.19E-03 2.91E-02 -0.041 
  SLC15A2 miR-136-3p 6.49E-03 3.01E-02 -0.1 
  SLC15A2 miR-654-5p 6.52E-03 3.01E-02 -0.021 
  SLC15A2 miR-184 8.03E-03 3.49E-02 -0.021 
  SLC15A2 miR-512-3p 8.33E-03 3.58E-02 -0.016 
  SLC15A2 miR-526b-5p 8.50E-03 3.64E-02 -0.030 
  SLC15A2 miR-432-5p 9.03E-03 3.77E-02 -0.024 
  SLC15A2 miR-18a-5p 1.21E-02 4.62E-02 -0.1 
  SLC15A2 miR-494-3p 1.29E-02 4.82E-02 -0.022 
  SLC22A1 miR-374a-3p 1.07E-06 1.24E-04 -10.3 
  SLC22A1 miR-99a-3p 1.30E-06 1.44E-04 -12.1 
  SLC22A1 miR-592 4.20E-06 3.01E-04 -12.5 
  SLC22A1 miR-22-5p 9.43E-06 5.42E-04 -16.2 
  SLC22A1 miR-30e-3p 1.49E-05 7.36E-04 -37.3 
  SLC22A1 miR-497-5p 2.07E-05 8.93E-04 -10.6 
  SLC22A1 miR-148b-5p 3.05E-05 1.13E-03 -13.6 
  SLC22A1 miR-223-5p 3.78E-05 1.28E-03 -16.3 
  SLC22A1 miR-340-3p 4.54E-05 1.45E-03 -20.3 
  SLC22A1 miR-216b-5p 5.01E-05 1.53E-03 -7.5 
  SLC22A1 miR-151a-5p 9.96E-05 2.21E-03 -15.0 
  SLC22A1 miR-29a-5p 1.06E-04 2.27E-03 -8.1 
  SLC22A1 miR-29b-3p 2.62E-04 3.96E-03 -27.8 
  SLC22A1 miR-744-3p 3.22E-04 4.55E-03 -16.6 
  SLC22A1 miR-320b 3.43E-04 4.71E-03 -12.5 
  SLC22A1 miR-505-5p 3.45E-04 4.73E-03 -8.4 
  SLC22A1 miR-511-5p 5.41E-04 6.09E-03 -15.9 
  SLC22A1 miR-590-3p 5.77E-04 6.23E-03 -15.5 
  SLC22A1 miR-197-3p 9.17E-04 8.27E-03 -38.2 
  SLC22A1 miR-375 9.66E-04 8.59E-03 -10.6 
  SLC22A1 miR-30a-3p 1.69E-03 1.21E-02 -25.5 
  SLC22A1 miR-532-3p 1.79E-03 1.25E-02 -55.4 
  SLC22A1 miR-576-3p 1.83E-03 1.27E-02 -10.2 
  SLC22A1 miR-199a-5p 1.89E-03 1.31E-02 -21.4 
  SLC22A1 miR-194-3p 2.25E-03 1.47E-02 -9.8 
  SLC22A1 miR-502-3p 2.34E-03 1.51E-02 -8.1 
  SLC22A1 miR-27b-5p 2.59E-03 1.61E-02 -25.0 
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  SLC22A1 miR-30d-5p 2.61E-03 1.62E-02 -27.0 
  SLC22A1 miR-152-3p 2.65E-03 1.64E-02 -33.3 
  SLC22A1 miR-331-3p 2.65E-03 1.64E-02 -26.1 
  SLC22A1 miR-625-5p 2.70E-03 1.66E-02 -6.9 
  SLC22A1 miR-145-3p 3.44E-03 1.96E-02 -5.6 
  SLC22A1 miR-28-5p 3.58E-03 2.00E-02 -25.8 
  SLC22A1 miR-31-5p 3.79E-03 2.08E-02 -5.0 
  SLC22A1 miR-195-5p 4.84E-03 2.47E-02 -11.3 
  SLC22A1 miR-590-5p 5.37E-03 2.65E-02 -34.6 
  SLC22A1 miR-192-3p 5.46E-03 2.68E-02 -12.8 
  SLC22A1 miR-335-5p 7.72E-03 3.39E-02 -28.2 
  SLC22A1 miR-30a-5p 8.21E-03 3.55E-02 -20.9 
  SLC22A1 miR-505-3p 8.48E-03 3.64E-02 -7.0 
  SLC22A1 miR-378a-5p 8.74E-03 3.70E-02 -5.9 
  SLC22A1 miR-29b-2-5p 1.09E-02 4.28E-02 -5.4 
  SLC22A2 miR-144-5p 4.32E-03 2.27E-02 -0.005 
  SLC22A2 miR-654-5p 4.39E-03 2.29E-02 -0.004 
  SLC22A2 miR-889-3p 4.71E-03 2.42E-02 -0.011 
  SLC22A2 miR-433-3p 4.83E-03 2.47E-02 -0.004 
  SLC22A2 miR-487a-3p 7.29E-03 3.26E-02 -0.004 
  SLC22A2 miR-431-5p 7.82E-03 3.42E-02 -0.003 
  SLC22A2 miR-668-3p 9.50E-03 3.90E-02 -0.004 
  SLC22A2 miR-18a-5p 1.21E-02 4.63E-02 -0.014 
  SLC22A2 miR-539-5p 1.31E-02 4.86E-02 -0.010 
  SLC22A2 miR-526b-5p 1.36E-02 5.00E-02 -0.005 
  SLCO1B1 miR-452-5p 5.97E-05 1.67E-03 -7.8 
  SLCO1B1 miR-99a-3p 1.60E-04 2.91E-03 -5.0 
  SLCO1B1 miR-216b-5p 2.04E-04 3.35E-03 -3.5 
  SLCO1B1 miR-199a-5p 2.90E-04 4.24E-03 -12.0 
  SLCO1B1 miR-192-3p 3.83E-04 5.03E-03 -7.8 
  SLCO1B1 miR-195-5p 4.38E-04 5.38E-03 -6.7 
  SLCO1B1 miR-505-5p 4.76E-04 5.67E-03 -4.1 
  SLCO1B1 miR-375 4.89E-04 5.73E-03 -5.5 
  SLCO1B1 miR-31-5p 5.63E-04 6.16E-03 -2.9 
  SLCO1B1 miR-331-3p 1.09E-03 9.18E-03 -13.9 
  SLCO1B1 miR-29b-3p 1.25E-03 9.94E-03 -12.5 
  SLCO1B1 miR-148b-5p 1.30E-03 1.02E-02 -5.5 
  SLCO1B1 miR-26b-3p 1.35E-03 1.04E-02 -6.5 
  SLCO1B1 miR-151a-5p 1.35E-03 1.04E-02 -6.4 
  SLCO1B1 miR-197-3p 1.36E-03 1.05E-02 -18.4 
  SLCO1B1 miR-340-3p 1.43E-03 1.09E-02 -8.3 
  SLCO1B1 miR-223-5p 1.66E-03 1.20E-02 -6.6 
  SLCO1B1 miR-625-5p 1.78E-03 1.25E-02 -3.6 
  SLCO1B1 miR-497-5p 2.05E-03 1.39E-02 -4.1 
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  SLCO1B1 miR-27a-3p 2.28E-03 1.48E-02 -13.1 
  SLCO1B1 miR-320b 2.36E-03 1.52E-02 -5.5 
  SLCO1B1 miR-505-3p 2.50E-03 1.58E-02 -3.9 
  SLCO1B1 miR-146b-3p 2.56E-03 1.60E-02 -4.0 
  SLCO1B1 miR-30e-3p 2.65E-03 1.64E-02 -14.0 
  SLCO1B1 miR-28-5p 2.83E-03 1.71E-02 -13.0 
  SLCO1B1 miR-592 3.12E-03 1.84E-02 -4.4 
  SLCO1B1 miR-576-3p 4.11E-03 2.19E-02 -4.7 
  SLCO1B1 miR-511-5p 4.22E-03 2.23E-02 -6.7 
  SLCO1B1 miR-200a-3p 4.59E-03 2.38E-02 -12.7 
  SLCO1B1 miR-148b-3p 5.00E-03 2.53E-02 -12.7 
  SLCO1B1 miR-502-3p 5.91E-03 2.83E-02 -3.7 
  SLCO1B1 miR-24-3p 6.15E-03 2.90E-02 -8.9 
  SLCO1B1 miR-27b-5p 6.34E-03 2.96E-02 -11.4 
  SLCO1B1 miR-152-3p 6.86E-03 3.12E-02 -15.1 
  SLCO1B1 miR-301a-3p 7.12E-03 3.20E-02 -10.7 
  SLCO1B1 miR-193a-5p 8.98E-03 3.76E-02 -12.8 
  SLCO1B1 miR-335-5p 9.10E-03 3.79E-02 -13.7 
  SLCO1B1 miR-199a-3p 9.13E-03 3.79E-02 -9.4 
  SLCO1B1 miR-590-5p 9.20E-03 3.81E-02 -16.2 
  SLCO1B1 miR-590-3p 9.68E-03 3.95E-02 -6.0 
  SLCO1B1 miR-324-5p 1.04E-02 4.17E-02 -14.8 
  SLCO1B1 miR-194-3p 1.12E-02 4.37E-02 -4.2 
  SLCO1B1 miR-221-3p 1.17E-02 4.53E-02 -16.1 
  SLCO1B1 miR-186-5p 1.17E-02 4.53E-02 -18.7 
  SLCO1B1 miR-26b-5p 1.18E-02 4.55E-02 -23.7 
  SLCO1B1 miR-194-5p 1.34E-02 4.94E-02 -16.9 
  SLCO1B3 miR-223-5p 4.02E-04 5.15E-03 -4.5 
  SLCO1B3 miR-27b-5p 1.04E-03 8.91E-03 -8.3 
  SLCO1B3 miR-148b-5p 5.77E-03 2.78E-02 -3.0 
  SLCO1B3 miR-199a-5p 6.34E-03 2.96E-02 -5.9 
  SLCO1B3 miR-200a-3p 1.09E-02 4.28E-02 -7.2 
  SULT1A1 miR-223-5p 8.63E-04 7.97E-03 -1.0 
  SULT1A1 miR-148b-5p 9.68E-04 8.59E-03 -0.8 
  SULT1A1 miR-99a-3p 1.71E-03 1.22E-02 -0.6 
  SULT1A1 miR-30e-3p 2.26E-03 1.48E-02 -2.0 
  SULT1A1 miR-625-5p 2.47E-03 1.57E-02 -0.5 
  SULT1A1 miR-505-3p 2.97E-03 1.77E-02 -0.6 
  SULT1A1 miR-22-5p 3.18E-03 1.86E-02 -0.8 
  SULT1A1 miR-151a-5p 3.42E-03 1.95E-02 -0.8 
  SULT1A1 miR-505-5p 4.16E-03 2.20E-02 -0.5 
  SULT1A1 miR-375 6.61E-03 3.04E-02 -0.6 
  SULT1A1 miR-497-5p 6.64E-03 3.05E-02 -0.5 
  SULT1A1 miR-199a-5p 7.96E-03 3.47E-02 -1.3 
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  SULT1A1 miR-340-3p 8.34E-03 3.58E-02 -1.0 
  SULT1A1 miR-320b 8.74E-03 3.70E-02 -0.7 
  SULT1A1 miR-26b-3p 9.20E-03 3.81E-02 -0.8 
  SULT1A1 miR-592 1.01E-02 4.09E-02 -0.6 
  SULT1A1 miR-301a-3p 1.19E-02 4.57E-02 -1.4 
  SULT1A1 miR-194-3p 1.23E-02 4.67E-02 -0.6 
  SULT1A1 miR-29a-5p 1.35E-02 4.99E-02 -0.4 
Regulatory HNF4A miR-374a-3p 1.21E-05 6.50E-04 -1.1 
 HNF4A miR-502-3p 1.88E-05 8.58E-04 -1.2 
 HNF4A miR-216b-5p 4.60E-05 1.47E-03 -0.8 
 HNF4A miR-497-5p 5.02E-05 1.53E-03 -1.1 
 HNF4A miR-29b-3p 5.81E-05 1.66E-03 -3.4 
 HNF4A miR-532-3p 5.94E-05 1.67E-03 -7.6 
 HNF4A miR-30e-3p 9.36E-05 2.15E-03 -3.9 
 HNF4A miR-132-3p 1.19E-04 2.44E-03 -4.3 
 HNF4A miR-145-3p 1.27E-04 2.53E-03 -0.8 
 HNF4A miR-152-3p 1.37E-04 2.62E-03 -4.5 
 HNF4A miR-590-3p 1.95E-04 3.25E-03 -1.9 
 HNF4A miR-99a-3p 1.96E-04 3.25E-03 -1.1 
 HNF4A miR-29b-2-5p 2.26E-04 3.59E-03 -0.8 
 HNF4A miR-30a-3p 3.83E-04 5.03E-03 -3.2 
 HNF4A miR-223-5p 4.07E-04 5.18E-03 -1.6 
 HNF4A miR-579-3p 4.29E-04 5.33E-03 -1.4 
 HNF4A miR-22-5p 4.49E-04 5.46E-03 -1.5 
 HNF4A miR-155-5p 5.18E-04 5.90E-03 -2.0 
 HNF4A miR-31-5p 8.75E-04 7.99E-03 -0.6 
 HNF4A miR-27b-5p 1.08E-03 9.11E-03 -3.0 
 HNF4A miR-125b-5p 1.23E-03 9.85E-03 -4.5 
 HNF4A miR-511-5p 1.26E-03 1.00E-02 -1.7 
 HNF4A miR-592 1.45E-03 1.10E-02 -1.1 
 HNF4A miR-340-3p 1.72E-03 1.22E-02 -1.9 
 HNF4A miR-331-3p 2.21E-03 1.45E-02 -3.0 
 HNF4A miR-28-5p 2.39E-03 1.54E-02 -3.0 
 HNF4A miR-30a-5p 2.45E-03 1.56E-02 -2.6 
 HNF4A miR-151a-5p 2.63E-03 1.63E-02 -1.4 
 HNF4A miR-24-3p 2.81E-03 1.70E-02 -2.2 
 HNF4A miR-505-5p 3.11E-03 1.83E-02 -0.8 
 HNF4A miR-199a-5p 3.20E-03 1.87E-02 -2.3 
 HNF4A miR-29c-3p 3.22E-03 1.88E-02 -2.7 
 HNF4A miR-27a-5p 3.47E-03 1.97E-02 -1.2 
 HNF4A miR-219a-5p 3.57E-03 2.00E-02 -0.7 
 HNF4A miR-744-3p 3.59E-03 2.00E-02 -1.6 
 HNF4A miR-375 4.99E-03 2.52E-02 -1.0 
 HNF4A miR-505-3p 5.17E-03 2.58E-02 -0.8 
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 HNF4A miR-320b 7.14E-03 3.21E-02 -1.1 
 HNF4A miR-27b-3p 7.97E-03 3.48E-02 -2.6 
 HNF4A miR-195-5p 9.36E-03 3.86E-02 -1.2 
 HNF4A miR-148b-5p 9.54E-03 3.91E-02 -1.0 
 HNF4A miR-34a-5p 1.00E-02 4.05E-02 -3.2 
 HNF4A miR-197-3p 1.11E-02 4.36E-02 -3.4 
 HNF4A miR-143-3p 1.16E-02 4.48E-02 -3.6 
 HNF4A miR-29a-5p 1.32E-02 4.89E-02 -0.6 
 NR1I2 miR-216b-5p 7.30E-06 4.53E-04 -0.7 
 NR1I2 miR-497-5p 1.58E-05 7.61E-04 -1.0 
 NR1I2 miR-374a-3p 2.57E-05 1.03E-03 -0.8 
 NR1I2 miR-99a-3p 4.38E-05 1.41E-03 -1.0 
 NR1I2 miR-592 1.45E-04 2.71E-03 -1.0 
 NR1I2 miR-223-5p 2.34E-04 3.68E-03 -1.3 
 NR1I2 miR-30e-3p 4.27E-04 5.32E-03 -2.9 
 NR1I2 miR-29b-3p 5.01E-04 5.82E-03 -2.4 
 NR1I2 miR-148b-5p 5.69E-04 6.21E-03 -1.1 
 NR1I2 miR-22-5p 6.77E-04 6.84E-03 -1.2 
 NR1I2 miR-197-3p 7.31E-04 7.16E-03 -3.5 
 NR1I2 miR-340-3p 8.66E-04 7.97E-03 -1.6 
 NR1I2 miR-532-3p 9.99E-04 8.73E-03 -5.2 
 NR1I2 miR-151a-5p 1.24E-03 9.93E-03 -1.2 
 NR1I2 miR-199a-5p 2.00E-03 1.36E-02 -1.9 
 NR1I2 miR-590-5p 2.16E-03 1.43E-02 -3.4 
 NR1I2 miR-505-5p 2.41E-03 1.54E-02 -0.7 
 NR1I2 miR-152-3p 3.54E-03 1.99E-02 -2.9 
 NR1I2 miR-502-3p 3.57E-03 2.00E-02 -0.7 
 NR1I2 miR-195-5p 3.62E-03 2.01E-02 -1.0 
 NR1I2 miR-27b-5p 3.93E-03 2.13E-02 -2.2 
 NR1I2 miR-511-5p 4.32E-03 2.27E-02 -1.2 
 NR1I2 miR-590-3p 4.32E-03 2.27E-02 -1.2 
 NR1I2 miR-28-5p 4.50E-03 2.33E-02 -2.3 
 NR1I2 miR-744-3p 5.69E-03 2.76E-02 -1.2 
 NR1I2 miR-30a-3p 5.96E-03 2.84E-02 -2.0 
 NR1I2 miR-29a-5p 6.07E-03 2.87E-02 -0.5 
 NR1I2 miR-320b 6.50E-03 3.01E-02 -0.9 
 NR1I2 miR-29b-2-5p 6.82E-03 3.11E-02 -0.5 
 NR1I2 miR-10b-3p 7.32E-03 3.27E-02 -0.4 
 NR1I2 miR-186-5p 8.04E-03 3.50E-02 -3.5 
 NR1I2 miR-625-5p 8.90E-03 3.74E-02 -0.6 
 NR1I2 miR-331-3p 9.86E-03 4.00E-02 -2.1 
 NR1I2 miR-145-3p 9.87E-03 4.00E-02 -0.5 
 NR1I2 miR-125b-5p 1.00E-02 4.05E-02 -3.0 
 NR1I2 miR-31-5p 1.04E-02 4.17E-02 -0.4 
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 NR1I2 miR-375 1.19E-02 4.56E-02 -0.8 
 NR1I3 miR-197-3p 4.69E-04 5.62E-03 -7.4 
 NR1I3 miR-216b-5p 5.66E-04 6.18E-03 -1.2 
 NR1I3 miR-452-5p 2.21E-03 1.45E-02 -2.3 
 NR1I3 miR-590-5p 4.67E-03 2.41E-02 -6.5 
 NR1I3 miR-27a-3p 6.28E-03 2.93E-02 -4.4 
 NR1I3 miR-505-3p 1.01E-02 4.06E-02 -1.3 
 NR1I3 miR-532-3p 1.14E-02 4.42E-02 -8.5 
 NR1I3 miR-199a-5p 1.20E-02 4.59E-02 -3.3 
 NR1I3 miR-497-5p 1.29E-02 4.81E-02 -1.3 
*Estimates indicate the changes in mRNA expressed as RPKM (reads per kilobases per 
million) per one threshold cycle decrease in miRNA expression. 
Note: Decrease in threshold cycle is an increase in miRNA expression. For example, an 
estimate of -40.0 means that for every one threshold cycle decrease in miRNA 
expression, the correlated mRNA decreased 40 RPKM. In other words, the miRNA and 
mRNA are negatively correlated. 
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Table 6: List of miRNA-mRNA predicted targets 
miRNA Seed Sequence mRNA Source Confidence 
miR-455-3p CAGUCCA ABCB1 TargetScan Human Moderate (predicted) 
let-7a-5p GAGGUAG ABCC2 TargetScan Human Moderate (predicted) 
miR-106a-5p AAAGUGC ABCG2 TargetScan Human Moderate (predicted) 
miR-154-3p AUCAUAC ABCG2 TargetScan Human Moderate (predicted) 
miR-512-3p AGUGCUG ABCG2 TargetScan Human Moderate (predicted) 
miR-519a-3p AAGUGCA ABCG2 miRecords Experimentally Observed 
miR-125b-5p CCCUGAG CYP1A1 miRecords Experimentally Observed 
miR-146b-3p GCCCUGU CYP1A1 TargetScan Human High (predicted) 
miR-193a-5p GGGUCUU CYP1A1 TargetScan Human Moderate (predicted) 
miR-143-3p GAGAUGA CYP1A2 TargetScan Human Moderate (predicted) 
miR-320b AAAGCUG CYP1A2 TargetScan Human High (predicted) 
miR-431-5p GUCUUGC CYP1A2 TargetScan Human Moderate (predicted) 
miR-668-3p GUCACUC CYP1A2 TargetScan Human Moderate (predicted) 
miR-942-5p CUUCUCU CYP2A6 TargetScan Human Moderate (predicted) 
miR-1275 UGGGGGA CYP2B6 TargetScan Human Moderate (predicted) 
miR-29b-3p AGCACCA CYP2B6 TargetScan Human Moderate (predicted) 
miR-483-3p CACUCCU CYP2B6 TargetScan Human Moderate (predicted) 
miR-625-5p GGGGGAA CYP2B6 TargetScan Human Moderate (predicted) 
miR-744-5p GCGGGGC CYP2B6 TargetScan Human Moderate (predicted) 
miR-939-5p GGGGAGC CYP2B6 TargetScan Human Moderate (predicted) 
miR-143-3p GAGAUGA CYP2C9 TargetScan Human Moderate (predicted) 
miR-155-5p UAAUGCU CYP2C9 TargetScan Human Moderate (predicted) 
miR-369-3p AUAAUAC CYP2C9 TargetScan Human Moderate (predicted) 
miR-150-5p CUCCCAA CYP3A4 TargetScan Human Moderate (predicted) 
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miRNA Seed Sequence mRNA Source Confidence 
miR-455-3p CAGUCCA CYP3A4 TargetScan Human Moderate (predicted) 
miR-21-5p AGCUUAU CYP3A5 TargetScan Human Moderate (predicted) 
miR-539-5p GAGAAAU CYP3A7 TargetScan Human Moderate (predicted) 
miR-106a-5p AAAGUGC DPYD TargetScan Human Moderate (predicted) 
miR-1271-5p UUGGCAC DPYD TargetScan Human Moderate (predicted) 
miR-199a-3p CAGUAGU DPYD TargetScan Human Moderate (predicted) 
miR-25-3p AUUGCAC DPYD TargetScan Human High (predicted) 
miR-31-5p GGCAAGA DPYD TargetScan Human Moderate (predicted) 
miR-34a-5p GGCAGUG DPYD TargetScan Human High (predicted) 
miR-376a-3p UCAUAGA DPYD TargetScan Human Moderate (predicted) 
miR-425-5p AUGACAC DPYD TargetScan Human High (predicted) 
miR-494-3p GAAACAU DPYD TargetScan Human Moderate (predicted) 
miR-519a-3p AAGUGCA DPYD TargetScan Human Moderate (predicted) 
miR-519e-5p UCUCCAA DPYD TargetScan Human Moderate (predicted) 
miR-628-5p UGCUGAC DPYD TargetScan Human Moderate (predicted) 
miR-151a-5p CGAGGAG GSTM1 TargetScan Human Moderate (predicted) 
miR-1247-5p CCCGUCC HNF4A TargetScan Human Moderate (predicted) 
miR-143-3p GAGAUGA HNF4A TargetScan Human Moderate (predicted) 
miR-216b-5p AAUCUCU HNF4A TargetScan Human Moderate (predicted) 
miR-34a-5p GGCAGUG HNF4A TargetScan Human Experimentally Observed 
miR-483-5p AGACGGG HNF4A TargetScan Human Moderate (predicted) 
miR-532-3p CUCCCAC HNF4A TargetScan Human Moderate (predicted) 
miR-625-5p GGGGGAA HNF4A TargetScan Human Moderate (predicted) 
miR-668-3p GUCACUC HNF4A TargetScan Human Moderate (predicted) 
miR-151a-5p CGAGGAG NAT1 TargetScan Human Moderate (predicted) 
miR-29b-3p AGCACCA NAT1 TargetScan Human High (predicted) 
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Table 6 cont’d     
miRNA Seed Sequence mRNA Source Confidence 
miR-320b AAAGCUG NAT1 TargetScan Human Moderate (predicted) 
miR-628-5p UGCUGAC NAT2 TargetScan Human Moderate (predicted) 
miR-142-5p AUAAAGU NR1I2 TargetScan Human Moderate (predicted) 
miR-148b-3p CAGUGCA NR1I2 miRecords Experimentally Observed 
miR-18a-5p AAGGUGC NR1I2 TargetScan Human High (predicted) 
miR-219a-5p GAUUGUC NR1I2 TargetScan Human Moderate (predicted) 
miR-34a-5p GGCAGUG NR1I2 TargetScan Human Moderate (predicted) 
miR-576-3p AGAUGUG NR1I2 TargetScan Human Moderate (predicted) 
miR-132-3p AACAGUC SLC15A2 TargetScan Human Moderate (predicted) 
miR-184 GGACGGA SLC15A2 TargetScan Human Moderate (predicted) 
miR-206 GGAAUGU SLC15A2 TargetScan Human High (predicted) 
miR-23b-3p UCACAUU SLC15A2 TargetScan Human High (predicted) 
miR-376a-3p UCAUAGA SLC15A2 TargetScan Human High (predicted) 
miR-519a-3p AAGUGCA SLC15A2 TargetScan Human Moderate (predicted) 
miR-576-3p AGAUGUG SLC15A2 TargetScan Human Moderate (predicted) 
miR-1275 UGGGGGA SLC22A1 TargetScan Human Moderate (predicted) 
miR-150-5p CUCCCAA SLC22A2 TargetScan Human Moderate (predicted) 
miR-155-5p UAAUGCU SLC22A2 TargetScan Human Moderate (predicted) 
miR-181a-5p ACAUUCA SLC22A2 TargetScan Human Moderate (predicted) 
miR-382-5p AAGUUGU SLC22A2 TargetScan Human Moderate (predicted) 
miR-431-5p GUCUUGC SLC22A2 TargetScan Human Moderate (predicted) 
miR-452-5p ACUGUUU SLC22A2 TargetScan Human Moderate (predicted) 
miR-211-5p UCCCUUU SLC22A6 TargetScan Human High (predicted) 
miR-331-3p CCCCUGG SLC22A6 TargetScan Human Moderate (predicted) 
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miRNA Seed Sequence mRNA Source Confidence 
miR-654-5p GGUGGGC SLC22A6 TargetScan Human Moderate (predicted) 
miR-139-5p CUACAGU SLCO1B1 TargetScan Human Moderate (predicted) 
miR-194-5p GUAACAG SLCO1B1 TargetScan Human Moderate (predicted) 
miR-206 GGAAUGU SLCO1B1 TargetScan Human High (predicted) 
miR-511-5p UGUCUUU SLCO1B1 TargetScan Human Moderate (predicted) 
miR-576-3p AGAUGUG SLCO1B1 TargetScan Human Moderate (predicted) 
miR-526b-5p UCUUGAG SULT1A1 TargetScan Human Moderate (predicted) 
miR-10a-5p ACCCUGU TPMT TargetScan Human Moderate (predicted) 
miR-185-5p GGAGAGA TPMT TargetScan Human Moderate (predicted) 
miR-206 GGAAUGU TPMT TargetScan Human Moderate (predicted) 
miR-28-5p AGGAGCU TPMT TargetScan Human Moderate (predicted) 
miR-526b-5p UCUUGAG TPMT TargetScan Human Moderate (predicted) 
miR-885-5p CCAUUAC TPMT TargetScan Human High (predicted) 
miR-9-5p CUUUGGU TPMT TargetScan Human Moderate (predicted) 
miR-141-3p AACACUG UGT1A1 TargetScan Human Moderate (predicted) 
miR-148b-3p CAGUGCA UGT1A1 TargetScan Human Moderate (predicted) 
miR-376a-3p UCAUAGA UGT1A1 TargetScan Human Moderate (predicted) 
miR-125b-5p CCCUGAG UGT2B15 miRecords Experimentally Observed 
miR-376c-3p ACAUAGA UGT2B15 TargetScan Human Moderate (predicted) 
miR-382-5p AAGUUGU UGT2B15 TargetScan Human Moderate (predicted) 
miR-125b-5p CCCUGAG UGT2B17 miRecords Experimentally Observed 
miR-376c-3p ACAUAGA UGT2B17 TargetScan Human Moderate (predicted) 
miR-382-5p AAGUUGU UGT2B17 TargetScan Human Moderate (predicted) 
miR-409-3p AAUGUUG UGT2B17 TargetScan Human Moderate (predicted) 
miR-494-3p GAAACAU UGT2B17 TargetScan Human Moderate (predicted) 
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Discussion 
The expression of pharmacogenes are known to be altered throughout development, 
especially during the early and late developmental stages in humans. For example, 
CYP3A7 is the predominant CYP gene expressed in the fetal liver, but its expression 
becomes undetectable in most children (Lacroix et al., 1997). Data also shows that 
expression of select UGTs and transporters increases in older children and adults 
compared to neonates and younger children (Miller et al., 1976; Mooij et al., 2014). 
However, the mechanisms that control these changes are not well understood. Recently, 
there is emerging evidence that hepatic miRNA expression changes with age in humans 
and rodents (Mimura et al., 2014; Rieger et al., 2013). Data from our study are in alignment 
with the emerging evidence that changes in hepatic miRNA expression may contribute to 
the known developmental changes in these drug disposition genes (Burgess et al., 2015). 
Since these findings, miRNAs have been shown to play a role in skeletal muscle 
development and developmental changes in the small intestines, hypothalamus, ear, and 
heart (Bianchi et al., 2017; Doubi-Kadmiri et al., 2016; Liang et al., 2016; Torres et al., 
2015; Zhang et al., 2015). 
 
Our data indicate that miRNA expression in the human liver is age-dependent; this is 
consistent with observations of developmental changes of hepatic miRNA expression 
patterns in rats (Mimura et al., 2014). Specifically, miRNAs 29c-3p, 195-5p, and 497-5p 
were significantly upregulated and 301a-3p, 106b-5p, 185-5p, and 539-5p downregulated 
between the human fetal and pediatric livers which is in agreement with miRNAs that 
changed with age in rat liver tissue; exceptions were miRNAs 148b-3p and let-7a-5p, 
which revealed opposite findings. Other miRNAs Mimura et al. found to change in aging 
rat liver were consistent with our data, but not significant after FDR-corrected. 
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The extent of mRNA induction or repression between developmental stages varied 
greatly, particularly between fetal and pediatric. Since drug metabolism and disposition is 
enzyme and transporter specific, these differences most certainly contribute to the 
variability in the developmental changes in drug metabolism and disposition. Furthermore, 
interindividual variability in the rate of change in the expression of these genes also likely 
contributes to the interindividual variability in drug efficacy and toxicity. There was 
substantial variability in the expression of many of the miRNAs during each of the 
developmental periods. This may be a result of the interindividual variability in the timing 
of the developmental changes. These developmental changes in miRNA expression are 
most likely not due to a discrete incremental change amongst individuals but more of a 
continual change over time; one that likely occurs in every individual, but at various rates 
and to variable extents. This may contribute to the variable rates of changes in hepatic 
drug disposition.  
 
A limitation to our study is that we do not have serial samples within individuals or broad 
coverage of time points during the various developmental stages. Hence, the exact timing 
of some of the changes cannot be determined from our data. Since liver biopsies within 
individuals would not be ethical, such a study is not feasible in human subjects. However, 
more liver samples less than one year of age, post-puberty, and adult livers to compare 
against the geriatric age groups, in addition to knowledge of menopausal status will be 
useful in determining if altered miRNA expression is more heavily influenced by these 
developmental events. Especially in children less than one year of age, as many known 
changes in drug metabolism enzymes have been observed in this age range from older 
children. Also, due to limited sample materials, we were not able to measure protein 
expression by Western blot analysis or activity of the drug disposition genes. Since 
miRNAs can affect protein translation without substantial effects on mRNA levels, our 
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miRNA-mRNA correlations may miss some gene-specific effects and will need to be 
tested in individual experiments.  
 
Our data support that these changes in hepatic miRNA expression throughout the 
developmental periods are important in regulating the mRNA expression of phase I and II 
enzymes, drug transporters, and regulatory genes. Six of these developmentally-
regulated miRNAs have previously been experimentally validated to target ABCG2, 
CYP1A1, HNF4A, NR1I2, UGT2B15 and UGT2B17 (Ramamoorthy et al., 2012; Shi et al., 
2007; Takagi et al., 2008; To et al., 2008). Twenty-seven miRNAs, undetectable during 
fetal development, were expressed in the pediatric and adults samples. Additionally, 43 
miRNAs expressed during the fetal period were not expressed in pediatric and adult livers. 
The changes in hepatic miRNA expression from pediatric to adult periods may also 
contribute to changes in hepatic pharmacogene expression as several of these miRNA 
changes were correlated with changes in hepatic mRNA expression.  
 
Previously, hepatic expression of miR-34a-5p, miR-200a-3p, and miR-200b-3p was 
associated with age in a Caucasian, mostly adult, population from Europe (Rieger et al., 
2013). In our data, miR-34a-5p was upregulated 1.7- and 2.1-fold from fetal to pediatric to 
adult and miR-200a-3p increased 2.7-fold from fetal to pediatric (Table 2 and 3). However, 
correlations of miRNAs and mRNAs between the two cohorts varied. For example, in both 
studies miR-28-3p negatively correlated with CYP2C9 mRNA, whereas miR-148b-3p was 
negatively correlated with CYP2C9 mRNA in our study (Table 5), but was described to be 
positively correlated with CYP2C9 by Rieger et al (Rieger et al., 2013). This could be due 
to a number of reasons as liver sample demographics varied between the studies as one 
population is based in Europe and the other, the United States. It has been shown that 
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environmental factors such as diet, smoking and drinking can alter miRNA expression in 
tissues (Rieger et al., 2013; Wilson et al., 2017). 
 
In conclusion, our data clearly demonstrates that there are major changes in hepatic 
miRNA expression between the developmental periods. These changes are most 
marked between fetal and pediatric ages; however, there were also notable changes 
between the pediatric and adult periods. Several of these miRNAs have either been 
validated to target pharmacogenes, as shown in Table 6, or are predicted to target these 
genes. These data strongly suggest that hepatic miRNA expression contributes to the 
clinical variability in hepatic drug disposition. The marked change in miRNA expression 
between the fetal and pediatric/adult groups may contribute to the high susceptibility of 
fetuses to adverse drug events. These developmental changes in miRNA expression 
may also contribute to changes in hepatic functions other than drug metabolism, such as 
cholesterol metabolism. Collectively, this information suggests that age-dependent 
miRNAs significantly impact a variety of human liver functions. Additional studies are 
warranted to: validate the hepatic miRNA-mRNA interactions; and determine indirect 
effects of miRNAs on pharmacogenes as well as the effects of SNPs on creating or 
abolishing miRNA target sites that control these genes. 
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CHAPTER 2 
Developmentally-regulated microRNA regulation of pharmacogenes 
Introduction 
Our studies in the previous chapter demonstrated that the hepatic expression of many 
miRNAs change during development. Several of these are predicted to regulate drug 
disposition genes. This discovery may explain part of the known developmental changes 
that occur in drug disposition. To follow up on these studies, we have begun validating the 
predicted miRNA-mRNA interactions. These validation experiments are important in 
determining exactly how these developmentally-regulated miRNAs contribute to changes 
in drug disposition gene expression by allowing us to understand which gene/genes a 
miRNA is targeting. With this knowledge, we will be able to predict the effects of miRNA 
expression changes that can occur from various diseases and environmental exposures 
(Gupta et al., 2014; Ramamoorthy et al., 2013; Tao et al., 2013). 
 
In this study, we focused on the miRNA regulation of CYP2B6 and CYP1A2. We used 
several cell culture models, such as the transfection of predicted miRNAs and measuring 
gene expression and activity. These data suggest that developmentally-regulated miRNAs 
have the ability to alter gene expression of drug disposition genes. 
 
Materials and Methods 
Cell culture maintenance 
HeLa, HepG2, and HEK293 cells supplied from ATCC (Manassas, VA) were thawed from 
liquid nitrogen storage. Cells were maintained according to manufacturer’s protocol using 
DMEM with 4.5 g/L glucose, L-glutamine & sodium pyruvate from Corning cellgro 
(Manassas, VA) supplemented with 10% fetal bovine serum from Atlanta Biologicals 
(Flowery Branch, GA). Approximately one million cells were used for freezing cell lines 
 77 
and stored in liquid nitrogen using Recovery Cell Culture Freezing Medium from Gibco 
(Grand Island, NY). Cryopreserved HepaRG cells were supplied by BioPredic 
International (Gibco, USA). Cells were maintained according to manufacturer’s protocol 
using Williams’ E Medium (Gibco, Grand Island, NY), supplemented with 10% fetal bovine 
serum (Atlanta Biologicals, Flowery Branch, GA), GlutaMax Supplement, HepaRG 
Maintenance/Metabolism Medium Supplement or HepaRG Thaw, Plate & General 
Purpose Medium Supplement (Gibco, Frederick, MD), ITS (Corning cellgro, Manassas, 
VA), Penicillin-Streptomycin Solution (GE Healthcare Life Sciences, Logan, UT). All cell 
lines were tested for mycoplasma contamination using Mycoplasma Detection Kit through 
Biotool (Houston, TX). Cells were rinsed using 1x phosphate buffered saline (Corning 
cellgro, Manassas, VA) and trypsinized using 1x TrypLE Express from Gibco (Grand 
Island, NY). Cells were stored at 37°C, 5% CO2 in Thermo Forma Series II Water-Jacketed 
CO2 Incubator. 
 
E. coli transformations 
TALE-TF, pIS-0 (Addgene, Cambridge, MA) (Yekta et al 2004), and Renilla luciferase 
reporter pGL4.74 (Promega, Madison, WI) plasmids were all transformed in One Shot 
OmniMax 2 TI Chemically Competent E. coli (Invitrogen, Carlsbald, CA). Briefly, E.coli 
was thawed on ice. Plasmids were diluted to 1 ng/µL and 1 µL was added to E. coli, 
incubated on ice for 30 minutes, heat-shocked for 30 seconds at 42°C, and placed on ice 
for 2 minutes. Next, 250 µL of SOC medium was added to each vial and shaken for 1 hour 
at 225 rpm at 37°C. Transformation mix was diluted 1:50 into LB Medium Miller (Alfa 
Aesar, Ward Hill, MA) or LB Broth (Amresco, Solon, OH) and 20 µL spread on ampicillin-
resistant agar plates. Ampicillin (100 mg/mL) was purchased from Sigma Aldrich (St. 
Louis, MO). Plated bacteria were incubated overnight at 37°C. TALE-TF plasmids were 
purified using Qiagen HiSpeed Plasmid Maxi Kit (Valencia, CA). Single colonies were 
 78 
selected and cultured in 4 mLs of ampicillin-resistant LB media overnight. Renilla 
luciferase and pIS-0 firefly luciferase plasmids were isolated using the NucleoSpin 
Plasmid (NoLid) DNA purification kit (Macherey-Nagel, Düren, Germany). DNA was 
quantified using Qubit dsDNA BR Assay Kit (Invitrogen, Eugene, OR). Plasmids stored at 
-20°C. 
 
Transfections 
HeLa (cervical cancer), HepG2 (liver carcinoma), and HEK293 (embryonic kidney) cells 
were seeded at 90,000 cells/well in a 24 well plate. Cells were transfected 24-48 hours 
after seeding, depending on when cells reach ~80% confluency. HepaRG (liver 
carcinoma) cells are plated at 400,000 cells/well in 24 well plates. Media was changed 
every two days and cells were transfected Day 6 after seeding. All cells were transfected 
using Lipofectamine 2000 or Lipofectamine 3000 Transfection Kits (Invitrogen, Carlsbad, 
CA) using OPTI-MEM I 1x (Gibco, Grand Island, NY). 
 
TALE-TFs used to validated miRNA targeting of CYPs 
Four TALE-TFs were synthesized per target, CYP2B6 and CYP1A2 (GeneCopoeia, 
Rockville, MD). 
 
CYP2B6 TALE-TF target sites: 
1) TAATGCTTCCTGGATGATGA, 2) TGGATGAAATTTTATAACAG 
3) TGGAGGCTGCAGCAGGGTGC, 4) TCTTCCTTGCACTCCTCACA. 
CYP1A2 TALE-TF target sites: 
1) TCCACACCAGCCATTACA, 2) TGGCCCAAGGCCAAGAGT 
3) TCAGGAGTGGCTGGAACA, 4) TCTCTTTAGGATGCAAAA. 
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Both 500 ng of individual TALE-TFs transfected per well for TALE-TF and 500 ng of total 
TALE-TFs transfected per well (125 ng of four TALE-TFs) were used for validation 
experiments. The combination of four TALE-TFs was used for all other experiments and 
cotransfected with 18 pmoles per well of Miridian microRNA mimics, Hairpin inhibitors or 
Negative Control #1 (GE Dharmacon, Chicago, IL). Negative Control #1 is cel-miR-67 
which has been shown to be functional in C. elegans but predicted not to target any human 
genes.  MicroRNA mimics and inhibitors were diluted to 20 µM working solutions, aliquoted 
to minimize freeze thaws, and stored at -80°C. Three technical replicates were done per 
biological replicate. 
 
Transfection in HepaRG cells 
Three different experiments were performed in HepaRG cells. First, 18 pmoles for each 
of seven miRNAs predicted to target CYP2B6 were transfected. Second, 18 pmoles for 
each of four different miRNAs predicted to target CYP1A2 were transfected. Third, for the 
developmental miRNA transfection experiment discussed in future directions, 18 pmoles 
for 18 different developmentally-regulated miRNAs were transfected per well in 24 well 
plates (Table 7). Lipofectamine 3000 reagent was scaled up according to the 
manufacturers protocol (Seven miRNAs: 3.4 µL, Four miRNAs: 1.9 µL, Eighteen miRNAs: 
8.6 µL). Three technical replicates were done in each of three biological replicates. 
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Table 7: List of miRNA mimics and inhibitors used 
Catalog No. Gene Symbol Type Gene Targeted* 
C-301407-00 hsa-miR-1275 Mimic CYP2B6/SLC22A1 
C-300608-03 hsa-miR-141-3p Mimic UGT1A1 
C-300611-05 hsa-miR-143-3p Mimic CYP1A2/2C9/HNF4A 
C-300634-03 hsa-miR-154-3p Mimic ABCG2 
C-300644-03 hsa-miR-206 Mimic SLC15A2/SLCO1B1/TPMT 
C-300578-05 hsa-miR-221-3p Mimic * 
C-300504-07 hsa-miR-29a-3p Mimic CYP2B6 
C-300520-05 hsa-miR-29b-3p Mimic CYP2B6 
C-300657-03 hsa-miR-301a-3p Mimic * 
C-301308-00 hsa-miR-320b Mimic CYP1A2/NAT 
C-300704-03 hsa-miR-324-5p Mimic * 
C-300708-05 hsa-miR-335-5p Mimic * 
C-301185-01 hsa-miR-339-3p Mimic * 
C-300675-03 hsa-miR-369-3p Mimic CYP2C9 
C-300857-01 hsa-miR-376a-3p Mimic DPYD/SLC15A2/UGT1A1 
C-300674-05 hsa-miR-376c-3p Mimic UGT2B15/17 
C-300691-03 hsa-miR-382-5p Mimic SLC22A2 
C-300729-03 hsa-miR-431-5p Mimic CYP1A2/SLC22A2 
C-300742-05 hsa-miR-483-3p Mimic CYP2B6 
C-300769-03 hsa-miR-512-3p Mimic ABCG2 
C-300835-05 hsa-miR-519a-3p Mimic ABCG2/DPYD/SLC15A2 
C-300951-03 hsa-miR-625-5p Mimic CYP2B6/HNF4A 
C-301001-01 hsa-miR-668-3p Mimic CYP1A2/HNF4A 
C-301242-01 hsa-miR-744-5p Mimic CYP2B6 
C-301268-01 hsa-miR-939-5p Mimic CYP2B6 
IH-301407-01 hsa-miR-1275 Inhibitor CYP2B6/SLC22A1 
IH-300611-06 hsa-miR-143-3p Inhibitor CYP1A2/2C9/HNF4A 
IH-300504-08 hsa-miR-29a-3p Inhibitor CYP2B6 
IH-300521-07 hsa-miR-29b-3p Inhibitor CYP2B6 
IH-301308-01 hsa-miR-320b Inhibitor CYP1A2/NAT 
IH-300729-05 hsa-miR-431-5p Inhibitor CYP1A2/SLC22A2 
IH-300742-06 hsa-miR-483-3p Inhibitor CYP2B6 
IH-300951-04 hsa-miR-625-5p Inhibitor CYP2B6/HNF4A 
IH-301001-03 hsa-miR-668-3p Inhibitor CYP1A2/HNF4A 
IH-301242-02 hsa-miR-744-5p Inhibitor CYP2B6 
IH-301268-02 hsa-miR-939-5p Inhibitor CYP2B6 
CN-001000-01 cel-miR-67 Control None 
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* These miRNAs were negatively correlated with increased gene expression from liver 
expression studies but were not predicted to target these specific genes. They were 
included in the experiment where 18 miRNAs were transfected in adult HepaRG cells. 
 
RNA isolation and storage 
RNA was isolated 48 hours after transfection with plasmids, miRNAs, or plasmid-miRNA 
combinations using Qiagen RNeasy Mini Kit or Qiagen miRNeasy Mini Kit. An on-column 
DNase digest was performed using Qiagen RNase-Free DNAse Set (Valencia, CA). RNA 
concentrations were measured using Invitrogen Qubit RNA BR Assay on the Qubit 
fluorometer (Invitrogen, Eugene, OR). 
 
cDNA and quantitative PCR 
cDNA was made using Qiagen QuantiTect Reverse Transcription Kit (Valencia, CA). 
Within each experiment, the RNA input was consistent among samples within each 
experiment. Reverse transcription reactions run according to manufacturer’s protocol 
using the Applied Biosystems GeneAmp PCR System 9700. TaqMan Gene Expression 
Assays for CYP2B6 (Hs04183483_g1, FAM-labelled), CYP1A2 (Hs00167927_m1, FAM-
labelled), and GAPDH (Hs02786624_g1, VIC-labelled) and TaqMan Universal Master Mix 
II, with UNG (Applied Biosystems, Foster City, CA) were used to measure gene 
expression according to the manufacturer’s protocol in 20 µL reaction on the BioRad 
Thermal Cycler and Applied Biosystems QuantStudio 12K Flex. 
 
Statistical analysis for quantitative PCR 
The Delta Delta CT (ddCT) method was used to calculate changes in CYP2B6 and CYP1A2 
mRNA expression when validating TALE-TF activity and miRNA ability to alter mRNA 
expression in HeLa, HepG2, and HepaRG cells. Delta Delta CT= experimental (average 
CT of CYP – average CT of GAPDH) – control (average CT of CYP – average CT of 
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GAPDH). Fold changes are calculated 2^ddCT and log2 transformed. Paired t-tests were 
used to assess the changes in mRNA expression using the dCT values. All analyses 
performed using Graphpad Prism 6 (La Jolla, CA), with p-values <0.05 considered 
statistically significant. 
 
Measurement of mRNA expression in HepaRG cells 
Library preparation and sequencing 
The concentration and quality of total RNA samples was first assessed using Agilent 2100 
Bioanalyzer. A RIN (RNA Integrity Number) of five or higher was required to pass the 
quality control. Then five hundred nanograms of RNA per sample were used to prepared 
single-indexed strand-specific cDNA library using TruSeq Stranded mRNA Library Prep 
Kit (Illumina). The resulting libraries were assessed for its quantity and size distribution 
using Qubit and Agilent 2100 Bioanalyzer. One and a half picomolar pooled libraries were 
sequenced with 2×75 bp paired-end configuration on NextSeq500 (Illumina) using 
NextSeq 500/550 High Output Kit. A Phred quality score (Q score) was used to measure 
the quality of sequencing. More than 90% of the sequencing reads reached Q30 (99.9% 
base call accuracy). 
 
Sequence alignment and gene counts 
The sequencing data were first assessed using FastQC (v.0.11.5, Babraham 
Bioinformatics, Cambridge, UK) for quality control. Then all sequenced libraries were 
mapped to the human genome (UCSC hg19) using STAR RNA-seq aligner (v.2.5) (Dobin 
et al., 2013) with the following parameter: “--outSAMmapqUnique 60”. The reads 
distribution across the genome was assessed using bamutils (from ngsutils v.0.5.9) 
(Breese and Liu, 2013). Uniquely mapped sequencing reads were assigned to hg19 
refGene genes using featureCounts (subread v.1.5.1) (Liao et al., 2014) with the following 
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parameters: “-s 2 –p –Q 10”. Genes with read count per million (CPM) < 0.5 in more than 
3 of the samples were removed. The data was normalized using TMM (trimmed mean of 
M values) method. Differential expression analysis was performed using edgeR (v.3.12.1) 
(McCarthy et al., 2012; Robinson et al., 2010). False discovery rate (FDR) was computed 
from p-values using the Benjamini-Hochberg procedure. 
 
In vitro drug probe assay and LC/MS/MS methods 
Reagents 
Bupropion, phenacetin, nevirapine, efavirenz and 8-hydroxyefavirenz were obtained from 
Toronto Research Chemicals Inc. (North York, ON, Canada). All other chemicals were 
high-performance liquid chromatography grade. 
 
Drug probe assay 
To measure CYP2B6 and CYP1A2 activity in HepaRG cells, a final concentration of 100 
µM bupropion (CYP2B6) or 200 µM phenacetin (CYP1A2) in 500 µLs was added Day 8, 
two days after transfection with synthetic miRNAs. Drug probe was incubated on cells for 
one hour. Media was removed and stored in -80°C until extraction for quantification of 
parent and metabolites. 
 
Bupropion extraction 
A liquid-liquid extraction was performed according to (Ward et al., 2003) by using 500 µL 
of media obtained from HepaRG cell drug probe assay and 25 µL of nevirapine internal 
standard (500 ng/µL). Then, 500 µL of Gly/NaOH pH 11.13 solution was added and 
vortexed. Six milliliters of ethyl acetate was added, vortexed, and shaken for 5 minutes. 
Samples were centrifuged at 3,600 rpm for 10 minutes and 4°C on an Allegra 6R Benchtop 
centrifuge (Beckman Coulter, Brea, CA) to remove the organic layer. Supernatants were 
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dried and reconstituted in 100 µL MeOH 0.1% formic acid 1:1 (mobile phase) for mass 
spectrometry analysis. 
 
LC-MS/MS quantification 
The liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for detection 
and quantification of EFV and 8-hydroxy efavirenz was developed to obtain the best 
selectivity and sensitivity (Ward et al., 2003). Some alterations were made to adapt to 
bupropion and hydroxyl-bupropion detection and quantification (Ogburn et al., 2010). The 
analysis was performed on an API 3200 triple-quadrupole mass spectrometry (Applied 
Biosystem/MDS Sciex, Foster City, CA) equipped with a turbo ion spray source. The 
HPLC system consists of two LC-20AD pumps, a SIL-20AHT UFLC autosampler, a DGU-
20A3 degasser and a CBM-20A controller (Shimadzu, Columbia, MD), all controlled by 
Analyst 1.5.1 software (Applied Biosystem/MDS Sciex, Foster City, CA) in conjunction 
with Windows XP (Microsoft, Redmond, WA). The chromatographic separation of EFV 
and 8-hydroxy efaviranz was performed on a Phenomenex (Torance, CA) Luna C18 
column (150 × 4.6 mm, 5 µm particle size). The injection volume was 10 µL. Before and 
after each injection, the needle was washed with ACN/H2O (75/25, v/v). Mobile phase (0.8 
ml/min) was (A) methanol: formic acid (0.1% in water) (1/99, v/v) and (B) methanol: formic 
acid (0.1% in water) (99/1, v/v) using the following gradient: starting from 25% B, linear 
gradient to 90% B between 0.01 and 16 min, then re-equilibrated to initial conditions 
between 16.01 min and 20.00 min; the separation of bupropion and 8-hydroxy bupropion 
was almost the same as EFV except the gradient from 90% A to 90% B within 10 min, 
then re-equilibrated until 14 min. 
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Statistical analysis for drug concentrations 
Metabolite parent ratios were calculated using the following formula: [(Metabolite Analyte 
Peak/IS Peak Area Counts) ÷ (Parent Analyte Peak/IS Peak Area Counts)]. Values were 
log10 transformed. Technical triplicates were done for three or four biological replicates. 
Technical triplicates were averaged and paired t-tests were performed between the 
combined miRNA-treated and control-treated HepaRG cells. All analyses performed using 
Graphpad Prism 6 (La Jolla, CA), with p-values <0.05 considered statistically significant. 
 
Results 
TALE-TFs induce expression of CYPs 
Among the miRNAs that were developmentally-regulated, we wanted to begin validating 
the miRNA-mRNA predictions observed in Chapter 1. Since expression of CYP2B6 and 
CYP1A2 was not expressed at quantifiable levels in HeLa or HepG2 cells, we utilized 
transcription activator-like effector-transcription factors (TALE-TFs), to induce gene 
expression in these cell culture models. We did not use primary human hepatocytes, as 
they originate from a pool of donors and may increase variability in miRNA targeting due 
to genetic variation effects. Primary human hepatocytes are also expensive, difficult to 
transfect, and have unknown histories (e.g. medication use, disease). TALE-TF proteins 
can be designed to induce the expression of any gene through a repeat variable di-amino 
acid code targeting sequences near the promoter region of the gene of interest. The 
protein coils around the targeted DNA sequence. Transcription activation is facilitated by 
the attached viral protein 64 (VP64) transcription factor as depicted in Figure 7. 
 
Four TALE-TFs were designed to target CYP2B6. These TALE-TFs each target a 20 bp 
sequence within or near the promoter region of CYP2B6 to facilitate the recruitment of 
transcription factors to increase transcription. When TALE-TFs (T1, T2) were transfected 
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into HeLa cells individually, CYP2B6 expression was increased 18- and 7-fold, 
respectively. TALE-TFs 3 and 4 had no effect of CYP2B6 expression; however, when all 
four were transfected simultaneously, CYP2B6 expression increased 121-fold (Figure 8). 
In HepG2 cells, CYP2B6 expression was increased 50-, 33-,15-, 14-fold for the four 
individual TALE-TFs and 70-fold when combined. 
 
Four TALE-TFs were also designed to target CYP1A2. The combination of all four TALE-
TFs increased expression 164- and 189-fold in HeLa and HepG2 cells respectively (Figure 
8). They were not tested individually since all four usually work better than individual 
transfections, which was consistent with our results for CYP2B6 induction. 
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Figure 7: TALE-TF protein structure and code 
TALE-TFs can induce the expression of target genes by binding to regions near the 
promoter through a central tandem repeating domain consisting of ~34 amino acid 
repeats. The residues at the 12th and 13th position of each repeat creates a code that 
determines which base pair it will bind. 
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Figure 8: Induction of CYP expression using TALE-TFs 
TALE-TFs were used to induce expression of CYP2B6 and CYP1A2. X-axis: Individual 
TALE-TFs (T1-4) and all four TALE-TFs (All) in either HeLa cells (black bars) or HepG2 
cells (gray bars). Y-axis: Fold-change compared to control pIS-0 plasmid. The control 
plasmid is a luciferase plasmid that does not affect CYP expression. 
 
  
HeLa 
HepG2 
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miRNA regulation of CYP2B6 
After induction of CYP2B6 gene expression in HeLa cells, miRNAs predicted to target 
CYP2B6 mRNA and their inhibitors were used to validate predictions. MicroRNAs that 
target CYP2B6 through degradation of mRNA should result in decreased CYP2B6 mRNA. 
Inhibitors function through perfect complimentary binding to sequester its target miRNA 
and prevent it from having an effect. MicroRNAs 744-5p and 1275 significantly 
downregulated CYP2B6 mRNA 3.6-fold (p<0.001) and 2.6-fold (p<0.05). In all other 
miRNAs, the decrease in CYP2B6 mRNA was not significant. Inhibitors for endogenous 
miR-29b-3p and miR-744-5p significantly increased CYP2B6 mRNA expression 2.4- and 
2.3-fold respectively (p<0.05) (Figure 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: miRNA regulation of CYP2B6 in HeLa cells 
Predicted miRNAs or their inhibitors transfected in HeLa cells. X-axis: miRNA mimics 
(black bars) and inhibitors (gray bars). MicroRNAs 29a-3p and 483-3p experiments were 
performed earlier using Lipofectamine 2000 instead of Lipofectamine 3000. Y-axis: log2 
fold-changes compared to C. elegans miRNA negative control. Errors bars are standard 
error of mean. (*=p<0.05, **=p<0.01, ***=p<0.001) 
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When comparing the combination of miRNA regulation, all seven miRNAs were 
transfected simultaneously in HeLa and HepG2 cells. In HeLa cells, there were no 
significant changes among the mimics, but the combined inhibitors significantly decreased 
CYP2B6 expression 5.7-fold (p<0.05) (Figure 10). Similar results were observed in HepG2 
cells with inhibitors decreasing CYP2B6 expression 4.3-fold (p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Regulation of CYP2B6 mRNA in HeLa and HepG2 cells transfected with 
seven miRNAs predicted to target CYP2B6 mRNA 
Seven miRNA mimics and inhibitors transfected together in HeLa and HepG2 cells. X-
axis: miRNA mimics (M: black bars) and inhibitors (I: gray bars). Y-axis: log2 fold-change 
compared to C. elegans miRNA negative control. Error bars are standard error of mean. 
(*=p<0.05, **=p<0.01) 
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miRNA regulation of CYP2B6 in HepaRG cells 
Due to cell-type specific differences and inability to measure CYP2B6 enzyme activity in 
HeLa and HepG2 cells, even after TALE-TF induction, future experiments were conducted 
in HepaRG cells. HepaRG cells are a human hepatic cell line that exhibit characteristics 
of primary human hepatocytes, such as expression of CYP genes, nuclear receptors, and 
drug transporters. 
 
When all seven miRNAs predicted to target CYP2B6 were transfected in HepaRG cells, 
mRNA expression was significantly decreased 1.3-fold (p=0.0078). No changes were 
observed in CYP2B6 activity as measured by bupropion hydroxylation (Figure 11). 
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Figure 11: miRNA regulation of CYP2B6 expression and activity in HepaRG cells 
A. CYP2B6 mRNA expression and B. activity measured by bupropion conversion to 
hydroxybupropion in HepaRG cells after miRNA regulation. Individual dots represent 
biological replicates paired with their control. Error bars are standard error of mean. 
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miRNA regulation of CYP1A2 
After induction of CYP1A2 gene expression in HeLa cells with the TALE-TFs, miRNAs 
predicted to target CYP1A2 and their inhibitors were used to validate predictions. None of 
the miRNA mimics significantly reduced CYP1A2 expression, but independently, three 
inhibitors significantly increased CYP1A2 expression (431-5p: 2.6-fold, 143-3p: 2.1-fold, 
320b: 2.4-fold (p<0.05)) (Figure 12). 
 
When comparing the combination of miRNA regulation, all four miRNAs were transfected 
simultaneously in HeLa and HepG2 cells. In HeLa cells, there were no significant changes 
among the mimics and inhibitors (Figure 13), but both were in the overall direction as the 
individually transfected miRNAs as shown in Figure 12. However, in HepG2 cells, the 
inhibitors significantly downregulated CYP1A2 mRNA expression (3.6-fold, p<0.05) 
suggesting that there are cell-type specific differences in miRNA regulation. 
 
When tested in HepaRG cells, CYP1A2 mRNA expression was not quantifiable by qPCR; 
however, because these cells were verified to have CYP1A2 activity, future experiments 
will focus on measuring the effect of the miRNAs on CYP1A2 activity as measured by the 
conversion of phenacetin to acetaminophen.  
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Figure 12: miRNA regulation of CYP1A2 in HeLa cells 
Predicted miRNAs or their inhibitors transfected in HeLa cells. X-axis: miRNA mimics 
(black bars) and inhibitors (gray bars). Y-axis: log2 fold changes compared to C. elegans 
miRNA negative control. Errors bars are standard error of mean. (*=p<0.05, **=p<0.01) 
 
 
 
 
Figure 13: Combined miRNA regulation of CYP1A2 in HeLa and HepG2 cells 
Combined four miRNA mimics and inhibitors transfected in HeLa and HepG2 cells. X-axis: 
miRNA mimics (M: black bars) and inhibitors (I: gray bars). Y-axis: log2 fold change 
compared to C. elegans miRNA negative control. Error bars are standard error of mean. 
(*=p<0.05) 
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Discussion 
Our studies identified developmentally-regulated miRNAs that are capable of regulating 
CYP gene expression. Validating miRNA-mRNA interactions provides additional support 
that the developmentally-regulated miRNAs observed in Chapter 1 likely have important 
roles in the ontogeny of the hepatic drug metabolism. These hepatic miRNAs can 
contribute to known developmental changes in pharmacogenes through the degradation 
of mRNA or through repression of translation, both mechanisms allowing for a reduction 
in activity. 
 
MicroRNAs were transfected into HeLa or HepG2 cells and gene expression of the target 
mRNA was measured; however, because these cell lines do not express the CYP genes, 
TALE-TFs were used to induce endogenous gene expression. TALE-TF induction 
increased gene expression levels to more physiological levels versus levels observed with 
over expression plasmids. A combination of four TALE-TFs targeting the promoter region 
of CYP2B6, increased CYP2B6 expression synergistically compared to individual TALE-
TFs. This synergistic regulation of gene expression is expected of TALE-TFs as the 
increase in transcription activators allows for increased binding and stabilization for 
proteins involved in transcription (Carey et al., 1990; Perez-Pinera et al., 2013). As a 
result, when validating CYP1A2, four different TALE-TFs were also used to increase gene 
expression in HeLa and HepG2 cells.  
 
Seven developmentally-regulated miRNAs were predicted to target CYP2B6. Gene 
expression was significantly decreased by two miRNAs, miR-1275 and miR-744-5p. When 
transfected with their inhibitors, CYP2B6 gene expression increased with miR-744-5p and 
miR-29b-3p. This suggests that endogenous miR-744-5p and miR-29b-3p must be 
present in HeLa cells as inhibitors sequester endogenous miRNAs through perfect 
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complimentary binding. When the combination of seven miRNA inhibitors was transfected, 
an unexpected decrease in CYP2B6 mRNA expression was observed in HeLa and HepG2 
cells. It is known that a single miRNA can have multiple targets, so observed changes can 
be due to other factors such as the inhibitors sequestering miRNAs responsible for 
targeting upstream transcription factors and repressor elements. It is of note that 
measuring gene expression using qPCR is limited to detecting only mRNA degradation by 
miRNAs as opposed to their ability to repress translation. A combination of techniques is 
necessary to fully characterize miRNA ability to target a particular mRNA. 
 
CYP2B6 has been validated to be targeted by miR-25-3p in HepaRG cells via reporter 
gene assays and electrophoretic mobility shift assays (Jin et al., 2016). The Jin et al group 
discovered the connection between CYP2B6 mRNA and miR-25-3p expression through 
inverse correlations in human hepatocytes. This particular miRNA was found to decrease 
in expression between fetal and pediatric human liver tissues (1.6-fold decrease: Table 
2); however, it was not predicted to target CYP2B6 using our prediction methods or found 
to be negatively correlated in our data. 
 
Next, we tested the combination of miRNAs in HepaRG cells, a cell line that expressed 
CYP2B6 and that had been validated to have CYP2B6 activity (Rubin et al., 2015). 
HepaRG cells are emerging as a popular cell line for validating miRNA-mRNA interactions 
in comparison to primary human hepatocytes, due to their consistency between batches 
as HepaRG cells originate from a single human source (Jin et al., 2016; Yu et al., 2015; 
Zeng et al., 2017). Primary human hepatocytes are usually pooled from various donors, 
introducing variability into experiments such as genetic variant effects which can lead to 
variable drug metabolism. In our experiments, CYP2B6 mRNA expression levels 
significantly decreased upon miRNA transfection compared to the control, but CYP2B6 
 97 
activity levels were not changed. This could suggest that either the decrease in mRNA 
levels was not large enough to affect CYP2B6 activity or the transfection period was not 
long enough for protein levels to be affected. In primary human hepatocytes, the half-life 
for CYP2B6 mRNA was approximately 38 hours and 68 hours for enzyme activity (Dixit et 
al., 2016). 
 
CYP1A2 was predicted to be targeted by four developmentally-regulated miRNAs. These 
miRNAs did not downregulate CYP1A2 gene expression in HeLa cells. However, 
individual inhibitors increased expression. This suggests that these miRNAs may be 
endogenously present in HeLa cells at levels high enough, that additional miRNAs did not 
have an additional effect. Furthermore, cell-type specific differences in miRNA regulation 
became apparent when CYP1A2 mRNAs levels were significantly decreased in HepG2 
cells but increased in HeLa cells when the combination of inhibitors was added. This 
prompted us to continue validations in HepaRG cells as this cell line was more 
representative of the human liver; however, CYP1A2 mRNA levels could not be detected 
in HepaRG cells, although these cells have been shown to have CYP1A2 activity (Rubin 
et al., 2015). This could be due to variability in processing of HepaRG cells on the supplier 
or on our behalf. Future studies will address phenacetin-O-deethlaytion as a measure of 
CYP1A2 activity by incubating phenacetin in the cell culture media in conjunction with 
transfected miRNAs in addition to measuring mRNA and protein levels. 
 
MicroRNA regulation is difficult to interpret without proof of miRNA binding, so novel 
techniques including Argonaute 2 high-throughput sequencing of RNA isolated by cross-
linked immunoprecipitation (Ago2-HITS-CLIP), will prove as a valuable unbiased 
approach to determine miRNA-mRNA interactions (Bottini et al., 2017; Spengler et al., 
2016). This tool captures the Argonaute protein bound to the miRNA and its target, 
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followed by sequencing to decipher direct binding of miRNAs and their targets. This is 
critical as miRNAs can have multiple targets and have been shown to bind to their targets 
via non-canonical pathways (Duursma et al., 2008; Orom et al., 2008). This is a limitation 
of using prediction algorithms and tools to predict miRNA-mRNA interactions as they focus 
on seed sequence binding within the 3’UTR of target genes. 
 
Furthermore, as the post-transcriptional activity of miRNAs have been extensively studied, 
very little is known about how miRNAs themselves are regulated. Studies pertaining to 
miRNA stability will be critical for understanding differential expression and miRNA activity 
in different human cell lines and tissues. It is known that miRNAs show tissue-specific 
regulation, which infer that a regulatory network exists (Biemar et al., 2005). Such a 
network remains to be elucidated. Their expression levels may also be regulated by RNA-
binding proteins and the various proteins that process miRNAs into mature miRNAs as 
shown previously in Figure 1. It is known that double-stranded RNA binding proteins bind 
their targets based on structure rather than sequence, so this may serve as a mechanism 
for why miRNAs are differentially expressed among cell types. Competition with other RNA 
binding proteins and the differential expression of these proteins can explain these 
differences in miRNA expression across cell types (Habig et al., 2007). As the regulation 
of miRNAs become well-studied, it will enable better understanding of miRNAs as 
regulators themselves. 
 
Collectively, our data show that miRNAs have the potential to alter gene expression of 
drug disposition genes. To better address the effects of miRNA regulation, selection of 
appropriate cell lines are necessary as cell-type specific differences can make it difficult 
to extrapolate results. HepaRG cells are a useful tool for drug metabolism and miRNA 
studies as they have been characterized to express drug disposition genes and eliminate 
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the genetic variability that may arise from the pooled primary human hepatocytes. 
However, there is also a need for understanding the expression levels of miRNAs in the 
different cell lines and human tissues, as this information becomes useful for the 
interpretation of the synthetic miRNA and miRNA inhibitor experiments. However, to best 
understand miRNA regulation, better characterization of miRNAs themselves are 
warranted.  
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CHAPTER 3 
Variants in the CYP2B6 3’UTR alter in vitro and in vivo CYP2B6 activity: potential 
role of microRNAs 
Introduction 
MicroRNAs have been shown to negatively regulate drug disposition gene expression. 
However, due to miRNA regulation via perfect complimentary binding in the ‘seed’ 
sequence region 7-8 nucleotides in length, genetic variants in this region have the 
potential to alter miRNA regulation. Pharmacogenetics, the study of genetic differences 
that can affect an individual’s response to drugs, has primarily focused on genetic 
variations in the promoter and coding region of drug disposition genes; however, emerging 
evidence has shown that genetic variations in the 3’UTR may contribute to variability in 
drug response by altering miRNA regulation. For example, miR-34a-5p has been 
previously validated to target hepatic nuclear factor 4α (HNF4A), a master regulator of 
many drug disposition genes (Ramamoorthy et al., 2012; Wirsing et al., 2011). 
Furthermore, a SNP in the 3’UTR of HNF4A (rs11574744) abolished the miRNA target 
sites of both miR-34a-5p. This SNP prevented the ability of miR-34a-5p to downregulate 
HNF4A and appeared to be associated with altered CYP2D6 activity in a cohort previously 
phenotyped with the CYP2D6 probe drug, dextromethorphan (Ramamoorthy et al., 2012). 
This SNP is also present only in African Americans, as we know that these genetic variants 
can occur at differing frequencies among populations.  
 
We hypothesize that genetic variants in the 3’UTR of CYP2B6 contribute to the variability 
in CYP2B6 activity among humans. In this study, we retrospectively sequenced the 
CYP2B6 3’UTR of healthy human volunteers with previously characterized efavirenz 
pharmacokinetics. Efavirenz has been shown to be a suitable probe drug substrate to 
measure CYP2B6 activity in vitro and in vivo (Administration, 2012). Cmax and AUC0-48 
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ratios (8-hydroxy-efavirenz/efavirenz) (8-OH-EFV/EFV) have been demonstrated to 
reflect CYP2B6 activity (Jiang et al., 2013; Xu et al., 2013). Functional variants in the 
CYP2B6 3’UTR observed in vivo were validated through in vitro models. Our findings 
suggest that genetic variants in the 3’UTR may explain additional variation in drug 
metabolism and disposition (Burgess et al., 2017). 
 
Materials and Methods 
CYP2B6 activity in healthy volunteers 
Data from 200 healthy non-pregnant female (n=83) and male (n=117) volunteers (18-55 
years old) administered a single efavirenz dose, a probe drug substrate of CYP2B6 
activity, was obtained from the single dose phase of three previous studies, published and 
unpublished (Desta et al., 2016; Robarge et al., 2017). These studies were approved by 
the Indiana University School of Medicine Institutional Review Board, conducted at the 
Indiana University School of Medicine Clinical Research Center and registered at 
http://www.clinicaltrials.gov (trial identifiers NCT00668395, NCT01104376, and 
NCT02401256). After written informed consent, volunteers were thoroughly screened 
using medical history, physical examination, and laboratory tests such as 
electrocardiography, HIV test, urinalysis and blood tests. During this screen, venous blood 
was drawn for DNA isolation. Dietary restrictions and inclusion and exclusion criteria have 
been previously reported (Michaud et al., 2014; Michaud et al., 2012). 
 
These open label studies were retrospectively used to evaluate the association of single 
dose efavirenz pharmacokinetics with the CYP2B6 3’UTR variants. Briefly, plasma 
samples were taken pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72 
and 144 hours after single dose efavirenz administration. Participants from two studies 
(127 participants total) were administered 600 mg of efavirenz and 73 participants from 
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another study were administered 100 mg of efavirenz (Sustiva, Bristol-Myers Squibb). 
Plasma efavirenz and 8-hydroxy-efavirenz concentrations were measured using a 
validated LC-MS/MS protocol as previously described (Robarge et al., 2017). Non-
compartmental analysis of data was performed using Phoenix® WinNonlin® (version 7.0, 
Pharsight Corp., Cary, NC) to determine Cmax (maximal plasma concentration) and  
AUC0-48 (area under the plasma concentration time curve from zero to 48 hours). Cmax was 
assessed directly from the concentration-time profile and AUC0-48 was determined using 
the trapezoidal rule with linear up/log down interpolation. 
 
CYP2B6 activity in human liver microsomes (HLMs) 
HLMs were prepared by differential centrifugation, as described by Lu and Levin (1972) 
(Lu and Levin, 1972). In vitro microsomal incubations were performed according to Pearce 
et al 2015 (Pearce et al., 2016). Briefly, HLMs (30 μg of microsomal protein), potassium 
phosphate buffer (50 mM, pH 7.4), MgCl2 (3 mM), EDTA (1 mM), and bupropion (500 μM) 
were incubated at the final concentrations listed. Reactions were initiated by the addition 
of a NADPH-generating system, consisting of NADP (1 mM), glucose-6-phosphate (5 
mM), and glucose-6-phosphate dehydrogenase (1 U/ml), incubated at 37°C in a Thermo 
Forma Benchtop Orbital Shaker (Marietta, OH) and terminated after 30 minutes by the 
addition of 50 μL of ice-cold acetonitrile. Incubations were performed in triplicate. 
Bupropion stock solutions were dissolved in methanol; however, the concentration of 
methanol present in the incubation mixtures did not exceed 0.25%. Hydroxyl-bupropion 
and bupropion were resolved by isocratic, reversed-phase high-performance liquid 
chromatography based on a modification of the method by Faucette et al. 2000 (Faucette 
et al., 2000) as described previously (Pearce et al., 2016). 
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Genotyping and sequencing in healthy volunteers 
Genomic DNA extracted from whole blood was used for genotyping (coding region 
variants) and Sanger sequencing of the 3’UTR. CYP2B6 genotyping was performed using 
TaqMan Genotyping Assays for rs3745274 (516G>T, Q172H) and rs28399499 (983T>C, 
I328T) (Life Technologies, Foster City, CA) according to the protocol provided. PCR was 
performed on BioRad iCycler and QuantStudio 12K Flex real-time PCR instruments. 
CYP2B6 rs2279343 (785A>G, K262R) genotyping was performed by first amplifying exon 
5 with primers 5’-CTCTCTCCCTGTGACCTGCTA-3’ (forward) and 5’-
CTCCCTCTGTCTTTCATTCTGTC-3’ (reverse) (Integrated DNA Technologies, Coralville, 
IA) as described by Lang et al. (Lang et al., 2001), then using 1 µL exon 5 PCR 
amplification product as a template for a custom TaqMan Genotyping Assay as previously 
described (Michaud et al., 2014). 
 
To sequence the 3’UTR region, this region was first amplified by adding the following 
reagents to each reaction: 1 μL of DNA (10 ng), 12 μL CloneAmp HiFi PCR Premix 
(CloneTech, Mountain View, CA), 10 μL ultrapure distilled water and 1 μL of each primer 
(final concentration: [0.4 μM]) (Integrated DNA Technologies, Coralville, IA). The primer 
sequences used were 5’-GGCAAAATACCCCCAACATA-3’ (forward) and 5’-
AGAGTTGGCATTGAGGTGAGAG-3’ (reverse) (Swart and Dandara, 2014). The PCR 
amplification conditions were 98°C for 5 minutes, 40 cycles at 98°C for 10 seconds, 69.5°C 
for 15 seconds, and 72°C for 2 minutes. Final extension was 72°C for 7 minutes. PCR 
purification was performed using a QIAquick PCR Purification Kit (Qiagen, Valencia, CA) 
according to the user manual. DNA concentrations were measured with a Qubit dsDNA 
BR Assay Kit (Invitrogen, Eugene, OR) according to the user manual. Samples were 
prepared for sequencing using 10 μL of DNA (50 ng) and 2 μL of one of four different 
 104 
primers [1.7 μM] and Sanger sequenced by ACGT (Germantown, MD). The 1.8 kb PCR 
product was sequenced in its entirety using the primers mentioned above and forward and 
reverse primers 5’-CTAAGCCTTGCTCTGTCTCC-3’ (forward) and 5’-
GGAGAATCACTTGAACCCAGG-3’ (reverse). 
 
Genotyping and sequencing in human liver tissue samples 
Genomic DNA extracted from 90 human liver samples was used for genotyping (coding 
region) and Sanger sequencing (3’UTR region). This protocol is different from the 
genotyping and sequencing of the healthy human volunteers, because the human liver 
microsomes were processed independently in a collaborating laboratory. Genotyping of 
coding region variants was performed on Applied Biosystems 7900 HT Real-Time PCR 
System or QuantStudio 12K Flex real-time PCR instruments using Life Technologies 
TaqMan assays for CYP2B6 rs3745274 (516G>T, Q172H) and rs28399499 (983T>C, 
I328T) (Life Technologies, Foster City, CA). To detect CYP2B6 rs2279343 (785A>G, 
K262R) a high-resolution melting (HRM) assay was performed as previously described 
(Twist et al., 2013). 
 
To sequence the 3’UTR, this region was first amplified by adding the following reagents 
to each reaction: 1 µL of DNA (15 ng), 4 µL KAPA LR Hotstart 2X, 2.4 µL ultrapure distilled 
water and 0.3 µL of each primer (final concentration: [0.375 µM]) (Integrated DNA 
Technologies, Coralville, IA). The primer sequences used were 5’-
AATCTGTTGCAGTGGACATTTG-3’ (forward) and 5’-AGAGTTGGCATTGAGGTGAGA-
3’ (reverse). The PCR amplification conditions were 94°C for 3 minutes, 48 cycles at 94°C 
for 10 seconds, 61.5°C for 15 seconds, and 68°C for 2 minutes. Final extension was 68°C 
for 7 minutes. PCR purification was performed using ExoSAP-IT (USB, Cleveland, OH). 
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A 1:20 dilution of the purified PCR product was used for sequencing, performed with 
BigDye terminator v3.1 and the STeP cycle sequencing protocol (Platt et al., 2007). Briefly, 
three cycle steps were performed: 1) at 95°C for 10 sec, 50°C for 5 sec and 60°C for 1 
min 15 sec for a total 15 cycles, 2) at 95°C for 10 sec, 50°C for 5 sec and 60°C for 1 min 
30 sec, a total of 5 cycles and 3) at 95°C for 10 sec, 50°C for 5 sec and 60°C for 2 min for 
15 cycles. The sequence reactions were cleaned up with AxyPrep Mag DyeClean 
(Axygen, Corning Life Sciences, Tewksbury, MA) and electrophoresis was performed on 
a 3730xl DNA Analyzer (Life Technologies, Foster City, CA). The 1962 bp PCR product 
was sequenced in its entirety using the following forward primers  
5’-TGTGTCTGGGCTTAGGGAC-3’, 5’-GTGATTCACCCACCTTAGCC-3’,  
5’-GTCTCAGCTCCCAAGTAGCTG-3’, and the reverse primers  
5’-CAGGTCTCTCAGAGGCAGG-3’, 5’-AGTTCGAGACCAGCCTGG-3’,  
5’-CCAGCTCCTCCAGAGGC-3’ and 5’-GCAGCTGGGAATGAGGA-3’.  
 
As a quality control, genotyping was repeated in random samples and genotyping and 
sequencing results were verified by a second person to assure accurate interpretation of 
the data. Sequences were analyzed using Sequencher (v.5.4.5, Gene Codes Corporation, 
Ann Arbor, MI) and BioEdit (v.7.2.5) (Hall, 1999) after alignment to the CYP2B6 reference 
sequence with GenBank Accession Number NC_000019.10. 
 
CYP2B6 allele, genotype, haplotype, diplotype analyses 
CYP2B6 star allele designations were assigned in accordance with the Human 
Cytochrome P450 Allele Nomenclature Database (http://cypalleles.ki.se/). Allele and 
genotype frequencies, Hardy-Weinberg equilibrium analysis, and linkage disequilibrium 
analysis were performed using SHEsis (Shi and He, 2005). Haplotype construction was 
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performed using PHASE version 2.1.1 (Stephens and Donnelly, 2003; Stephens et al., 
2001). Haplotype and diplotype Venn diagrams were generated using BioVenn (Hulsen et 
al., 2008). 
 
In silico microRNA predictions 
The PolymiRTS Database 3.0 (accessed June 2014) was used to identify SNPs predicted 
to create or abolish miRNA target sites for CYP2B6 (Bhattacharya et al., 2014). For the 
dinucleotide variant, rs70950385, manual seed sequence alignment was performed. 
 
In vitro luciferase assay to test effects of the rs70950385 (CA) variant on 
microRNA targeting 
The pIS-0 firefly luciferase vector (Yekta et al., 2004) (Addgene, Cambridge, MA) was 
used to study 3’UTR function in relation to miRNA regulation. The oligo containing either 
the wild-type (5’-GCCGTGTAATTCTAGGAGCTCGTCACACACTGCTGTAGTCTTCCCC 
AGTCCTCATCGTTCTAGAGTCGGGGC-3’) or variant (5’-GCCGTGTAATTCTAGGAGC 
TCGTCACACACTGCTGTAGTCTTCCCCCATCCTCATCGTTCTAGAGTCGGGGC-3’) 
miRNA target sites for the rs70950385 SNP (Integrated DNA Technologies, Coralville, IA) 
were amplified and then cloned into the pIS-0 vector 3’UTR using the NEBuilder HiFi DNA 
assembly system as instructed by the user manual (New England BioLabs, Ipswich, MA). 
The plasmids were then transformed into One Shot OmniMax 2 TI Chemically Competent 
E. coli (Invitrogen, Carlsbad, CA) and plated on ampicillin-treated agar plates. Individual 
colonies were selected and grown in ampicillin-treated liquid culture overnight. Plasmid 
DNA was isolated using a NucleoSpin Plasmid (NoLid) DNA Purification Kit (Macherey-
Nagel, Düren, Germany) and quantified using a DNA dsDNA BR Assay Kit (Qiagen, 
Invitrogen, Eugene, OR). DNA was subsequently sequenced using the 5’-
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GTGGTTTGTCCAAACTCATC-3’ reverse primer to ensure clones with the correct wild-
type and variant sequences were selected. 
 
HepG2 human liver carcinoma cells were seeded at a density of 90,000 cells per well in 
24 well plates and cultured for 48 hours. HepG2 cells were then transfected using 
Lipofectamine 3000 (Life Technologies, Foster City, CA) for 48 hours with each plasmid 
(500 ng/well) with or without the miRNAs (hsa-miR-625-5p and hsa-miR-1275; final 
concentration: [30 pM]) (GE Dharmacon, Chicago, IL) predicted to target the CYP2B6 
3’UTR region encompassing the genetic variant. Renilla luciferase reporter pGL4.74 (10 
ng/well) was used as the transfection control. C. elegans cel-miR-67 was employed as a 
negative control. Luciferase activity was measured with the Dual-Glo Luciferase Assay as 
instructed by the user manual (Promega, Madison, WI). 
 
Statistical analyses for CYP2B6 3’UTR study 
Efavirenz Cmax, AUC0-48 metabolite:parent ratios, and bupropion hydroxylase activity 
(untransformed data) were analyzed among each genotype, haplotype, or diplotype using 
Kruskal-Wallis followed by Dunn’s post-hoc tests. In vitro luciferase assay results were 
analyzed using paired ratio t-tests. All analyses were performed using Graphpad Prism 
version 6 (La Jolla, CA); p-values <0.05 were considered statistically significant. 
  
 108 
Results 
Association of CYP2B6 3’UTR SNPs with efavirenz Cmax and AUC0-48 
metabolite:parent ratios in healthy volunteers 
Among 200 healthy volunteers sequenced for CYP2B6 3’UTR variants, 187 volunteers 
had a complete set of efavirenz metabolism data and 197 were genotyped for CYP2B6*6 
and CYP2B6*18. Of the 197 volunteers for whom CYP2B6 genotyping data were 
available, 47% were normal metabolizers, 42% intermediate metabolizers, and 11% were 
classified as poor metabolizers (Table 8). Plasma efavirenz Cmax and AUC0-48 ratios (8-
OH-EFV/EFV) were used for the analysis. 
 
Twenty-five variants were observed in the 3’UTR of this population; however, only seven 
variants were observed at a frequency that allowed us to assess pharmacokinetic 
differences among the genotypes (Table 9). Among the normal metabolizers, altered 
efavirenz metabolism was detected in subjects with the following 3’UTR variants: 
rs3181842, rs7246465, rs707265, rs70950385, and rs1042389 (Figure 14; Table 10). The 
rs70950385 and rs1042389 variants were in complete linkage disequilibrium (r2=1.0, 
D’=1.0) in our cohort and thus not shown separately (Figure 15). For rs3181842, an 
increase in CYP2B6 activity, as shown by the Cmax ratio, was detected between the T/T 
and C/C genotypes (43.9% increase; p<0.01) and AUC ratio between volunteers with T/T 
versus T/C (31.9% increase; p<0.05) and C/C genotypes (70.6% increase; p<0.0001) 
(Figure 14A; Table 10). An increase in CYP2B6 activity was observed among volunteers 
carrying the rs7246465 variant allele (Cmax: C/C vs. T/T [40.0% increase; p<0.01]; AUC: 
C/C vs. C/T [38.0% increase; p<0.01] and T/T [67.9% increase; p<0.0001]) and rs707265 
(Cmax: G/G vs. G/A [20.0% increase; p<0.05] and A/A [46.6% increase; p<0.01]; AUC: G/G 
vs. G/A [34.2% increase; p<0.05] and A/A [72.4% increase; p<0.0001]) (Figure 14B,E; 
Table 10). These two variants were in partial linkage disequilibrium in our study cohort 
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(r2=0.80, D’=0.91) (Figure 15). The rs70950385 variant allele was associated with a 
decrease in CYP2B6 activity using Cmax between AG/AG vs. CA/CA (32.6%; p<0.01) and 
AG/CA vs. CA/CA genotypes (25.4%; p<0.05) and AUC between AG/AG and CA/CA 
genotypes (32.7%; p<0.05) (Figure 14F; Table 10). Comparable changes in efavirenz 
metabolism among the 3’UTR variants were also observed when all volunteers were 
included, even those with CYP2B6*6 and CYP2B6*18 alleles (Figure 16; Table 11). 
 
 
Table 8: CYP2B6 star allele frequency 
 
Metabolizer Status Observed Star Alleles Count (%) 
Normal *1/*1, *1/*2, *1/*4  92 (47) 
Intermediate *1/*6, *4/*6, *1/*18 83 (42) 
Poor *6/*6, *6/*18,*18/*18 22 (11) 
* No genotyping data for 3 volunteers 
 
  
  
1
1
0
 
Table 9: CYP2B6 3’UTR variant frequencies in healthy volunteers 
 
SNP 
Chromosome 
19 Position¹ MAF HWE Genotype (n) 
rs34749331 41016899 0.005 Yes G/G (198) G/A (2)  
rs139818840² 41017033 0.055 Yes 7/7 (179) 7/8 (20) 8/8 (1) 
rs528886765 41017103 0.003 Yes C/C (199) C/T (1)  
rs3181842 41017111 0.343 Yes T/T (89) T/C (85) C/C (26) 
rs28969414 41017171 0.037 Yes T/T (185) T/A (15)  
rs28969415 41017172 0.037 Yes A/A (185) G/A (15)  
rs553398143 41017187 0.003 Yes C/C (199) C/T (1)  
rs28969416 41017188 0.003 Yes A/A (199) A/G (1)  
rs535525152 41017191 0.003 Yes C/C (199) C/T (1)  
rs764949833 41017192 0.003 Yes A/A (199) A/G (1)  
rs150701000 41017208 0.007 Yes A/A (197) A/G (3)  
rs185153760 41017249 0.005 Yes G/G (198) G/A (2)  
rs142189613 41017333 0.003 Yes G/G (199) G/A (1)  
rs7260525 41017349 0.117 Yes A/A (156) A/G (41) G/G (3) 
rs7246465 41017398 0.323 No C/C (99) C/T (73) T/T (28) 
novel variant 41017895 0.003 Yes C/C (199) C/T (1)  
rs28969420 41017899 0.050 No G/G (166) G/T (24) T/T (10) 
rs145450819 41017916 0.005 Yes C/C (198) C/G (2)  
rs567303715 41018016 0.003 Yes C/C (199) C/G (1)  
rs28969421 41018082 0.010 No G/G (197) G/A (2) A/A (1) 
rs1038376 41018104 0.333 Yes A/A (89) A/T (89) T/T (22) 
rs707265 41018182 0.318 Yes G/G (101) G/A (71) A/A (28) 
rs70950385 41018226 0.228 Yes AG/AG (122) AG/CA (65) CA/CA (13) 
  
1
1
1
 
rs1042389 41018248 0.228 Yes C/C (122) C/T (65) T/T (13) 
rs538901499 41018270 0.010 Yes A/A (198) A/G (2)  
¹ Chromosome position is according to GenBank Accession Number NC_000019.10 [GRCh37.p17 108 annotation] 
² rs139818840 variant includes 7 or 8 AT repeats 
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Figure 14: Association of CYP2B6 3’UTR variants with efavirenz metabolism in 
healthy volunteers with CYP2B6 genotypes predicting normal metabolism (n=86) 
Efavirenz Cmax and AUC metabolite:parent ratios (8-OH-EFV/EFV) among normal 
metabolizers; subjects with CYP2B6*6 and *18 alleles excluded. X-axis: CYP2B6 3’UTR 
genotypes F. rs70950385 variant is in complete LD with rs1042389 (data not shown 
separately). Y-axis: 8-hydroxy-efavirenz/efavirenz ratio#. (*=p<0.05, **=p<0.01, 
***=p<0.001, ****=p<0.0001). # Higher 8-OH-EFV/EFV ratios mean higher CYP2B6 
activity. 
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Table 10: Association of CYP2B6 3’UTR variants with efavirenz metabolism in 
healthy volunteers without any CYP2B6*6 and CYP2B6*18 alleles (n=86) 
* Ratio=(8-OH-EFV/EFV) 
Cmax=maximum concentration 
AUC=area under the curve 0-48 hours 
CI=confidence intervals 
 
  
  n 
Mean    
Cmax 
Ratio* 
Lower    
95% CI 
Upper    
95% CI 
Mean    
AUC 
Ratio* 
Lower    
95% CI 
Upper    
95% CI 
rs3181842        
T/T 31 0.270 0.230 0.310 0.378 0.319 0.437 
T/C 36 0.317 0.286 0.349 0.498 0.440 0.556 
C/C 19 0.389 0.312 0.465 0.645 0.533 0.756 
rs7246465        
C/C 28 0.268 0.225 0.312 0.365 0.301 0.429 
C/T 36 0.317 0.285 0.348 0.504 0.450 0.559 
T/T 22 0.376 0.308 0.443 0.614 0.508 0.719 
rs28969420        
G/G 68 0.321 0.292 0.351 0.502 0.451 0.552 
G/T 11 0.335 0.244 0.427 0.482 0.351 0.614 
T/T 7 0.236 0.158 0.315 0.353 0.193 0.514 
rs1038376        
A/A 70 0.320 0.290 0.350 0.506 0.456 0.556 
A/T 14 0.284 0.227 0.341 0.391 0.296 0.487 
T/T 2 0.402 -0.729 1.532 0.498 -2.107 3.103 
rs707265        
G/G 32 0.266 0.227 0.305 0.374 0.314 0.433 
G/A 34 0.319 0.288 0.351 0.501 0.444 0.559 
A/A 20 0.390 0.318 0.462 0.644 0.539 0.749 
rs70950385        
AG/AG 46 0.342 0.305 0.380 0.536 0.473 0.599 
AG/CA 28 0.309 0.268 0.351 0.461 0.392 0.531 
CA/CA 12 0.231 0.161 0.301 0.361 0.241 0.481 
  
1
1
4 
 
Figure 15: r2 linkage disequilibrium diagram of CYP2B6 variants genotyped in samples from all four studies (3 clinical trials 
and one liver sample set) The r2 values for CYP2B6 3’UTR variants and CYP2B6*6 (SNP 1 and 2) and CYP2B6*18 (SNP 3). 
*SNP 1 (516G>T) and 2 (785A>G) denote CYP2B6*6, +SNP 3 (983T>C) denotes CYP2B6*18 
 *   *   + 
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Figure 16: Association of CYP2B6 3’UTR variants with efavirenz metabolism in 
healthy volunteer population (n=187) 
Efavirenz Cmax and AUC metabolite:parent ratios among all volunteers. X-axis: CYP2B6 
3’UTR genotypes F. rs70950385 variant is in complete LD with rs1042389 (data not shown 
separately). Y-axis: #8-hydroxy-efavirenz/efavirenz ratio. (*=p<0.05, **=p<0.01, 
****=p<0.0001). # Higher 8-OH-EFV/EFV ratios mean higher CYP2B6 activity. 
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Table 11: Association of CYP2B6 3’UTR variants with efavirenz metabolism in all 
volunteers including those with CYP2B6*6 and CYP2B6*18 alleles (n=187)  
 
  n 
Mean    
Cmax 
Ratio* 
Lower    
95% 
CI 
Upper    
95% 
CI 
Mean    
AUC 
Ratio* 
Lower    
95% 
CI 
Upper    
95% 
CI 
rs3181842        
T/T 86 0.286 0.249 0.322 0.355 0.321 0.390 
T/C 76 0.314 0.283 0.346 0.454 0.410 0.498 
C/C 25 0.364 0.300 0.428 0.568 0.464 0.671 
rs7246465        
C/C 94 0.285 0.252 0.319 0.351 0.319 0.383 
C/T 68 0.323 0.289 0.357 0.472 0.427 0.518 
T/T 25 0.351 0.284 0.418 0.566 0.457 0.674 
rs28969420        
G/G 155 0.312 0.286 0.339 0.429 0.396 0.462 
G/T 22 0.314 0.265 0.363 0.437 0.364 0.510 
T/T 10 0.224 0.169 0.278 0.312 0.200 0.424 
rs1038376        
A/A 81 0.308 0.279 0.336 0.482 0.435 0.529 
A/T 85 0.311 0.271 0.350 0.391 0.351 0.430 
T/T 21 0.296 0.232 0.361 0.333 0.261 0.405 
rs707265        
G/G 97 0.289 0.256 0.321 0.358 0.327 0.390 
G/A 65 0.315 0.280 0.350 0.461 0.412 0.509 
A/A 25 0.363 0.296 0.431 0.582 0.478 0.686 
rs70950385        
AG/AG 113 0.317 0.289 0.344 0.440 0.401 0.479 
AG/CA 63 0.305 0.261 0.349 0.405 0.360 0.450 
CA/CA 12 0.231 0.161 0.301 0.361 0.241 0.481 
* Ratio= (8-OH-EFV/EFV) 
Cmax=maximum concentration 
AUC=area under the curve 0-48 hours 
CI=confidence intervals 
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To assess the changes in efavirenz metabolism among combinations of variants, 
haplotype and diplotype analyses were performed. A significant overall change was 
detected among the Cmax ratios between the different haplotypes, but no significant 
changes were detected after post-hoc analysis (Table 12). A decrease in CYP2B6 activity 
as measured by AUC ratios were observed between haplotype 4 versus 2 (p<0.01), 12 
(p<0.0001), 13 (p<0.05), and 24 (p<0.01) (Table 12). Haplotypes 2, 4, 12, 13, and 24 
distinguished from the wild-type variations in the following 3’UTR variants: rs3181842, 
rs7260525, rs7246465, rs28969420, rs1038376, rs707265, rs70950385, and rs1042389. 
A significant overall change was also observed in AUC ratios between the different 
diplotypes, but no significant changes were observed after post-hoc analysis. The sample 
size for many haplotypes and diplotypes were too small to assess, i.e. many haplotypes 
and diplotypes were observed only within one of the metabolizer groups (Figure 17). Out 
of the 38 inferred 3’UTR haplotypes, two haplotypes were found among volunteers or 
samples that did not have CYP2B6*6 and *18 genotyping data for. Of the remaining 36 
haplotypes, 8, 9, and 3 were unique to normal, intermediate, and poor metabolizers, 
respectively, whereas 16 overlapped (Figure 17A). Haplotype 4 was detected among only 
genotypic normal and intermediate metabolizers, whereas haplotype 2, 12, and 13 were 
detected among all three groups; however, haplotype 24 (associated with decreased 
CYP2B6 activity) was also specific to genotypic normal and intermediate metabolizers 
suggesting the 3’UTR variants contribute to the variability in CYP2B6 activity (data not 
shown). Out of the 76 predicted diplotypes, 33, 21, and 8 were unique to normal, 
intermediate, and poor metabolizers, respectively, whereas 14 overlapped (Figure 17B). 
There were no diplotypes overlapping between the normal and poor metabolizer groups. 
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Figure 17: Venn diagrams of haplotypes and diplotypes observed in all studies  
The Venn diagrams depict the number of haplotypes (A) and diplotypes (B) within each 
CYP2B6 metabolizer group, as assigned by CYP2B6*6 and CYP2B6*18. Normal (blue), 
intermediate (green), and poor (red) metabolizers. 
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Table 12: CYP2B6 3’UTR variant haplotype association with CYP2B6 activity in healthy volunteers and human liver 
microsomes 
 
Haplotype 
ID 
Haplotype** Count 
Mean 
Cmax 
(8-OH-
EFV/EFV) 
Mean 
AUC0-48   
(8-OH-
EFV/EFV) 
Mean  
OH-BUP 
Rates 
(pmol/mg 
protein/min) 
1 G7CCTACACAAGGACCGCCGAGAGTA 7 0.25±0.07 0.33±0.19 265.7±167.6 
  2* G7CCTACACAAGGACCGCCGTGAGTA 25 0.27±0.03 0.33±0.03* 453.5±375.3 
3 G7CCTACACAAGGACCGCGGAGAGTA 1 0.36 0.38 - 
  4* G7CCTACACAAGGATCGCCGAAAGTA 128 0.35±0.02 0.55±0.03* 572.0±135.8 
5 G7CCTACACAAGGATCTCCGAAAGTA 1 0.39 0.66 - 
6 G7CCTACACAAGGATCTCCGAGCACA 1 - -  
7 G7CCTACACAAGGGCCGCCGAGCACA 1 - - 32.79 
8 G7CTTACACAAGGACCGCCGAAAGTA 5 0.30±0.06 0.46±0.09 125.2 
9 G7CTTACACAAGGACCGCCGAGAGTA 62 0.29±0.02 0.40±0.03 480.8±104.4 
10 G7CTTACACAAGGACCGCCGAGCACA 7 0.30±0.06 0.40±0.03 - 
11 G7CTTACACAAGGACCGCCGTAAGTA 1 0.52 0.59 - 
  12* G7CTTACACAAGGACCGCCGTGAGTA 128 0.31±0.02 0.38±0.02* 512.1±106.1 
  13* G7CTTACACAAGGACCTCCGAGCACA 50 0.28±0.01 0.39±0.03* 153.3±61.7 
14 G7CTTACACAAGGACTGCCGTGAGTA 1 0.34 0.60 - 
15 G7CTTACACAAGGATCGCCGAAAGTA 6 0.26±0.05 0.32±0.08 967.3±582.5 
16 G7CTTACACAAGGATCGCCGAAAGTG 2 0.35±0.10 0.38±0.003 - 
17 G7CTTACACAAGGATCGCCGAGAGTA 6 0.36±0.04 0.56±0.07 116.5 
18 G7CTTACACAAGGATCGCCAAAAGTA 3 0.038 0.04 67.0 
19 G7CTTACACAAGGATCGGCGAGAGTA 4 0.27 0.34 623.5±545.3 
20 G7CTTACACAAGGATCTCCGAGAGTA 1 0.18 0.28 - 
  
1
2
0
 
21 G7CTTACACAAGGATCTCCGAGCACA 2 0.22 0.28 - 
22 G7CTTACACAAGGATCTCCAAAAGTA 2 0.17±0.03 0.21±0.02 - 
23 G7CTTACACAAGGGCCGCCGAAAGTA 1 - - - 
  24* G7CTTACACAAGGGCCGCCGAGCACA 65 0.29±0.03 0.40±0.03* 403.9±137.6 
25 G7CTTACACAAGGGCCGCCGTGAGTA 1 0.30 0.38 - 
26 G7CTTACACAAGGGTCGCCGAGCACA 1 - - - 
27 G7CTTACACAAGAACCGCCGTGAGTA 1 0.45 0.39 - 
28 G7CTTACACAAAGACCGCCGAAAGTA 1 0.28 0.49 - 
29 G7CTTACACAAAGACCGCCGAGAGTA 1 0.36 0.46 - 
30 G7CTTACACAGGGACCGCCGAGAGTA 3 0.24±0.03 0.33 - 
31 G7CTTATGTGAGGACCGCCGAGAGTA 1 - - 33.2 
32 G7CTTATGTGAGGACCGCCGTGAGTA 1 0.26 0.39 - 
33 G7CTAGCACAAGGACCGCCGAGAGTA 1 - - 68.65 
34 G7CTAGCACAAGGACCGCCGTGAGTA 22 0.28±0.03 0.37±0.05 342.4±168.6 
35 G7TCTACACAAGGACCGCCGAGAGTA 1 - - 42.46 
36 G7TCTACACAAGGACCTCCGTGAGTA 1 0.23 0.23 - 
37 G8CCTACACAAGGATCGCCGAAAGTA 32 0.32±0.04 0.51±0.05 444.8±162.7 
38 A7CTTACACAAGGACCGCCGAAAGTA 3 0.09 0.14 - 
* Haplotypes that are statistically significant versus haplotype 4 when comparing AUC ratios. 
** The order of variants composing the haplotypes are corresponding with the individual variants listed in Table 1 as follows: 
rs34749331, rs139818840, rs528886765, rs3181842, rs28969414, rs28969415, rs553398143, rs28969416, rs535525152, 
rs764949833, rs150701000, rs185153760, rs142189613, rs7260525, rs7246465, novel variant, rs28969420, rs145450819, 
rs567303715, rs28969421, rs1038376, rs707265, rs70950385 (AG>CA), rs1042389, rs538901499.
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3’UTR SNPs association with altered CYP2B6 activity in human liver microsomes 
To further evaluate the changes observed in our healthy volunteer population, DNA from 
90 human liver microsomal preparations isolated from pediatric and adult liver tissue 
samples were sequenced and characterized for CYP2B6 activity by measuring bupropion 
hydroxylation (one sample had an undetectable bupropion hydroxylation rate). In this 
tissue panel, based on the CYP2B6*6 and CYP2B6*18 genotypes, there were 51 
genotypic normal, 31 intermediate, 4 poor metabolizers. The CYP2B6*6 and CYP2B6*18 
genotypes of 4 samples were unknown (data not shown). A decrease in CYP2B6 activity 
was observed among samples with the rs70950385 homozygous (AG/AG) genotype 
(543.3 pmol/mg protein/min) versus carriers of the CA allele (326.3 pmol/mg protein/min) 
in the panel (39.9% decrease; p<0.05 based on untransformed data) (Figure 18 – log2-
transformed velocities for visualization purposes; Table 13). Differences were not 
significant in normal metabolizers, likely because there were too few samples in this 
subset. The rs70950385 and rs1042389 variants were also in complete linkage 
disequilibrium in this sample population (r2=1.0, D=1.0) (Figure 15). There were no 
statistically significant changes for any of the other variants, haplotypes, and diplotypes, 
as their frequencies were low (Figure 19 and Table 13). 
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Figure 18: Association of CYP2B6 rs70950385 with bupropion metabolism in human 
liver microsomes 
Bupropion hydroxylation activity observed in human liver microsomes among A. all 
samples and B. normal metabolizers (i.e. volunteers with no CYP2B6*6 and CYP2B6*18 
alleles). X-axis: Genotype (rs70950385 in complete linkage disequilibrium with 
rs1042389). Y-axis: log2 transformed rate of hydroxyl-bupropion (pmol/mg protein/min). 
(*=p<0.05) Note: Data was log2-transformed for visual purposes only. 
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Figure 19: Association of CYP2B6 3’UTR variants with bupropion metabolism in 
human liver microsomes (n=89)   
Bupropion hydroxylation rates among normal metabolizers; subjects with CYP2B6*6 and 
*18 alleles excluded. X-axis: CYP2B6 3’UTR genotypes. Y-axis: log2 transformed 
bupropion hydroxylation rate (pmol/mg protein/min). F. rs70950385 variant is in complete 
LD with rs1042389 (data not shown separately).  
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Table 13: Association of CYP2B6 3’UTR variants with bupropion metabolism in human liver microsomes (n=89) 
 
  Normal Metabolizers   Total Population 
  n 
Mean 
Bupropion 
Hydroxylation 
Rate* 
Lower 
95% CI 
Upper 
95% CI   n 
Mean 
Bupropion 
Hydroxylation 
Rate* 
Lower 
95% 
CI 
Upper 
95% 
CI 
rs3181842             
T/T 17 414.6 -35.98 865.2  41 392.5 213.9 571.1 
T/C 21 365.5 117.8 613.2  35 520.1 302.7 737.5 
C/C 12 539.1 84.06 994.1  13 495.6 -103.3 1095 
rs7246465             
C/C 18 376.2 68.53 683.9  39 331.6 171 492.3 
C/T 23 387 158 616  40 555.8 345.8 765.8 
T/T 9 613.3 -288.4 1515  10 557.2 -244.1 1358 
rs28969420             
G/G 43 471.4 242.2 700.7  77 503.6 345.8 661.5 
G/T 6 147.4 26.47 268.3  11 174.7 15.62 333.8 
T/T 1 35.7 - -  1 35.72 - - 
rs1038376             
A/A 45 415.6 210.2 620.9  50 402.9 214.3 591.5 
A/T 5 498.5 -663.5 1660  30 596.9 331.2 862.7 
T/T 0 - - -  9 298.3 -13.09 609.6 
rs707265             
G/G 18 376.2 68.53 683.9  42 340.4 185.4 495.4 
G/A 23 387 158 616  36 576.2 348.8 803.7 
A/A 9 613.3 -288.4 1515  11 517.9 -201.3 1237 
rs70950385             
AG/AG 25 494.1 162 826.2  56 543.3 350.8 735.8 
  
1
2
5 
AG/CA 23 375.8 112.6 639  31 326.3 126.3 526.3 
CA/CA 2 98.3 -697.1 893.7   2 98.33 -697.2 893.9 
*pmol/mg protein/min 
CI= confidence intervals
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The rs70950385 (CA) variant allele alters luciferase activity due to altered miR-
1275 regulation 
The rs70950385 variant (AG>CA) is a combination of rs12979270 (A>C) and rs12979898 
(G>A). Those two SNPs were in complete linkage disequilibrium in our total population. 
The rs12979270 (A>C) was predicted by PolymiRTS to create miRNA target site for miR-
625-5p (Figure 20A) through perfect complimentary alignment within the seed sequence 
region, nucleotides 2-8 from the 5’ end of the miRNA. Manual seed sequence comparisons 
revealed the dinucleotide variant created an additional base pair match for the first 
nucleotide of miR-1275 (Figure 20B). So, we tested the effect of the variant by cloning 
either the wild-type or the variant sequence into the 3’UTR of the luciferase plasmid. We 
would expect to see a decrease in luciferase activity compared to the wild-type luciferase 
plasmid, if the CA variant created a binding site for predicted miRNAs. When this 
mechanism was tested in a luciferase model in HepG2 cells without co-transfection of 
predicted miRNAs, there were no differences in luciferase activity between the plasmid 
containing the wild-type and variant miRNA target sites with C. elegans negative control 
miRNA or no miRNA transfection controls (Figure 21A). However, when transfected with 
the miRNAs whose binding was predicted to be altered by the variant, miR-1275 reduced 
luciferase activity by 11.3% (p=0.0035) in the presence of the variant allele compared to 
the wild-type allele (Figure 21B). MicroRNA 625-5p did not impact luciferase activity 
suggesting that the CA allele did not create a binding site for this predicted miRNA. 
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Figure 20: rs70950385 creates miR-625-5p and miR-1275 target site in CYP2B6 
3’UTR 
Proposed mechanism for miRNA A. 625-5p and B. 1275 binding to the CYP2B6 3’UTR 
among carriers of the rs70950385 (CA) allele. 
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Figure 21: miRNA regulation of a predicted target site within CYP2B6 3’UTR in vitro 
MicroRNA regulation of CYP2B6 through measurement of luciferase activity in pIS-0 
plasmids containing either the reference (wild-type) or variant miRNA target sites. A. X-
axis: Luciferase plasmids were co-transfected with the following miRNAs: none (no 
transfected miRNAs), C. elegans (negative control cel-miR-67), miR-1275, and miR-625. 
Y-axis: Wild-type (firefly/Renilla luciferase) / Variant (firefly/Renilla luciferase). A ratio of 
1=no change, >1=wild-type had higher luciferase activity, <1=variant had higher luciferase 
activity. B. X-axis: Plasmids containing either the wild-type 3’UTR sequence (5’-
GCCGTGTAATTCTAGGAGCTCGTCACACACTGCTGTAGTCTTCCCCAGTCCTCA 
TCGTTCTAGAGTCGGGGC-3’) or variant (5’-GCCGTGTAATTCTAGGAGCTCGTCAC 
ACACTGCTGTAGTCTTCCCCCATCCTCATCGTTCTAGAGTCGGGGC-3’) 
 co-transfected with miR-1275. Y-axis: Firefly/Renilla luciferase ratio. (*=p<0.05) 
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Discussion 
Variability in the pharmacokinetics of efavirenz and other drugs that undergo CYP2B6-
mediated metabolism has been attributed to genetic variants in the CYP2B6 coding 
region; however, variability in clinical response and adverse events are not completely 
explained by these genetic differences. Data from this study indicates that genetic 
variations in the 3’UTR of CYP2B6 have an effect on CYP2B6 activity, independent of 
CYP2B6 metabolizer status (assigned based on CYP2B6*6 and *18). There were 25 
unique variants detected in the 3’UTR of CYP2B6 in our study population. Of these 
variants, seven were observed at a frequency that allowed us to assess differences in 
efavirenz pharmacokinetics between the homozygous and heterozygous volunteers. The 
rs3181842, rs7246465, and rs707265 had a similar increase in CYP2B6 activity for 
homozygous volunteers (Figure 14 A,B, and E). These three variants were not predicted 
to remove or create a miRNA target site through the PolymiRTS database at the time the 
database was accessed. Although the mechanism behind these observed changes are 
unknown, the mechanism may be related to only one of the variants as there is partial 
linkage disequilibrium among the three variants. The rs3181842 vs. rs7246465, 
rs3181842 vs. rs707265, and rs7246465 vs. rs707265 have r2 values of 0.58, 0.58, and 
0.80 respectively (Figure 15). 
 
The rs70950385 and rs1042389 variants were shown to be in complete LD in our 
volunteers and the human liver microsome samples. These two variants conveyed 
decreased CYP2B6 activity among efavirenz pharmacokinetics in subjects genotyped as 
normal metabolizers. They were also associated with a decrease in bupropion 
hydroxylation in the human liver microsome panel. The rs1042389 variant has previously 
been associated with a decrease in median efavirenz plasma concentration among black 
South African HIV/AIDS patients in a study assessing the effect of 3’UTR variants on 
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efavirenz response (Swart and Dandara, 2014). The rs70950385 and rs1042389 SNPs 
were shown to be in complete LD in this population as well. We propose that the observed 
decrease in CYP2B6 activity is mediated by miRNA regulation owing to the rs70950385 
variant creating a miRNA target site for miR-1275. This hypothesis is further corroborated 
by our in vitro data (Figure 21). In HepG2 cells treated with miR-1275 that expressed the 
variant (CA) miRNA target site, reduced luciferase activity was observed compared to cells 
that expressed the reference (wild-type) (AG) miRNA target site. This suggests that this 
miRNA has the ability to reduce protein activity either through degradation of mRNA or 
through repressing translation. Previously, we showed that miR-1275 expression is 
increased in pediatric and adult human livers compared to fetal livers, unequivocally 
demonstrating that this miRNA is expressed in the human liver (Burgess et al., 2015). 
These data suggest that this miRNA may play a role in regulating CYP2B6 activity; 
however, further studies are warranted to validate that this is the underlying mechanism 
as opposed to other mechanisms, such as variant-induced structural changes in the 
mRNA that may affect its stability. 
 
No significant changes in efavirenz pharmacokinetics were observed among the 3’UTR 
variants within the genetic intermediate and poor metabolizers in our human volunteer 
population for any variant with the exception of rs7246465 (C/T vs. T/T; p<0.05) (data not 
shown). All other variants yielded similar trends. This is likely due to inadequate sample 
numbers among the intermediate and poor metabolizer groups to detect these changes. 
Alternatively, this observation may be due to a limited effect size of the 3’UTR variants in 
the presence of coding region variants known to reduce CYP2B6 activity. The rs70950385 
homozygous variant and other genotypes were only detected in normal metabolizers in 
our population. Interestingly, many 3’UTR haplotypes and diplotypes were unique to the 
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metabolizer status. This may be due to partial LD with the CYP2B6*6 and CYP2B6*18 
alleles or that our sample size was too small to detect an overlap. 
 
This study shows that 3’UTR variants impact drug metabolism. Although the mechanisms 
are not known for all altered efavirenz pharmacokinetics associated with 3’UTR variants 
in CYP2B6, miRNA regulation is a likely contributor. Limitations on linking the other 
variants to miRNAs may be due to the limitations of miRNA prediction algorithms and tools 
which focus mostly on the seed sequence region as the main mechanism for miRNA 
binding. As in the case of rs70950385, our data suggest that miRNA regulation may 
explain, at least in part, the decreased CYP2B6 activity in healthy volunteers carrying the 
variant allele, as corroborated by our in vitro data. Although pharmacogenetics has 
primarily focused on genetic variants in the coding and promoter regions, our findings, i.e. 
that genetic variants in the 3’UTR contribute to variability in drug response, will open up 
the field to consider 3’UTR variants as a source of variability in the activities of many drug 
disposition genes. 
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CHAPTER 4 
Novel high-throughput bioassay to functionally test genetic variants in microRNA 
target sites 
Introduction 
Due to the large number of variants in the 3’UTR predicted to alter miRNA regulation of 
drug disposition genes, the traditional individual variant-miRNA validation assays will 
prove to be costly and time-consuming. Although individual luciferase assays remain the 
gold-standard for validations, a more high-throughput way to functionally test these 
variants will aid in the selection of candidate variants to test individually. Our lab created 
such an assay, PASSPORT-sequencing (Parallel ASSessment of POlymorphisms in 
miRNA Target sites), that will allow hundreds of variants to be tested simultaneously in 
multiple cell lines. In this study, we use PASSPORT-seq to test over 100 wild-type-variant 
pairs in four different cell lines. Our findings support the emerging role of variants in miRNA 
target sites in altering miRNA regulation. 
 
Materials and Methods 
PASSPORT-sequencing 
Selection of miRNA variants 
SNPs to test in the high-throughput bioassay were selected from the PolymiRTS database 
for variants that were predicted to alter binding of our list of developmentally-regulated 
miRNAs to our pharmacogenes of interests. Additional variants were obtained from SNPs 
identified by our sequencing of the 3’UTRs of the 30 human liver tissues. TargetScan was 
used to identify miRNA binding within these sequenced samples. Lastly, several variants 
that showed allele-specific expression in this sequenced dataset were selected. There 
were 119 SNPs identified in the assay: 55 from the RNA-sequencing data (17 of those 
showing allele-specific expression); and 64 within the PolymiRTS database. 
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Test sequence design 
The 5’ and 3’ flanking regions for each of the 119 variants were extracted from dbSNP. A 
32-nucleotide region containing either the wild-type or variant allele flanked by 9 
nucleotides on the 3’ end and 22 nucleotides on the 5’ end was used as the test sequence. 
Since it is known that miRNAs are 17-22 nucleotides in the length, the 9 nucleotides on 
the 3’ end allow the targeting miRNA to fully bind whether the variant is at nucleotide 
positions 1 or 8 of the target mRNA. Two hundred and thirty-eight of these 32-nucleotide 
regions were created to test the 119 SNPs (Table 14). Universal primer binding regions 
were added on both sides of each test region, 5’-GTAATTCTAGGAGCTC and 3’-
CGTTCTAGAGTCGGG resulting in a final 63 base pair oligonucleotide. These 238 test 
oligonucleotides were commercially synthesized as pooled single-stranded 
oligonucleotides (Oligomix, LC Sciences, Houston, TX). The oligonucleotides were 
amplified using the universal primer regions by PCR with CloneAmp HiFi PCR Premix 
(CloneTech, Mountain View, CA). 
 
Plasmid library preparation 
The pIS-0 vector was linearized using SacI-HF and BmtI-HF restriction endonucleases 
(New England Biolabs, Ipswich, MA) and purified using QIAquick PCR spin columns 
(Qiagen, Germantown, MD). The linearized plasmid was mixed with 2 μL of unpurified 
double-stranded pooled oligonucleotides and plasmid assembly was performed using 
NEBuilder HiFi DNA assembly kit (NEB, Ipswich, MA) according to manufacturer’s 
instructions. The universal primers matched the ends of the linearized pIS-0 plasmid and 
were used to amplify the test oligonucleotides, serving as the flanking homology regions 
for the NEBuilder assembly. Next, 2 μL of assembled product was transformed into One 
Shot OmniMax 2 TI Chemically Competent E. coli (Invitrogen, Carlsbald, CA). 
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Transformed cells were plated on six 10 cm LB-agar plates containing 100 μg/mL 
ampicillin. After overnight incubation, all colonies were harvested and added to 12 mL LB-
broth containing 100 μg/mL ampicillin. The liquid culture was grown at 37°C for five hours, 
and plasmids were isolated using 10 QIAprep Spin Miniprep Columns (Qiagen, 
Germantown, MD) according to manufacturer’s protocol. All plasmids isolated were 
combined to create the plasmid library for future experiments. DNA concentrations were 
measured using Qubit dsDNA BR Assay Kit (Invitrogen, Eugene, OR). 
 
Cloning efficiency and plasmid representation 
To assess representation of the 238 constructs in the plasmid library, 18 individual 
colonies were selected from the transformed bacteria plates and were grown in four mLs 
LB-broth containing 100 μg/mL ampicillin. Plasmids were isolated from each liquid culture 
using QIAprep Spin Miniprep Columns (Qiagen, Germantown, MD). Samples were Sanger 
sequenced using the reverse primer 5’-GTGGTTTGTCCAAACTCATC-3’ (ACGT, 
Wheeling, IL). Target site representation was also determined from Next-generation 
sequencing of the plasmid pool described below. All wild-type and variant sequences were 
detected in the sequencing run. 
 
Cell culture transfection 
The pool of luciferase plasmids was transfected into HeLa, HepG2, HEK293, and HepaRG 
cells at 500 ng total plasmid for 48 hours as described previously for each cell line. After 
48 hours, cells were lysed and total RNA was isolated and quantified for RNA-sequencing. 
cDNA was synthesized from 800 ng of total RNA using the QuantiTect Reverse 
Transcription Kit (Qiagen, Germantown, MD).  
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Molecular barcoding 
PCR amplification was used to barcode the miRNA target sites within the 3’UTR of the 
luciferase gene using the flanking universal primer regions. Two microliters of cDNA and 
one picogram of the input plasmid pool were used as the PCR templates in separate 
reactions. A unique 6-nucleotide molecular barcode was added to the 5’ end of both the 
forward and reverse primer. Five replicates of the input pool, five biological replicates for 
four different cell lines resulted in 25 unique pair of barcodes as listed in Table 15. The 
barcoded PCR products were purified using MinElute PCR Purification Kit (Qiagen, 
Germantown, MD). DNA was quantified and equimolar concentrations of each PCR 
product were combined to form the sequencing pool. 
 
Next-generation sequencing 
Pooled PCR products were sequenced using a modified protocol for Ion Proton system 
(Thermo Fisher Scientific, Waltham, MA). Briefly, the sequencing library was created by 
end polishing the barcoded PCR products, followed by adapter ligation and amplification. 
The resulting library was quantified and its quality assessed by Agilent Bioanalyzer 
(Agilent Technologies, Santa Clara, CA). Eight microliters of the 100 pM library was then 
applied to Ion Sphere Particles to prepare the sequencing template. The template was 
amplified using Ion OneTouch 2. The Ion Sphere Particles with the amplified template 
were loaded onto an IonPI chip and sequenced on the Ion Proton system per 
manufacturer’s instructions. Approximately 41 million reads were generated from the 
sequencing run. Raw reads were generated as fastq files for bioinformatic analysis. 
 
Bioinformatics and statistical analysis 
The raw reads were aligned to the reference library containing the 238 test sequences 
(TMAP- Ion Torrent Suite, Thermo Fisher Scientific, Waltham, MA). The reads that aligned 
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to the reference library were filtered to retain reads with a mapping quality greater than 
20. These reads were further filtered to include only those sequences with perfect 
barcodes at both ends.  
 
Differential expression analysis was done by comparing the expression of each variant 
allele to the respective reference allele for all 119 SNPs. To account for differences in the 
concentrations of the variant and reference plasmids that were used for the transfections, 
the plasmid input correction factor for each target site was calculated as the average of 
the number of reads from the variant plasmid divided by the number of reads from the 
reference plasmid across 5 replicates of the plasmids. The reads from the variant alleles 
for all biological replicates were divided by the input correction factor. The corrected read 
counts were fit into a generalized linear model using EdgeR (Robinson et al., 2010) 
assuming a negative binomial distribution. Biological replicates and the genotype were 
used as covariates. The p-values and log2 fold-change of the variant alleles compared to 
the respective reference alleles were derived using likelihood ratio test on the genotype 
variable in the generalized linear model. The p-values were corrected for a false discovery 
rate (FDR) using the Benjamini and Hochberg algorithm (Benjamini and Hochberg, 1995).
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Table 14: Wild type and variant miRNA sequences inserted into firefly luciferase 
plasmids 
 
No. RS no. 
Wild-type 
Sequence 
No. 
Variant 
Sequence 
SNP 
1 rs10580 CCCCAACACCA
CCCCTTGCCCA
ACCAATGCAC 
120 CCCCAACACCA
CCCCTTGCCCA
GCCAATGCAC 
AG 
2 rs4352283 ATCAGGTGCCA
AGCCCTGTTCTA
GGTGCTGGG 
121 ATCAGGTGCCA
AGCCCTGTTCT
CGGTGCTGGG 
AC 
3 rs11581122 TCTACTTAGAAG
GCTTGGGGCCC
AGGGTAATG 
122 TCTACTTAGAAG
GCTTGGGGCCT
AGGGTAATG 
CT 
4 rs5875 CCCCACCCACT
CCTATACCATGA
CATCAGTGT 
123 CCCCACCCACT
CCTATACCATGT
CATCAGTGT 
AT 
5 rs28382751 GGAGGCCGAGG
CGGGCAGATCA
ACTGAGGTCG 
124 GGAGGCCGAG
GCGGGCAGATC
ACCTGAGGTCG 
AC 
6 rs3947 GGGGCCACAGT
CAGCTGGGGCA
ACAGGTACTC 
125 GGGGCCACAGT
CAGCTGGGGCA
GCAGGTACTC 
AG 
7 rs3134615 TACTGCTGCCTC
TTTCCCACCTGC
CTCATCTC 
126 TACTGCTGCCT
CTTTCCCACCTT
CCTCATCTC 
GT 
8 rs186026692 AGACATCATCAA
GTGGAGAGAAA
TCATAGTTT 
127 AGACATCATCA
AGTGGAGAGAA
GTCATAGTTT 
AG 
9 rs200253092 TTTGTTTATATTT
TCCCATTTGGAC
TGTAACT 
128 TTTGTTTATATT
TTCCCATTTGAA
CTGTAACT 
GA 
10 rs200519094 AGAGAAATCATA
GTTTAAACTGCA
TTATAAAT 
129 AGAGAAATCAT
AGTTTAAACTGT
ATTATAAAT 
CT 
11 rs201524771 ATTATGAAGAGG
TATCTGTTTAAC
ATTTCCTC 
130 ATTATGAAGAG
GTATCTGTTTAC
CATTTCCTC 
AC 
12 rs202026600 ATTAAAAAGTAT
TTAACATCTCTT
ACAGTCAG 
131 ATTAAAAAGTAT
TTAACATCTCAT
ACAGTCAG 
TA 
13 rs28364275 GAACTCTGACTG
TATGAGATGTTA
AATACTTT 
132 GAACTCTGACT
GTATGAGATGT
CAAATACTTT 
TC 
14 rs28364280 ACTGCCTTGCTA
AAAGATTATAGA
AGTAGCAA 
133 ACTGCCTTGCT
AAAAGATTATAA
AAGTAGCAA 
GA 
Table 14 cont’d     
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No. RS no.  
Wild-type 
Sequence 
No. 
Variant 
Sequence 
SNP 
15 rs150176505 GAAACCCCTCG
ATTGTCTACCTC
GATCGTACT 
134 GAAACCCCTCG
ATTGTCTACCTT
GATCGTACT 
CT 
16 rs139156785 TTGGGAGCTGC
CAAGAGTGAAG
GGAAGAGACA 
135 TTGGGAGCTGC
CAAGAGTGAAG
AGAAGAGACA 
GA 
17 rs17861086 AAGGTAATTGAA
ATACCCCCCCG
TCACTCCAG 
136 AAGGTAATTGA
AATACCCCCCC
CTCACTCCAG 
GC 
18 rs35427048 AGGGAAGAGAC
AGCCCAGGATA
CTGGCACAGA 
137 AGGGAAGAGAC
AGCCCAGGATA
TTGGCACAGA 
CT 
19 rs4986884 TGTAAGACCCTT
ATTGCTGTCCTG
GAGGGGCT 
138 TGTAAGACCCT
TATTGCTGTCC
CGGAGGGGCT 
TC 
20 rs11636419 GGAGGATCATTT
GAGCCCAGGAA
TTGGAAAGC 
139 GGAGGATCATT
TGAGCCCAGGA
GTTGGAAAGC 
AG 
21 rs17861162 ATTACAGGTGTG
AGCCACGGTGC
CCGGCCCAC 
140 ATTACAGGTGT
GAGCCACGGTG
GCCGGCCCAC 
CG 
22 rs8192733 GAGGGAAGAGA
AGAAACAGAAG
GGGCTCAGTT 
141 GAGGGAAGAGA
AGAAACAGAAG
CGGCTCAGTT 
GC 
23 rs1038376 GATCCACCCAC
CTCAGTGTTCCA
AAGTGCTGA 
142 GATCCACCCAC
CTCAGTGTTCC
TAAGTGCTGA 
AT 
24 rs1042389 AGTCCTCATTCC
CAGCTGCCTCTT
CCTACTGC 
143 AGTCCTCATTC
CCAGCTGCCTC
CTCCTACTGC 
TC 
25 rs28399502 GCTTCCTTCCCC
TCCATGGCACC
AGTTGTCTG 
144 GCTTCCTTCCC
CTCCATGGCAC
AAGTTGTCTG 
CA 
26 rs28969420 TAAGCCTTGCTC
TGTCTCCCAGG
CTGGAGTGC 
145 TAAGCCTTGCT
CTGTCTCCCAG
TCTGGAGTGC 
GT 
27 rs3181842 CTGGAGTGCAG
TGGCGTGATCT
CGGCTCACTG 
146 CTGGAGTGCAG
TGGCGTGATCT
TGGCTCACTG 
CT 
28 rs4803420 ctaaattttgtatttttagG
TGGTCTTGAACT 
147 ctaaattttgtatttttag
GTGTTCTTGAA
CT 
GT 
29 rs707265 TTGAATGCTATT
TTTGAGGTTCAT
GCCTGTTG 
148 TTGAATGCTATT
TTTGAGGTTCG
TGCCTGTTG 
AG 
30 rs7246465 ATTCACATAACA
TAAAATTAGCTG
TTTTAAAG 
149 ATTCACATAACA
TAAAATTAGCC
GTTTTAAAG 
TC 
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31 rs7260525 gtcaccgtgcccagcC
ATGTATATATAT
AAtt 
150 gtcaccgtgcccagcC
ATGTATGTATAT
AAtt 
AG 
32 rs1058932 GAATGCTAGCC
CATCTGGCTGC
CGATCTGCTA 
151 GAATGCTAGCC
CATCTGGCTGC
TGATCTGCTA 
CT 
33 rs9332242 TGCCTTTTCTCA
CCTGTCATCTCA
CATTTTCC 
152 TGCCTTTTCTCA
CCTGTCATCTG
ACATTTTCC 
CG 
34 rs2480256 CCCCGCTTTCAA
ACAAGTTTTCAA
ATTGTTTG 
153 CCCCGCTTTCA
AACAAGTTTTCG
AATTGTTTG 
AG 
35 rs2480257 GAACCCCCCGC
TTTCAAACAAGA
TTTCAAATT 
154 GAACCCCCCGC
TTTCAAACAAGT
TTTCAAATT 
AT 
36 rs56307258 CCCCCGCTTTCA
AACAAGTTTTCA
AATTGTTT 
155 CCCCCGCTTTC
AAACAAGTTTTA
AAATTGTTT 
CA 
37 rs7081484 AGTGTGTGGAG
GACACCCTGAA
CCCCCCGCTT 
156 AGTGTGTGGAG
GACACCCTGAA
TCCCCCGCTT 
CT 
38 rs28371763 GAGTGAGACTC
AGTCTTAAAAAT
ATATGCCTT 
157 GAGTGAGACTC
AGTCTTAAAAAA
ATATGCCTT 
TA 
39 rs15524 GGAGAATGAGT
TATTCTAAGGAT
TTCTACTTT 
158 GGAGAATGAGT
TATTCTAAGGAC
TTCTACTTT 
TC 
40 rs17161788 ATGAGTTATTCT
AAGGATTTCTAC
TTTGGTCT 
159 ATGAGTTATTCT
AAGGATTTCTG
CTTTGGTCT 
AG 
41 rs10211 CACAATGCACGT
ACAGAATCCCC
GATTATTTA 
160 CACAATGCACG
TACAGAATCCC
TGATTATTTA 
CT 
42 rs12360 TAAGGACTTCTG
GTTTGCTCTTCA
AGAAAGCT 
161 TAAGGACTTCT
GGTTTGCTCTTT
AAGAAAGCT 
CT 
43 rs139849737 TGCTGGGGAAG
TAGATTTGGCTT
CTCTGCTTC 
162 TGCTGGGGAAG
TAGATTTGGCT
CCTCTGCTTC 
TC 
44 rs183800671 TCCTATTTTTATT
AATGATTGTCGT
TGAAATT 
163 TCCTATTTTTAT
TAATGATTGTG
GTTGAAATT 
CG 
45 rs17470762 AATATAATGTTG
ATAATATATATTA
AGTGTGC 
164 AATATAATGTTG
ATAATATATACT
AAGTGTGC 
TC 
46 rs184161277 TCTTTCCAAATT
AAAACAAATATA
CATTTTCT 
165 TCTTTCCAAATT
AAAACAAATACA
CATTTTCT 
TC 
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Table 14 cont’d    
No. RS no.  
Wild-type 
Sequence 
No. 
Variant 
Sequence 
SNP 
47 rs188501488 AAATTAAAGGTA
ATTTTTAATGTTA
AAATGTT 
166 AAATTAAAGGTA
ATTTTTAATGAT
AAAATGTT 
TA 
48 rs2151562 AGAACAGAATTT
ATTAGAAACTTA
CTAAAATT 
167 AGAACAGAATTT
ATTAGAAACTCA
CTAAAATT 
TC 
49 rs291592 AGATCCTGGTTA
CCACTCTTTTGC
TGTGCACA 
168 AGATCCTGGTT
ACCACTCTTTTA
CTGTGCACA 
GA 
50 rs291593 CCACTCTTTTGC
TGTGCACATACG
GGCTCTGA 
169 CCACTCTTTTGC
TGTGCACATAT
GGGCTCTGA 
CT 
51 rs41285690 TCTCCTCTTCAT
GGCATCTTCAAT
ATGAATCT 
170 TCTCCTCTTCAT
GGCATCTTCAG
TATGAATCT 
AG 
52 rs55696854 GTTGATAATATA
TATTAAGTGTGC
CAAATCAG 
171 GTTGATAATATA
TATTAAGTGTTC
CAAATCAG 
GT 
53 rs56160474 GGATGTTCACTG
CCAGTTGTCTTA
TGTGAAAA 
172 GGATGTTCACT
GCCAGTTGTCT
CATGTGAAAA 
TC 
54 rs201925035 TCCTTTCTCCAG
GACCAATAAAAT
TTCTAAGA 
173 TCCTTTCTCCAG
GACCAATAAAC
TTTCTAAGA 
AC 
55 rs4630 CCAGAAAGCAG
GAATGGCTTGC
CTAAGACTTG 
174 CCAGAAAGCAG
GAATGGCTTGC
TTAAGACTTG 
CT 
56 rs11086926 GTGCTTCTCCTC
TCCTAGCCCCT
GTCATGGTG 
175 GTGCTTCTCCT
CTCCTAGCCCC
GGTCATGGTG 
TG 
57 rs114764820 CTCATCCTCCTT
CTTCAGGGACTT
GGGTGGGT 
176 CTCATCCTCCTT
CTTCAGGGACC
TGGGTGGGT 
TC 
58 rs11574744 TGGCCTAAGGG
CCACATCCCACT
GCCACCCTT 
177 TGGCCTAAGGG
CCACATCCCAC
AGCCACCCTT 
TA 
59 rs11574745 GAAGCCACTGC
CTTCACCTTCAC
CTTCATCCA 
178 GAAGCCACTGC
CTTCACCTTCAT
CTTCATCCA 
CT 
60 rs183246640 GGAACACCAGG
CTGAGGTCCTG
ATCAGCTTCA 
179 GGAACACCAGG
CTGAGGTCCTG
GTCAGCTTCA 
AG 
61 rs189107638 TCCTGTTTGCTG
ATAAATATTAAG
GAGAATTC 
180 TCCTGTTTGCT
GATAAATATTAG
GGAGAATTC 
AG 
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62 rs200905283 AAGGATGAAGG
GCCCGAGAACA
TGGCCTAAGG 
181 AAGGATGAAGG
GCCCGAGAACA
AGGCCTAAGG 
TA 
63 rs3212210 AGAACAGCCTG
AGCCAAGGCCT
AGTGGTAGTA 
182 AGAACAGCCTG
AGCCAAGGCCT
CGTGGTAGTA 
AC 
64 rs41280258 GGCCCGAGAAC
ATGGCCTAAGG
GCCACATCCC 
183 GGCCCGAGAAC
ATGGCCTAAGG
ACCACATCCC 
GA 
65 rs41282030 CTACTGCCTTGG
ACAACTTTTCTC
ATGTTGAA 
184 CTACTGCCTTG
GACAACTTTTCC
CATGTTGAA 
TC 
66 rs6103734 caactaggaagtggct
gagtcaGgacttgaac 
185 caactaggaagtggct
gagtcaAgacttgaac 
GA 
67 rs4986993 TGAATTCCTAGA
AAAGTTTTATTG
GTAGATGA 
186 TGAATTCCTAGA
AAAGTTTTATGG
GTAGATGA 
TG 
68 rs45539742 ATAAAGGCATTT
TAAGGATGGCC
TGTGATTAT 
187 ATAAAGGCATTT
TAAGGATGGCG
TGTGATTAT 
CG 
69 rs10460826 TGCCCCCCACC
CCCAGTTCAGTC
TGTAGGGAG 
188 TGCCCCCCACC
CCCAGTTCAGT
GTGTAGGGAG 
CG 
70 rs10511395 TTCCGAGCTGCT
TTGTGGGCTCC
AGGCCTGTA 
189 TTCCGAGCTGC
TTTGTGGGCTC
AAGGCCTGTA 
CA 
71 rs1054190 ATTTGAACACAT
TATTAAGCACCG
ATAATAGG 
190 ATTTGAACACAT
TATTAAGCACTG
ATAATAGG 
CT 
72 rs1054191 GTGGATGCTGA
GCTGTGATGGC
GGGCACTGGG 
191 GTGGATGCTGA
GCTGTGATGGC
AGGCACTGGG 
GA 
73 rs113594465 CAGCCAGACCC
AGAGCCCTCTG
AGCCGCCACT 
192 CAGCCAGACCC
AGAGCCCTCTG
GGCCGCCACT 
AG 
74 rs12107248 ACAAGGCTACG
CTGACAATCAGT
TAAACACAC 
193 ACAAGGCTACG
CTGACAATCAG
ATAAACACAC 
TA 
75 rs12721615 AAATTTTTTTGC
ATTTTCACAAAT
TATACTTT 
194 AAATTTTTTTGC
ATTTTCACAAGT
TATACTTT 
AG 
76 rs149397784 CAGGAAGGACA
TGGGTGCCCCC
CACCCCCAGT 
195 CAGGAAGGACA
TGGGTGCCCCC
AACCCCCAGT 
CA 
77 rs185946310 CGCTTCCTGAGT
CTTTTCATTGCT
ACCTCTAA 
196 CGCTTCCTGAG
TCTTTTCATTGT
TACCTCTAA 
CT 
78 rs200737867 GCTGCCCTTGG
GTGACACCTCC
GAGAGGCAGC 
197 GCTGCCCTTGG
GTGACACCTCC
AAGAGGCAGC 
GA 
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Table 14 cont’d     
No. RS no.  
Wild-type 
Sequence 
No. 
Variant 
Sequence 
SNP 
79 rs2472683 GGGTACCCAAG
TGAAGGTTCCCA
AGGACATGA 
198 GGGTACCCAAG
TGAAGGTTCCC
GAGGACATGA 
AG 
80 rs3732358 GTAGCTGAGCG
GCTGCCCTTGG
GTGACACCTC 
199 GTAGCTGAGCG
GCTGCCCTTGG
ATGACACCTC 
GA 
81 rs3732359 AAGGGACCAAG
CGACCAAGGAT
GGGCCATCTG 
200 AAGGGACCAAG
CGACCAAGGAT
AGGCCATCTG 
GA 
82 rs3732360 CAGGCCTGTAC
TCATCGGCAGG
CGCATGAGTA 
201 CAGGCCTGTAC
TCATCGGCAGG
TGCATGAGTA 
CT 
83 rs3814057 TATATAAGGCAT
TCCACACCTAAG
AACTAGTT 
202 TATATAAGGCAT
TCCACACCTAC
GAACTAGTT 
AC 
84 rs3814058 AAATGTAGCCCT
GGGTTTAATGTC
AAATCAAG 
203 AAATGTAGCCC
TGGGTTTAATG
CCAAATCAAG 
TC 
85 rs6438550 AAAAACAAACAG
AAACACAAACGA
TTTGGATC 
204 AAAAACAAACA
GAAACACAAAC
AATTTGGATC 
GA 
86 rs76580593 TTTCCTTTTAAA
AGGCCCTGTGG
TCTGGGGAG 
205 TTTCCTTTTAAA
AGGCCCTGTGT
TCTGGGGAG 
GT 
87 rs112532686 TGAAAAAATGTG
GACACACAAATT
GGAAAAGA 
206 TGAAAAAATGT
GGACACACAAA
CTGGAAAAGA 
TC 
88 rs114029015 GAGAAGTTATAT
CTCTCTGATTAT
GATAGTAT 
207 GAGAAGTTATAT
CTCTCTGATTGT
GATAGTAT 
AG 
89 rs13860 CTTCAGTTTTAA
TGACAAGCATTT
CAGAAATA 
208 CTTCAGTTTTAA
TGACAAGCATC
TCAGAAATA 
TC 
90 rs180751034 CAAACAATGCAC
TTCTGTTAATGC
AGTGTAAG 
209 CAAACAATGCA
CTTCTGTTAATT
CAGTGTAAG 
GT 
91 rs185103906 AGGTTCCTATCA
AAATTTGTGGGA
GTAGGGAT 
210 AGGTTCCTATC
AAAATTTGTGGT
AGTAGGGAT 
GT 
92 rs189039600 GTTTAAATTAAC
ATGTACGCTGCA
GAACATTG 
211 GTTTAAATTAAC
ATGTACGCTGA
AGAACATTG 
CA 
93 rs189331203 ATTCTTCTTAGC
CTCTATGGCGCT
GGTCTATG 
212 ATTCTTCTTAGC
CTCTATGGCGT
TGGTCTATG 
CT 
 143 
94 rs9457846 GCACCTGAGAG
AGATGTTTTGCG
GCGATGTCG 
213 GCACCTGAGAG
AGATGTTTTGCA
GCGATGTCG 
GA 
95 rs4149087 CACAGAGTTTGA
ACTATAATACTA
AGGCCTGA 
214 CACAGAGTTTG
AACTATAATACG
AAGGCCTGA 
TG 
96 rs4149088 AGGCCTGAAGT
CTAGCTTGGATA
TATGCTACA 
215 AGGCCTGAAGT
CTAGCTTGGAT
GTATGCTACA 
AG 
97 rs71581985 CTTCTGTGTTTC
CAAACAGCATTG
CATTGATT 
216 CTTCTGTGTTTC
CAAACAGCATG
GCATTGATT 
TG 
98 rs71581986 GGATATATGCTA
CAATAATATCTG
TTACTCAC 
217 GGATATATGCT
ACAATAATATCC
GTTACTCAC 
TC 
99 rs79775553 CTTCTGCTTCTG
TGTTTCCAAACA
GCATTGCA 
218 CTTCTGCTTCTG
TGTTTCCAAAGA
GCATTGCA 
CG 
100 rs189727189 CCTGTAGCCAG
TCAGAAATGAGC
TTATTCATA 
219 CCTGTAGCCAG
TCAGAAATGAG
TTTATTCATA 
CT 
101 rs79132805 TTTCTACTGGAC
CCATGGAAGTG
GATTAAGAA 
220 TTTCTACTGGAC
CCATGGAAGTA
GATTAAGAA 
GA 
102 rs1042157 AATAAAATATGA
ATTGAGGGCCC
GGGACGGTA 
221 AATAAAATATGA
ATTGAGGGCCT
GGGACGGTA 
CT 
103 rs6839 GAGCTGTGAGA
GGGGCTCCTGG
AGTCACTGCA 
222 GAGCTGTGAGA
GGGGCTCCTGG
GGTCACTGCA 
AG 
104 rs1142365 GAAAagcaaccccgt
ctctactAaaaatacaa 
223 GAAAagcaaccccg
tctctactGaaaataca
a 
AG 
105 rs144017186 GAGGCTGACAA
GACATATCTCTC
GGGAGAGTA 
224 GAGGCTGACAA
GACATATCTCT
GGGGAGAGTA 
CG 
106 rs1802650 TGCACCTGGCC
TGACATTCTTTA
TGAAATTTA 
225 TGCACCTGGCC
TGACATTCTTTT
TGAAATTTA 
AT 
107 rs189810658 GGCTAATTTTTT
TGTATTTTTACT
AGAGACGG 
226 GGCTAATTTTTT
TGTATTTTTAGT
AGAGACGG 
CG 
108 rs55661878 AAACAATCTATA
TGGAACAAACAT
TCCCAAAT 
227 AAACAATCTATA
TGGAACAAACG
TTCCCAAAT 
AG 
109 rs55818790 TAAAAAAATATT
TCAAAATGCAAT
GCATATTA 
228 TAAAAAAATATT
TCAAAATGCAG
TGCATATTA 
AG 
110 rs55839603 TTCAAGGTGGTC
CCAAAAGTTATA
TAAAAGAT 
229 TTCAAGGTGGT
CCCAAAAGTTA
CATAAAAGAT 
TC 
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No. RS no.  Wild-type 
Sequence 
No. Variant 
Sequence 
SNP 
111 rs9465100 TTTACttttatgtagag
acaggGtctcacttt 
230 TTTACttttatgtaga
gacaggAtctcacttt 
GA 
112 rs1042640 CGGGATTCAAA
GGTGGTCCCAC
GGCTGCCCCT 
231 CGGGATTCAAA
GGTGGTCCCAC
CGCTGCCCCT 
GC 
113 rs10929303 TGAATATGTATC
GTGCCCCCTCT
GGTGTCTTT 
232 TGAATATGTATC
GTGCCCCCTCC
GGTGTCTTT 
TC 
114 rs8330 ATGGTCAGTCCT
CATCTCTGTCGT
GCTTCATA 
233 ATGGTCAGTCC
TCATCTCTGTCC
TGCTTCATA 
GC 
115 rs35791822 AAATACAATGGG
GGGAAGGATAG
CATTTGGAG 
234 AAATACAATGG
GGGGAAGGATA
TCATTTGGAG 
GT 
116 rs138053056 GTAGACAATGG
CTCTGACTCCCC
GCAACTTC 
235 GTAGACAATGG
CTCTGACTCCC
TGCAACTTC 
CT 
117 rs146050194 GGAGCTGGTAT
CACAGGCGTCC
CCCACCACG 
236 GGAGCTGGTAT
CACAGGCGTCC
TCCACCACG 
CT 
118 rs183641079 CTCCAAATGTTT
TCATTATCTCCC
CCCCAAC 
237 CTCCAAATGTTT
TCATTATCTCTC
CCCCAAC 
CT 
119 rs12979270  ACACACTGCTGT
AGTCTTCCCCAG
TCCTCAT 
238 ACACACTGCTG
TAGTCTTCCCC
CGTCCTCAT 
AC 
*Empty vector sequence (if no miRNA target site was inserted) [26 bp]: 
TATACGCGTCTCAAGCTTACTGCTAG 
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Table 15: Barcodes and primers in 5’>3’ direction 
No Sample 5’ Barcode and 
Primer (27 nt)  
3’ Barcode and Primer* 
(25 nt) 
1 HeLa Rep 1 ACATGTGCCGTGTA
ATTCTAGGAGCTC 
ACAACCCCGCCCCGA
CTCTAGAACG 
2 HeLa Rep 2 ACCTTTGCCGTGTA
ATTCTAGGAGCTC 
ACGGTTCCGCCCCGA
CTCTAGAACG 
3 HeLa Rep 3 AGAAGGGCCGTGT
AATTCTAGGAGCTC 
AGACGTCCGCCCCGA
CTCTAGAACG 
4 HeLa Rep 4 AGTGGAGCCGTGT
AATTCTAGGAGCTC 
AGTTACCCGCCCCGA
CTCTAGAACG 
5 HeLa Rep 5 ATCAACGCCGTGTA
ATTCTAGGAGCTC 
ATGCACCCGCCCCGA
CTCTAGAACG 
6 HEK Rep 1 ATGTTGGCCGTGTA
ATTCTAGGAGCTC 
CAATACCCGCCCCGA
CTCTAGAACG 
7 HEK Rep 2 CACAAGGCCGTGT
AATTCTAGGAGCTC 
CATCTACCGCCCCGA
CTCTAGAACG 
8 HEK Rep 3 CCAAATGCCGTGTA
ATTCTAGGAGCTC 
CGTTTCCCGCCCCGA
CTCTAGAACG 
9 HEK Rep 4 CTATGGGCCGTGTA
ATTCTAGGAGCTC 
CTCCTTCCGCCCCGA
CTCTAGAACG 
10 HEK Rep 5 GAAACCGCCGTGT
AATTCTAGGAGCTC 
GACAATCCGCCCCGA
CTCTAGAACG 
11 HepG2 Rep 1 GCACTAGCCGTGTA
ATTCTAGGAGCTC 
GCGTTTCCGCCCCGA
CTCTAGAACG 
12 HepG2 Rep 2 GGTCTAGCCGTGTA
ATTCTAGGAGCTC 
GTAATCCCGCCCCGA
CTCTAGAACG 
13 HepG2 Rep 3 GTAGAGGCCGTGT
AATTCTAGGAGCTC 
GTTAGTCCGCCCCGA
CTCTAGAACG 
14 HepG2 Rep 4 TAACCCGCCGTGTA
ATTCTAGGAGCTC 
TACAGACCGCCCCGA
CTCTAGAACG 
15 HepG2 Rep 5 TAGAACGCCGTGTA
ATTCTAGGAGCTC 
TATGCCCCGCCCCGA
CTCTAGAACG 
16 HepaRG Rep 1 TCAAAGGCCGTGTA
ATTCTAGGAGCTC 
TCCATACCGCCCCGA
CTCTAGAACG 
17 HepaRG Rep 2 TCGATTGCCGTGTA
ATTCTAGGAGCTC 
TCTACCCCGCCCCGA
CTCTAGAACG 
18 HepaRG Rep 3 TGCTAGGCCGTGTA
ATTCTAGGAGCTC 
TGAACCCCGCCCCGA
CTCTAGAACG 
19 HepaRG Rep 4 TTCGAAGCCGTGTA
ATTCTAGGAGCTC 
TTAACGCCGCCCCGA
CTCTAGAACG 
20 HepaRG Rep 5 AAACACGCCGTGT
AATTCTAGGAGCTC 
TTCTGGCCGCCCCGA
CTCTAGAACG 
21 Plasmid Input 1 TAAGACGCCGTGTA
ATTCTAGGAGCTC 
TGCTCACCGCCCCGA
CTCTAGAACG 
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22 Plasmid Input 2 TGGGATGCCGTGTA
ATTCTAGGAGCTC 
TCTTAGCCGCCCCGA
CTCTAGAACG 
23 Plasmid Input 3 TCTGCTGCCGTGTA
ATTCTAGGAGCTC 
AAGAACCCGCCCCGA
CTCTAGAACG 
24 Plasmid Input 4 AACGGTGCCGTGT
AATTCTAGGAGCTC 
AACTTCCCGCCCCGA
CTCTAGAACG 
25 Plasmid Input 5 AATGTGGCCGTGTA
ATTCTAGGAGCTC 
GCAGAACCGCCCCGA
CTCTAGAACG 
*Please note that the 3’ barcode as shown above will be read on the complimentary 
(bottom) strand. The reverse compliment of the 3’ barcode will be seen on the main (top) 
strand.   
 147 
Results 
Our bioinformatic predictions identified hundreds of variants in the 3’UTR in 
pharmacogenes that could alter miRNA regulation. It is not practical to test all these 
variants individually using the traditional luciferase reporter assay. As a novel approach to 
functionally test the large number of variants in the 3’UTR that could affect gene 
expression, we modified the luciferase reporter assay to develop PASSPORT-seq 
(Parallel Assessment of Polymorphisms in miRNA Target Sites sequencing) (Figure 22). 
PASSPORT-seq is a high-throughput bioassay that can functionally test hundreds of 
variants in miRNA target sites in parallel, as well as the functional testing of these variants 
in different cell lines to subject miRNA target sites to different miRNA environments. We 
synthesized and cloned 238 miRNA target sites into the pIS-0 luciferase plasmid; each 
contained either the wild-type or variant miRNA target site (119 wild-type-variant pairs). 
The pool of 238 plasmids was then transfected into four cell lines and the luciferase gene 
expression was measured by next-generation sequencing. The difference in mRNA 
expression between the wild-type and variant plasmids indicate a functional variant in 
miRNA target sites. 
 
We tested 119 variants in HeLa (cervical cancer), HepG2 (liver carcinoma), HEK293 
(embryonic kidney), and HepaRG (liver carcinoma). Out of the 119 wild-type and variant 
pairs tested, 38 variants resulted in FDR-significantly altered expression in at least one 
cell line (Table 16). Twenty-one variants were observed to have increased expression, 
whereas, 17 variants had decreased expression compared to the wild-type allele. There 
were many differences and similarities in wild-type versus variant expression levels 
between the cell lines. Only four variants were FDR-significant and 34 went in the same 
direction among all four cell lines when considering SNPs that were FDR-significant in at 
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least one cell line (Figure 23). These differences between cell lines, most likely reflect 
differences in the miRNA expression profiles between these different cell types. 
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Figure 22: PASSPORT-sequencing workflow 
 
PASSPORT-sequencing workflow: A) 119 wild-type and variant miRNA target regions each with the same 15-20 bp flanking sequence 
were synthesized as an oligonucleotide pool B) using the flanking universal sequences, the oligonucleotide pool was amplified and 
made double stranded by PCR. The pIS-0 plasmid was linearized by restriction enzymes. C) The double stranded oligonucleotides 
were inserted into the linear plasmid using the NEBuilder gene assembly system. D) Chemically competent bacteria were transformed 
with the plasmid pool containing the test miRNA target regions. Transformed bacteria were plated on 4 plates. E) All colonies from the 
plates were harvested, combined and scaled up in liquid culture. Plasmids were isolated from the liquid culture. F) Four cell lines were 
B.  C.  D.  
H.  G.  F.  E.  
A.  
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transfected with the plasmid pool and incubated for 48 hours after which cDNA was prepared from total RNA. G) miRNA target regions 
were amplified using universal primers that were uniquely barcoded for replicates within cell lines and for the input plasmid pool. H) 
The barcoded PCR products were combined to form the sequencing pool.                                                             .                      
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Table 16: 3'UTR variants predicted to alter miRNA targeting among four cell lines 
 
SNP 
Wild-
type 
Variant 
HEK293 
(Var/WT) 
logFC* 
HeLa    
(Var/WT) 
logFC 
HepG2 
(Var/WT) 
logFC 
HepaRG 
(Var/WT) 
logFC 
rs11086926 T G 0.94 0.73 0.81 1.29 
rs7081484 C T 0.44 0.16 0.38 0.72 
rs5875 A T -0.03 0.27 0.11 0.62 
rs139156785 G A 0.42 0.36 0.11 0.61 
rs45539742 C G 0.47 0.23 0.23 0.57 
rs12721615 A G 0.17 0.11 0.22 0.55 
rs7246465 T C 0.19 0.11 0.23 0.54 
rs2480256 A G 0.55 0.39 0.44 0.51 
rs1058932 C T 0.17 -0.01 0.08 0.49 
rs7260525 A G 0.14 0.55 0.42 0.45 
rs3947 A G 0.70 0.30 0.52 0.45 
rs202026600 T A 0.12 0.15 0.32 0.42 
rs10929303 T C 0.14 0.10 0.11 0.41 
rs17161788 A G 0.12 0.11 0.15 0.40 
rs3814057 A C 0.27 0.15 0.29 0.38 
rs55818790 A G 0.22 0.20 0.19 0.35 
rs13860 T C 0.32 0.48 0.54 0.34 
rs112532686 T C 0.12 0.27 0.24 0.34 
rs28382751 A C 0.35 0.27 0.31 0.31 
rs189810658 C G 0.28 0.21 0.31 0.31 
rs1038376 A T 0.22 0.22 0.37 0.29 
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Table 16 cont’d      
SNP 
Wild-
type 
Variant 
HEK293 
(Var/WT) 
logFC 
HeLa    
(Var/WT) 
logFC 
HepG2 
(Var/WT) 
logFC 
HepaRG 
(Var/WT) 
logFC 
rs4803420 G T -0.27 -0.29 -0.47 0.28 
rs1042640 G C 0.27 0.14 0.36 0.26 
rs17470762 T C 0.11 0.09 0.02 0.25 
rs4149088 A G 0.28 0.12 0.16 0.25 
rs9465100 G A 0.15 0.27 0.19 0.25 
rs71581985 T G 0.35 0.04 0.14 0.23 
rs146050194 C T 0.31 0.06 0.24 0.21 
rs56160474 T C 0.35 0.27 0.29 0.20 
rs15524 T C 0.29 0.27 0.39 0.19 
rs1142365 A G 0.25 0.04 0.17 0.18 
rs183800671 C G 0.26 0.11 0.23 0.17 
rs4352283 A C 0.08 0.09 0.31 0.16 
rs3732359 G A 0.02 -0.15 0.01 0.16 
rs79132805 G A -0.13 0.10 0.07 0.16 
rs185946310 C T 0.10 0.01 -0.15 0.16 
rs707265 A G 0.16 0.22 0.19 0.15 
rs41285690 A G 0.41 0.23 0.18 0.15 
rs2472683 A G 0.32 0.13 0.16 0.15 
rs3732358 G A 0.28 0.13 0.18 0.15 
rs184161277 T C 0.12 0.10 0.17 0.14 
rs8192733 G C 0.46 0.28 0.37 0.14 
rs201925035 A C 0.26 0.30 0.21 0.13 
rs3212210 A C 0.30 0.06 -0.04 0.11 
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rs139849737 T C 0.17 0.12 0.09 0.11 
rs180751034 G T -0.19 -0.07 -0.13 0.08 
rs79775553 C G 0.10 0.08 0.10 0.07 
rs201524771 A C 0.14 -0.10 0.12 0.06 
rs3814058 T C 0.20 0.16 0.13 0.06 
rs200737867 G A -0.07 -0.14 0.18 0.06 
rs11574745 C T 0.23 0.01 0.11 0.04 
rs2151562 T C 0.17 -0.02 0.07 0.03 
rs56307258 C A 0.21 0.16 0.04 0.03 
rs41280258 G A 0.17 0.38 -0.07 0.03 
rs1042157 C T 0.11 0.23 0.31 0.02 
rs8330 G C 0.08 0.21 0.07 0.02 
rs28364280 G A -0.14 -0.08 -0.26 0.01 
rs138053056 C T 0.12 0.15 0.28 0.01 
rs114764820 T C 0.18 0.18 0.11 0.00 
rs10580 A G 0.15 0.10 0.28 0.00 
rs41282030 T C 0.07 0.06 -0.04 -0.01 
rs114029015 A G 0.22 0.13 0.19 -0.01 
rs28364275 T C 0.10 0.09 0.08 -0.03 
rs188501488 T A 0.16 0.12 0.06 -0.03 
rs183641079 C T 0.33 -0.18 0.05 -0.05 
rs11574744 T A 0.10 0.07 0.07 -0.08 
rs185103906 G T 0.08 0.02 0.07 -0.08 
rs4986993 T G 0.19 -0.09 -0.13 -0.08 
rs189107638 A G 0.13 0.06 0.13 -0.09 
rs28969420 G T 0.07 0.17 -0.01 -0.11 
rs200519094 C T 0.02 -0.04 -0.08 -0.11 
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Table 16 cont’d      
SNP 
Wild-
type 
Variant 
HEK293 
(Var/WT) 
logFC 
HeLa    
(Var/WT) 
logFC 
HepG2 
(Var/WT) 
logFC 
HepaRG 
(Var/WT) 
logFC 
rs11636419 A G 0.12 -0.05 -0.06 -0.12 
rs17861086 G C -0.12 -0.25 -0.02 -0.12 
rs12360 C T -0.13 -0.04 0.03 -0.13 
rs4630 C T -0.06 -0.01 -0.20 -0.13 
rs1054191 G A -0.05 -0.04 0.09 -0.14 
rs200905283 T A 0.02 -0.09 -0.26 -0.14 
rs149397784 C A 0.10 0.06 0.02 -0.15 
rs3134615 G T -0.23 -0.13 -0.30 -0.15 
rs6438550 G A 0.00 0.09 -0.06 -0.16 
rs12107248 T A 0.14 0.15 -0.01 -0.17 
rs291593 C T -0.18 -0.26 -0.22 -0.17 
rs9457846 G A -0.14 -0.03 -0.06 -0.17 
rs10460826 C G 0.06 0.05 0.07 -0.18 
rs28399502 C A -0.14 -0.12 -0.17 -0.22 
rs76580593 G T -0.08 0.05 -0.19 -0.24 
rs1042389 T C -0.03 0.00 -0.09 -0.24 
rs1802650 A T 0.06 -0.11 -0.21 -0.26 
rs10511395 C A -0.22 -0.21 -0.26 -0.28 
rs189727189 C T -0.18 -0.10 -0.18 -0.28 
rs6103734 G A 0.04 -0.01 -0.03 -0.29 
rs4149087 T G 0.07 0.06 0.19 -0.30 
rs183246640 A G -0.26 -0.31 -0.25 -0.32 
rs291592 G A -0.31 -0.15 -0.22 -0.32 
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rs11581122 C T -0.12 -0.32 -0.27 -0.33 
rs2480257 A T 0.02 -0.13 -0.06 -0.33 
rs71581986 T C -0.07 -0.05 -0.03 -0.33 
rs4986884 T C -0.33 -0.08 -0.41 -0.33 
rs144017186 C G -0.35 -0.15 -0.36 -0.35 
rs3732360 C T -0.15 -0.20 -0.29 -0.36 
rs10211 C T -0.40 -0.10 -0.05 -0.37 
rs55696854 G T -0.31 -0.22 -0.44 -0.37 
rs35427048 C T 0.11 -0.10 0.19 -0.39 
rs150176505 C T -0.40 -0.22 -0.35 -0.39 
rs189039600 C A -0.15 -0.40 -0.51 -0.41 
rs28371763 T A -0.51 -0.33 -0.47 -0.42 
rs189331203 C T -0.52 -0.41 -0.44 -0.42 
rs200253092 G A -0.07 -0.14 0.06 -0.43 
rs9332242 C G 0.14 0.10 0.10 -0.48 
rs3181842 C T -0.19 -0.16 -0.07 -0.48 
rs1054190 C T -0.44 -0.15 -0.33 -0.49 
rs55839603 T C 0.14 0.12 0.05 -0.50 
rs186026692 A G -0.01 0.01 -0.06 -0.56 
rs35791822 G T -0.37 -0.24 -0.37 -0.56 
rs55661878 A G -0.28 -0.19 -0.26 -0.58 
rs6839 A G -0.59 -0.47 -0.69 -0.61 
rs17861162 C G -0.42 -0.30 -0.39 -0.64 
rs12979270  A C -0.03 -0.02 -0.12 -0.71 
rs113594465 A G -0.84 -0.95 -0.98 -1.49 
* logFC= log2 fold change 
FDR Negative FC p-value Negative FC Not Sig Negative FC 
FDR Positive FC p-value Positive FC Not Sig Positive FC 
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Figure 23: Significance and directionality overlap between four cell lines among 
variants that were FDR-significant in at least one cell line 
The number of variants that overlap between the four different cells by A. FDR-
significance or B. directionality among variants that were FDR-significant in at least one 
cell line. 
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Discussion 
Due to the large number of 3’UTR genetic variants predicted to alter miRNA regulation, a 
more high-throughput way to functionally test these variants is necessary versus 
traditional individual luciferase assays as previously performed (Figure 21). Our lab 
created PASSPORT-seq to test hundreds of variants simultaneously in multiple cell lines 
(Figure 22). As a result, we functionally tested 119 wild-type-variant pairs to determine if 
the variant resulted in differential expression in HeLa, HepG2, Hek293, and HepaRG cells. 
These variants were predicted to alter miRNA binding using prediction tools such as 
PolymiRTS and from allele specific expression analysis in our RNA-seq data of 30 human 
liver tissues discussed in Chapter 1. This high-throughput assay allows us to better select 
candidate SNP pairs for further validation.  
 
This high-throughput assay will be useful for the testing of 3’UTR variants in any set of 
genes of interests, including variants that affect the 3’UTR though the binding of 
repression elements other than miRNAs. A major benefit of PASSPORT-seq is that it 
enables you test hundreds of variants in a couple of weeks. The testing of the wild-type 
and variant sequence plasmids within the same transfected well of cells, eliminates much 
of the variability within biological replicates. Data from this high-throughput assay highlight 
effects at the transcript level as miRNAs are known to lead to the degradation of target 
mRNA. Although a limitation of this assay is that protein levels are not measured, which 
may increase the number of false negatives (i.e. variants that alter miRNA’s ability to 
repress translation), it is also an advantage in that additional experiments are not needed 
to dissect whether the mechanism is on mRNA stability or translation. Subsequent 
individual luciferase assays will determine if protein activity is altered. 
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Other limitations of this assay include testing the miRNA target sites out of context, as 
only a 32-base pair region is tested. As a result, any effects regarding structural changes, 
such as mRNA secondary structures that may make the 3’UTR more or less accessible 
to miRNAs, will not be captured. The same holds true for individual luciferase experiments, 
so studies involving the full length mRNA with and without the variant miRNA binding sites 
will aid in determining the variant effect on mRNA regulation. Such a study can be 
performed utilizing CRISPR-Cas9, a tool that can be used to manipulate the DNA of genes 
of interest. However, PASSPORT-seq should prove to be a time-efficient way to functional 
test hundreds of 3’UTR variants, aiding in the selection of variants for further testing using 
other methods. 
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CONCLUSION 
Collectively, our studies provide evidence that hepatic miRNA expression changes during 
the developmental periods. These changes have the potential to impact and explain 
known developmental changes in hepatic gene expression and subsequent processes, 
such as drug metabolism, as miRNAs are able to negatively regulate protein expression 
through the degradation of mRNA or translational repression. Better characterization of 
these developmental changes in hepatic miRNA expression can be obtained through 
measuring expression levels at more narrow age intervals, as well as during periods of 
well-documented physiological changes such as less than one year old, pre/post-puberty 
and menopause, and in geriatric populations. However, more liver samples will be needed 
at these various intervals for assessment. These changes in miRNA expression can then 
be linked to corresponding alterations in hepatic gene expression between the 
developmental periods, but further testing is warranted to elucidate the meaning of these 
changes. 
 
In the case of drug metabolism, alterations in mRNA expression can be mediated through 
targeting not only enzymes directly involved in the biotransformation of drugs, but through 
the targeting of upstream transcription factors. This complexity of miRNA regulation 
becomes difficult to interpret as upstream transcription factors have multiple downstream 
targets and miRNAs themselves have multiple targets. Studies regarding miRNA stability, 
differential expression in various tissues and cell lines, and factors that are responsible for 
the regulation of miRNAs will aid in the interpretation of miRNA-related experiments. In 
the case of miRNA inhibitors, if the endogenous miRNA is not expressed in the cell culture 
model, then no effect would be observed with the inhibitor as there is no miRNA to be 
sequestered. Knowledge of these miRNA expression profiles in different cell lines is a way 
to address this limitation and may explain cell-type specific differences in gene regulation. 
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Furthermore, an array of techniques is necessary to validate the role of miRNAs in 
contributing to these developmental changes in pharmacogenes. Measuring mRNA and 
protein activity after miRNA and/or inhibitor treatment are only a few ways to validate 
miRNA-mRNA interactions. Measuring protein activity is crucial as miRNAs can prevent 
the translation of mRNA to protein, a consequence that is not captured when measuring 
mRNA expression alone. Proof of miRNA binding will also be a highly valuable area to 
explore as techniques are being developed to measure miRNA-mRNA interactions in an 
unbiased approach that is not limited to the seed sequence and other canonical binding 
requirements. 
 
Our studies have also shown that genetic variations in the 3’UTR have the potential to 
further impact miRNA targeting and provide evidence for the inter-individual variability in 
drug pharmacokinetic profiles. As the field of pharmacogenetics has primarily focused on 
genetic variants in the coding and promoter regions, our findings will open up the field to 
consider 3’UTR variants as a source of variability in the activities of many pharmacogenes.  
Furthermore, studies that prove more definitively that miRNAs bind to these target sites 
will be able to confirm miRNAs as a source of variability as opposed to variant-induced 
structural changes in the mRNA that may affect its accessibility and stability. Also, more 
popularly used techniques to validate miRNA-variant interactions, involve cloning a 
section of the miRNA binding site into a luciferase plasmid. However, removing the binding 
site out of context prevents the assessment of structural changes and alterations by other 
repressor elements. To overcome these limitations in studying genetic variation effects on 
miRNA regulation, tools such as CRISPR-Cas9 will prove useful in manipulating a gene 
of interest while maintaining other contextual factors. 
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Overall, this research uncovers the fact that these miRNA expression profiles differ 
between fetal, pediatric, and adult human livers, suggesting epigenetic regulation by 
miRNAs as a potential mechanism for the regulation of gene expression in the human 
liver. Our studies provide evidence that hepatic miRNAs, in part, may be a contributor of 
these known developmental changes in pharmacogenes and changes in the 
pharmacokinetic profiles of various drugs. Additional studies are necessary to better 
understand the connection between these developmentally-regulated miRNAs and altered 
hepatic gene expression across the developmental stages. Through uncovering how 
miRNAs are regulated, better understanding of the mechanisms by which these 
developmental changes occur will follow.  
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FUTURE DIRECTIONS 
Conversion of liver cell gene expression by miRNAs 
Our current findings have provided evidence that miRNA expression changes throughout 
development, revealing new questions to be answered. It has been well known that large 
changes occur among the expression of hepatic drug disposition genes during liver 
development. It would be important to determine if these developmentally-regulated 
miRNAs are directly linked to developmental drug disposition gene changes. In order to 
link developmentally-regulated hepatic miRNAs to gene expression changes in the liver, 
18 of the 72 hepatic miRNAs downregulated from fetal to pediatric were transfected into 
HepaRG cells (an adult cell line) and RNA and protein was isolated to measure 
pharmacogene expression using RNA-sequencing and mass-spectrometry based 
proteomic methods. 
 
The goal was to determine if the HepaRG cells revert back to a more fetal-like gene 
expression state when transfected with miRNA that was highly expressed in fetal liver 
tissues. Preliminary results show that the highly expressed fetal miRNAs altered mRNA 
expression profiles in adult HepaRG cells compared to C. elegans cel-miR-67 negative 
control (Figure 24 and 25) as there were 683 genes significantly upregulated and 480 
downregulated after fetal miRNA transfection. However, bioinformatics analysis is 
necessary to compare these changes between the fetal and pediatric changes discussed 
in Chapter 1, as our comparator is fetal liver tissue and not the C. elegans miRNA negative 
control. Next, this experiment can either be repeated with the remaining 54 downregulated 
miRNAs and changes can be bioinformatically combined to assess the entire effects of all 
72 miRNAs or a custom library of the 72 miRNAs can be transfected at lower 
concentrations per miRNA so that all miRNA interactions can be assessed in the same 
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biological replicate. Information from this study will further improve our fundamental 
understanding of miRNAs role in the ontogeny of hepatic pharmacogenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Multiple dimensional scaling plot comparing mRNA expression profiles 
of HepaRG cells transfected with fetal miRNAs or control (C.elegans) miRNA 
Multi-dimensional scaling plot shows the level of similarity between the two groups of 
transfected cells. X-axis: log2 fold change for dimension 1 (dim 1). Y-axis: log2 fold change 
for dimension 2 (dim 2). 18-1, 18-2, 18-3 are biological replicates for HepaRG cells 
transfected with a combination of fetally miRNAs. C1, C2, C3 are biological replicates for 
HepaRG cells transfected with control miRNAs. 
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Figure 25: Bland-Altman plot comparing mRNA expression profiles of HepaRG cells 
transfected with fetal miRNAs or control (C.elegans) miRNA 
Bland-Altman plot as a representation of the mRNA expression data. X-axis: Average 
logCPM (log2 counts per million); Y-axis: log2 fold change. The blue line represents a 2-
fold change. Black dots are genes that are not significantly different between the fetal 
miRNA-treated and control-treated HepaRG cells. Red dots are statistically significant 
after FDR correction. 
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Assessing the effects of 3’UTR polymorphisms on miRNA regulation 
In continuation of our study assessing the effects of polymorphisms in miRNA target sites 
in Chapter 4, individual luciferase assays to assess 3’UTR variants is necessary to 
validate our high-throughput assay findings. Due to the large number of variants predicted 
to alter miRNA regulation, the high-throughput assay aided in the selection of candidate 
SNPs to test individually. The clinical implications of these candidate polymorphisms in 
the 3’UTR can be followed up in human pharmacokinetic clinical trials through 
collaborative efforts as described in Chapter 3. Utilizing pharmacokinetic data of the drug 
disposition gene/genes of interests, will help determine if the 3’UTR variant accounts for 
variability in enzyme activity. Information from these studies will further progress utilizing 
genetic testing to predict patient response to drugs. 
 
A novel approach to validate genetic variant effects on gene expression is to utilize the 
CRISPR-Cas9 genome editing system (Yu et al., 2016). This technique will allow for 
genetic variation comparisons within the same cell line. This is critical as cell-specific 
differences exist such as miRNA expression profiles, gene expression, and genetic 
differences within the 3’UTR. For example, the rs70950385 variant discussed in Chapter 
3, differs between the cell lines. We sequenced the 3’UTR of CYP2B6 in HeLa, HepG2, 
and HepaRG cells. For the rs70950385 variant that had been previously shown to alter 
miRNA targeting of miR-1275, HeLa cells were homozygous for the CA allele, whereas 
the HepG2 and HepaRG cells are heterozygous. 
 
To precisely alter this variant in the 3’UTR, we transfect the platinum Cas9 protein, guide 
RNA (gRNA), and single-stranded oligo into HeLa cells using a lipid-based transfection. 
The gRNA ‘AGGCAGCTGGGAATGAGGAT’ will guide the Cas9 protein to create a double 
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strand break near our site of interest. A single-stranded oligo harboring the precise 3’UTR 
edit 5’-EEAACCTGGGCCAAGGGGGCTTTTTGATAGACGGAAGCAGTA 
GGAGGAGGCAGCTGGGAATGAGGACTGGGGAAGACTACAGCAGTGTGTGACTGTE
ET-3’ will serve as a template for the cellular homology-directed repair pathway. 
Transfected cells are then plated individually, cultured and DNA is isolated for sequencing 
to determine if gene editing was achieved. So, by utilizing the CRISPR-Cas9 genome 
editing system, we are able to use HeLa cells which are (CA/CA) and create stable lines 
that are either heterozygous or homozygous (AG/AG) and compare CYP2B6 gene 
expression changes when miR-1275 is transfected. This will provide additional evidence 
that miR-1275 targets CYP2B6 and that the rs70950385 variant is associated with 
decreased CYP2B6 activity. 
 
miRNAs as biomarkers for predicting patient response and outcomes 
Lastly, the miRNAs focused on in this project were expressed in liver tissue samples; 
however, it is known that miRNAs are found in the blood and can circulate between tissues 
via exosomes (Conde-Vancells et al., 2008; Kogure et al., 2011; Vickers et al., 2011). As 
liver biopsies are not feasible for predicting patient outcomes, it is necessary to understand 
how miRNAs are secreted between the different cell types as well as patterns in plasma 
miRNA levels. Individual or groups of miRNAs can serve as biomarkers for many biological 
disease states and progression such as breast cancer and diagnosis of liver disease, as 
well as for predicting patient response to drugs (Cortez et al., 2012; Dickinson et al., 2013; 
Fayyad-Kazan et al., 2013; Murakami et al., 2012; Salomon et al., 2017). For example, 
miR-150 and miR-342 were shown to be down-regulated in the plasma of patients with 
acute myeloblastic leukemia compared to healthy controls. These two miRNAs combined 
were able to discriminate AML patients with a sensitivity and specificity of 73% and 78%, 
respectively (Fayyad-Kazan et al., 2013). The use of miRNAs as biomarkers is an 
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emerging field as over 400 clinical trials have been conducted or are currently ongoing 
focused on miRNAs as biomarkers and screening mechanisms for a wide range of 
indications focused on diabetes, liver, kidney, and heart disease, cancers, etc. 
(ClinicalTrials.gov). Collectively, these studies will further our understanding of miRNAs 
role in various physiological processes, as well as provide information on how miRNAs 
circulate between cells and their involvement in drug metabolism, disease progression 
and diagnosis.  
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Delta Pi Sigma Graduate Chapter of FVSU (2012) 
Vice President, Zeta Pi Undergraduate Chapter of FVSU (2011) 
A community service based organization whose goals are to 
enhance the quality of life within the community, public service, 
and leadership development. 
2006-2016  Pianist 
Mount Zion Baptist Church, Indianapolis, IN (2013-2016) 
Green Grove Baptist Church, Elko, GA (2010-2012) 
New Beginnings Church of Christ, Milledgeville, GA (2006-2009) 
Play piano for church on Sunday, Wednesday, and/or special 
services. 
 
PROFESSIONAL 
ASSOCIATIONS 
  
2013-Present American Society for Clinical Pharmacology and Therapeutics 
(ASCPT) 
2011-2015  American Association for Cancer Research 
2010-Present  Beta Kappa Chi Scientific Honor Society 
2008-Present  Louis Stokes Alliance for Minority Participation (LSAMP) 
INVITED 
PRESENTATIONS LSAMP Meeting, Fort Valley State University 
Fort Valley, GA, April 11, 2016 
Presentation: My Academic Journey 
Biology Colloquium, Willamette University 
   Salem, Oregon, April 4-5, 2016 
Presentation: Age-related Changes in MicroRNA Expression 
Effect on Drug Metabolism in Human Liver 
NOBCChE Meeting, IUPUI 
Indianapolis, IN, February 9, 2015 
Presentation: Getting Into and Through Graduate School 
 
CONFERENCES Great Lakes Drug Metabolism and Disposition Group 
(GLDMDG) Meeting (Student Abstract Presentation Winner) 
 Kalamazoo, MI, May 4-5, 2017 
Oral & Poster Presentation: In Vitro and In Vivo Functional Testing 
of SNPs in the 3’UTR of CYP2B6 
118th Annual Meeting ASCPT 
   Washington, DC, March 15-18, 2017 
Oral & Poster Presentation: In Vitro and In Vivo Functional Testing 
of SNPs in the 3’UTR of CYP2B6 
Poster Presentation: Association of UGT1A1*80 on Bilirubin 
Levels in Healthy Volunteers Treated with Efavirenz 
   117th Annual Meeting ASCPT 
San Diego, CA, March 8-12, 2016 
Poster Presentation: Use of Transcription Activator Like Effector-
Transcription Factors (TALE-TFs) To Induce CYP1A2 Expression 
and Validate miRNA Predictions 
22nd Annual Institute for Teaching and Mentoring 
Arlington, VA, October 29-November 1, 2015 
Indiana University Simon Cancer Center/Purdue University 
Center for Cancer Research Joint Scientific Retreat 
West Lafayette, IN, May 2, 2015 
Poster Presentation: Use of Transcription Activator Like Effector-
Transcription Factors (TALE-TFs) As A New Technique to Induce 
CYP Gene Expression and Validate miRNA Predictions 
116th Annual Meeting ASCPT (Travel Scholarship Recipient) 
New Orleans, LA, March 3-7, 2015 
Poster Presentation: Use of Transcription Activator Like Effector-
Transcription Factors (TALE-TFs) As A New Technique to Induce 
CYP Gene Expression and Validate miRNA Predictions 
21st Annual Institute for Teaching and Mentoring 
  
Atlanta, GA, October 30-November 2, 2014 
NOBCChE 41st Annual Conference New Orleans, LA, 
September 22-27th  
IUPUI Exhibitor 
Cancer Research Day 
Indianapolis, IN, May 29, 2014 
Poster Presentation: Effects of Developmental MicroRNA 
Regulation in Liver On Drug Disposition and Response 
115th Annual Meeting ASCPT 
Atlanta, GA, March 17-22, 2014 
20th Annual Institute for Teaching and Mentoring 
Arlington, VA, October 31-November 3, 2013 
Annual Biomedical Research Conference for Minority 
Students 
St. Louis, MO, November 9-12, 2011 
Poster Presentation: Neutralization of FGF-23 Alters Phosphate 
Requirements of Growing Chicks 
Society for Advancement of Hispanics/Chicanos and Native 
Americans in Science National Conference (Travel 
Scholarship Recipient) 
San Jose, CA, October 27-30, 2011 
Poster Presentation: Neutralization of FGF-23 Alters Phosphate 
Requirements of Growing Chicks 
6th Annual Peach State LSAMP Fall Symposium & Research 
Conference 
Savannah, GA, October 14-15, 2011 
Oral Presentation: Assessing the Reproducibility of Real-Time 
Polymerase Chain Reaction on the Quantitation of DNA 
Recovered from Crime Scene 
Committee on Institutional Cooperation/Summer Research 
Opportunity Program Summer Research Conference 
Columbus, OH, July 15-17, 2011 
Poster Presentation: Neutralization of FGF-23 Alters Phosphate 
Requirements of Growing Chicks 
68th Joint Annual Meeting of Beta Kappa Chi Scientific Honor 
Society &National Institute of Science 
Atlanta, GA, March 23-27, 2011 
Oral Presentation: Assessing the Reproducibility of Real-Time 
Polymerase Chain 
Reaction on the Quantitation of DNA Recovered from Crime 
Scene 
Georgia Life Sciences Summit 2010 
Atlanta, GA, October 28, 2010 
Poster Presentation: Which Has More Touch DNA? Cell Phones 
vs. Drinking Straws 
  
5th Annual Peach State LSAMP Fall Symposium & Research 
Conference 
Athens, GA, September 24-25, 2010 
Oral Presentation: Assessing the Reproducibility of Real-Time 
Polymerase Chain Reaction on the Quantitation of DNA 
Recovered from Crime Scene 
HONORS/ 
AWARDS 
IUSM 
2017 GLDMDG Student Abstract Presentation Winner: $250 
2017 ASCPT Presidential Trainee Award 
2017 IUSM Travel Grant: $571 
2017 Graduate-Professional Educational Travel Grant: $500 
2017 ASCPT Dedicated Member: March 2017 
2016 Premier 10 Award 
2016 Elite 50 Award 
2015 American Association of Pharmaceutical Sciences Drug 
Metabolism Newsletter Special Feature-Junior Scientist: 
December 
2015   K.K. Chen Fellowship in Pharmacology & Toxicology: $1000 
2015   Diversity Emissary Award: $300 
2015   Elite 50 Award 
2015   IUPUI Travel Fellowship Award: $1000  
2015   Paradise Travel Award: $400  
2015   Graduate-Professional Educational Travel Grant: $500 
2015   ASCPT Jason Morrow Trainee Award (top trainee abstract)  
2015   ASCPT Presidential Trainee Award: $750 
2015 IUPUI EMBRACE Inaugural Magazine-Student Spotlight: January 
2014 ASCPT New Member of the Month: April 2014 
FVSU 
2011   Valedictorian 
2011   Summa Cum Laude 
2011   Sigma Gamma Rho Sorority Highest GPA  
2009    National Dean’s List (3 years) 
2009 Florine and Linda Early Health Sciences Departmental Award 
Scholarships/Grants, 
2009   LSAMP Scholar (3 years) 
2008   James H. Porter Merit Scholarship (2 years) 
2008   FVSU Presidential Scholarship (4 years) 
2008 Georgia’s Helping Outstanding Pupils Educationally (HOPE) 
Scholarship (4 years) 
2008   Kiwanis Club Scholarship (4 years) 
2008   FVSU Women’s Basketball Scholarship (2 years) 
2008   Federal Smart Grant (2 years) 
2008   Federal Academic Competitiveness Grant (2 years) 
Championship 
2008-2009 Division II Southern Intercollegiate Athletic Conference Women’s 
Basketball Championship 
 
